0001564590-19-003090 | 10-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2018	Feb. 11, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Type	10-K
Trading Symbol	CC
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		167,037,003
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 7.8

Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Cost of goods sold	1,064	1,151	1,259	1,193	1,090	1,119	1,150	1,081	4,667	4,438	4,297
Gross profit									1,971	1,745	1,103
Selling, general, and administrative expense									657	626	946
Research and development expense									82	81	81
Restructuring, asset-related, and other charges									49	57	170
Total other operating expenses									788	764	1,197
Equity in earnings of affiliates									43	33	29
Interest expense, net									(195)	(214)	(219)
(Loss) gain on extinguishment of debt									(38)	(1)	6
Other income, net									162	113	267
Income (loss) before income taxes	182	269	323	381	264	250	225	173	1,155	912	(11)
Provision for (benefit from) income taxes									159	165	(18)
Net income (loss)	142	275	282	297	228	207	161	151	996	747	7
Less: Net income attributable to non-controlling interests									1	1	0
Net income (loss) attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	$ 995	$ 746	$ 7
Per share data
Basic earnings per share of common stock	$ 0.83	$ 1.56	$ 1.58	$ 1.63	$ 1.23	$ 1.12	$ 0.87	$ 0.82	$ 5.62	$ 4.04	$ 0.04
Diluted earnings per share of common stock	$ 0.81	$ 1.51	$ 1.53	$ 1.58	$ 1.19	$ 1.08	$ 0.84	$ 0.79	$ 5.45	$ 3.91	$ 0.04

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net income (loss), pre-tax	$ 1,155	$ 912	$ (11)
Net Income (loss), tax	(159)	(165)	18
Net income (loss)	996	747	7
Hedging activities:
Unrealized gain (loss) on net investment hedge, pre-tax	32	(86)	14
Unrealized gain (loss) on net investment hedge, tax	(8)	24	0
Unrealized gain (loss) on net investment hedge, after-tax	24	(62)	14
Unrealized gain on cash flow hedge, pre-ax	10	0	0
Unrealized gain on cash flow hedge, tax	(1)	0	0
Unrealized gain on cash flow hedge, after-tax	9	0	0
Reclassifications to net income - cash flow hedge, pre-tax	(4)	0	0
Reclassifications to net income - cash flow hedge, tax	1	0	0
Reclassifications to net income - cash flow hedge, after-tax	(3)	0	0
Hedging activities, net, pre-tax	38	(86)	14
Hedging activities, net, tax	(8)	24	0
Hedging activities, net, after-tax	30	(62)	14
Cumulative translation adjustments, pre-tax	(75)	200	(73)
Cumulative translation adjustments, tax	0	0	0
Cumulative translation adjustments, after-tax	(75)	200	(73)
Defined benefit plans:
Net (loss) gain,pre-tax	(115)	24	(17)
Net (loss) gain, tax	29	(5)	5
Net (loss) gain, after-tax	(86)	19	(12)
Effect of foreign exchange rates, pre-tax	8	(38)	15
Effect of foreign exchange rates, tax	0	0	(3)
Effect of foreign exchange rates, after-tax	8	(38)	12
Amortization of prior service gain, pre- tax	(2)	(2)	(1)
Amortization of prior service gain, tax	0	0	0
Amortization of prior service gain, after-tax	(2)	(2)	(1)
Amortization of actuarial loss, pre-tax	16	24	23
Amortization of actuarial loss, tax	(4)	(6)	(6)
Amortization of actuarial loss, after-tax	12	18	17
Settlement loss, pre-tax	0	0	5
Settlement loss, tax	0	0	(1)
Settlement loss, after-tax	0	0	4
Curtailment gain, pre-tax	0	0	(2)
Curtailment gain, tax	0	0	0
Curtailment gain, after-tax	0	0	(2)
Defined benefit plans, net, pre-tax	(93)	8	23
Defined benefit plans, net, tax	25	(11)	(5)
Defined benefit plans, net, after-tax	(68)	(3)	18
Other comprehensive (loss) income, pre-tax	(130)	122	(36)
Other comprehensive (loss) income, tax	17	13	(5)
Other comprehensive (loss) income, after-tax	(113)	135	(41)
Comprehensive income (loss), pre-tax	1,025	1,034	(47)
Comprehensive income (loss), tax	(151)	(152)	13
Comprehensive income (loss), after-tax	874	882	(34)
Less: Comprehensive income attributable to non-controlling interests, pre-tax	1	1	0
Less: Comprehensive income attributable to non-controlling interests, tax	0	0	0
Less: Comprehensive income attributable to non-controlling interests, after-tax	1	1	0
Comprehensive income (loss) attributable to Chemours,pre tax	1,024	1,033	(47)
Comprehensive income (loss) attributable to Chemours, tax	(151)	(152)	13
Comprehensive income (loss) attributable to Chemours, after-tax	873	881	(34)
Accounting Standards Update 2018-02 [Member]
Defined benefit plans:
Cumulative effect of adopting ASU No. 2018-02, pre-tax	0	0	0
Cumulative effect of adopting ASU No. 2018-02, tax	(9)	0	0
Cumulative effect of adopting ASU No. 2018-02, after-tax	$ (9)	$ 0	$ 0

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,201	$ 1,556
Accounts and notes receivable, net	861	919
Inventories	1,147	935
Prepaid expenses and other	84	83
Total current assets	3,293	3,493
Property, plant, and equipment	8,992	8,511
Less: Accumulated depreciation	(5,701)	(5,503)
Property, plant, and equipment, net	3,291	3,008
Goodwill and other intangible assets, net	181	166
Investments in affiliates	160	173
Other assets	437	453
Total assets	7,362	7,293
Current liabilities:
Accounts payable	1,137	1,075
Current maturities of long-term debt	13	15
Other accrued liabilities	559	558
Total current liabilities	1,709	1,648
Long-term debt, net	3,959	4,097
Deferred income taxes	217	208
Other liabilities	457	475
Total liabilities	6,342	6,428
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 187,204,567 shares issued and 170,780,474 shares outstanding at December 31, 2018; 185,343,034 shares issued and 182,956,628 shares outstanding at December 31, 2017)	2	2
Treasury stock at cost (16,424,093 shares at December 31, 2018; 2,386,406 shares at December 31, 2017)	(750)	(116)
Additional paid-in capital	860	837
Retained earnings	1,466	579
Accumulated other comprehensive loss	(564)	(442)
Total Chemours stockholders’ equity	1,014	860
Non-controlling interests	6	5
Total equity	1,020	865
Total liabilities and equity	$ 7,362	$ 7,293

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, shares authorized (in shares)	810,000,000	810,000,000
Common stock , par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares Issued (in shares)	187,204,567	185,343,034
Common stock, shares outstanding (in shares)	170,780,474	182,956,628
Treasury stock (in shares)	16,424,093	2,386,406

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	(Accumulated Deficit) Retained Earnings [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interests [Member]
Total stockholders' equity, beginning balance at Dec. 31, 2015	$ 130	$ 2		$ 775	$ (115)	$ (536)	$ 4
Shares, beginning balance at Dec. 31, 2015		181,069,751
Common stock issued - compensation plans (in shares)		583,859
Exercise of stock options, net	11			11
Exercise of stock options, net (in shares)		946,923
Stock-based compensation expense	19			19
Net income	7				7
Dividends	(22)			(16)	(6)
Dividends per Share declared during period		$ 0.12
Other comprehensive income (loss)	(41)					(41)
Total stockholders' equity, ending balance at Dec. 31, 2016	104	$ 2		789	(114)	(577)	4
Shares, ending balance at Dec. 31, 2016		182,600,533
Dividends per Share, as of December 30 at Dec. 31, 2016		$ 0.12
Common stock issued - compensation plans (in shares)		569,263
Exercise of stock options, net	31			31
Exercise of stock options, net (in shares)		2,173,238
Purchases of treasury stock at cost	(116)		$ (116)
Purchases of treasury stock at cost (in shares)			2,386,406
Stock-based compensation expense	29			29
Cancellation of unissued stock awards withheld to cover taxes	(12)			(12)
Net income	747				746		1
Dividends	(53)				(53)
Dividends per Share declared during period		$ 0.29
Other comprehensive income (loss)	135					135
Total stockholders' equity, ending balance at Dec. 31, 2017	865	$ 2	$ (116)	837	579	(442)	5
Shares, ending balance at Dec. 31, 2017		185,343,034	2,386,406
Dividends per Share, as of December 30 at Dec. 31, 2017		$ 0.29
Common stock issued - compensation plans (in shares)		783,346
Exercise of stock options, net	16			16
Exercise of stock options, net (in shares)		1,078,187
Purchases of treasury stock at cost	(634)		$ (634)
Purchases of treasury stock at cost (in shares)			14,050,098
Shares issued under employee stock purchase plan (in shares)			(12,411)
Stock-based compensation expense	24			24
Cancellation of unissued stock awards withheld to cover taxes	(17)			(17)
Cumulative effect of adopting ASU No. 2018-02					9	(9)
Net income	996				995		1
Dividends	(117)				(117)
Dividends per Share declared during period		$ 0.67
Other comprehensive income (loss)	(113)					(113)
Total stockholders' equity, ending balance at Dec. 31, 2018	$ 1,020	$ 2	$ (750)	$ 860	$ 1,466	$ (564)	$ 6
Shares, ending balance at Dec. 31, 2018		187,204,567	16,424,093
Dividends per Share, as of December 30 at Dec. 31, 2018		$ 0.67

Consolidated Statements of Cash Flows $ in Millions	12 Months Ended
Consolidated Statements of Cash Flows $ in Millions	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Cash flows from operating activities
Net income	$ 996	$ 747	$ 7
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	284	273	284
Asset-related charges	4	3	124
Gain on sales of assets and businesses	(45)	(22)	(254)
Equity in earnings of affiliates, net	18	(33)	(12)
Loss (gain) on extinguishment of debt	38	1	(6)
Amortization of debt issuance costs and issue discounts	11	13	16
Deferred tax provision (benefit)	23	83	(111)
Other operating charges and credits, net	17	41	62
Decrease (increase) in operating assets:
Accounts and notes receivable, net	47	(88)	5
Inventories and other operating assets	(297)	(208)	147
(Decrease) increase in operating liabilities:
Accounts payable and other operating liabilities	44	(170)	332
Cash provided by operating activities	1,140	640	594
Cash flows from investing activities
Purchases of property, plant, and equipment	(498)	(411)	(338)
Acquisition of business, net	(37)	0	0
Proceeds from sales of assets and businesses, net	46	39	708
Investments in affiliates	0	0	(1)
Foreign exchange contract settlements, net	2	2	(12)
Cash (used for) provided by investing activities	(487)	(370)	357
Cash flows from financing activities
Proceeds from issuance of debt, net	520	495	0
Debt repayments	(679)	(27)	(381)
Payments related to extinguishment of debt	(29)	(1)	0
Payments of debt issuance costs	(12)	(6)	(4)
Purchases of treasury stock, at cost	(644)	(106)	0
Proceeds from exercised stock options, net	16	31	11
Payments related to tax withholdings on vested restricted stock units	(17)	(12)	0
Payments of dividends	(148)	(22)	(22)
Cash (used for) provided by financing activities	(993)	352	(396)
Effect of exchange rate changes on cash and cash equivalents	(15)	32	(19)
(Decrease) increase in cash and cash equivalents	(355)	654	536
Cash and cash equivalents at January 1,	1,556	902	366
Cash and cash equivalents at December 31,	1,201	1,556	902
Cash paid during the year for:
Interest, net of amounts capitalized	206	208	208
Income taxes, net of refunds	75	79	50
Non-cash investing and financing activities:
Changes in property, plant, and equipment included in accounts payable	37	(14)	(12)
Obligations incurred under build-to-suit lease arrangement	47	8	0
Purchases of treasury stock not settled by year-end	0	10	0
Dividends accrued but not yet paid	$ 0	$ 31	$ 0

Background and Description of the Business

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Background and Description of the Business

Note 1. Background and Description of the Business

The Chemours Company (“Chemours,” or the “Company”) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. The Company’s principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (“TiO₂”) pigment. Chemours’ manages and reports its operating results through three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications. The Titanium Technologies segment is a leading, global producer of TiO₂ pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protections in a variety of applications.

Chemours has manufacturing facilities, sales centers, administrative offices, and warehouses located throughout the world. Chemours’ operations are primarily located in the U.S., Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, and France. At December 31, 2018, the Company operated 28 major production facilities globally, of which, 20 were dedicated to Fluoroproducts, one was dedicated to Chemical Solutions, five were dedicated to Titanium Technologies, and two supported multiple segments.

Chemours began operating as an independent company on July 1, 2015 (the “Separation Date”) after separating from E.I. DuPont de Nemours and Company (“DuPont”) (the “Separation”). The Separation was completed pursuant to a separation agreement and other agreements with DuPont, including an employee matters agreement, a tax matters agreement, a transition services agreement, and an intellectual property cross-license agreement. These agreements govern the relationship between Chemours and DuPont following the Separation and provided for the allocation of various assets, liabilities, rights, and obligations at the Separation Date. On August 31, 2017, DuPont completed a merger with The Dow Chemical Company (“Dow”), pursuant to which, Dow and DuPont became subsidiaries of DowDuPont, Inc. with the intent to form three independent, publicly-traded companies. At this time, the agreements related to Chemours’ Separation remain between Chemours and DuPont.

Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the Company,” “our company,” “we,” “us,” and “our,” refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Separation. References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

Basis of Presentation

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Presentation

Note 2. Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In the opinion of management, all adjustments (consisting of normal, recurring adjustments) considered necessary for a fair presentation of the Company’s financial position and results of operations have been included for the periods presented herein. The notes that follow are an integral part of the Company’s consolidated financial statements.

Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which, was not material to the Company’s consolidated financial statements.

Comprehensive income as of December 31, 2016 includes an out of period adjustment of $31 related to 2015 cumulative translation adjustments, with a corresponding adjustment to other current assets. This adjustment was not material to the Company’s consolidated financial statements.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

Preparation of Financial Statements

The consolidated financial statements have been prepared in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experiences, facts, and circumstances available at the time and various other assumptions that management believes are reasonable. Actual results could differ from those estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of Chemours and its subsidiaries, as well as entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock, or has the ability to exercise significant influence over the operating and financial policies of the investee, are accounted for using the equity method of accounting. As a result, Chemours’ share of the earnings or losses of such equity affiliates is included in the consolidated statements of operations, and Chemours’ share of such equity affiliates’ equity is included in the consolidated balance sheets.

The Company assesses the requirements related to the consolidation of any variable interest entity (“VIE”), including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that most significantly impact the VIE’s economic performance, and has the right to receive any benefits or the obligation to absorb any losses of the VIE. No such VIE was consolidated by the Company for the periods presented.

All intercompany accounts and transactions were eliminated in the preparation of the accompanying consolidated financial statements.

Revenue Recognition

Chemours recognizes revenue using a five-step model resulting in revenue being recognized as performance obligations within a contract have been satisfied. The steps within that model include: (i) identifying the existence of a contract with a customer; (ii) identifying the performance obligations within the contract; (iii) determining the contract’s transaction price; (iv) allocating the transaction price to the contract’s performance obligations; and, (v) recognizing revenue as the contract’s performance obligations are satisfied. A contract with a customer exists when: (i) the Company enters into an enforceable agreement that defines each party’s rights regarding the goods or services to be transferred, and the related payment terms; (ii) the agreement has commercial substance; and, (iii) it is probable that the Company will collect the consideration to which it is entitled to in the exchange. A performance obligation is a promise in a contract to transfer a distinct good or service, or a series of distinct goods or services to a customer. The transaction price is the customary amount of consideration that the Company expects to be entitled to in exchange for a transfer of the promised goods or services to a customer, excluding any amounts collected by the Company on behalf of third-parties (e.g., sales and use taxes). Judgment is required to apply the principles-based, five-step model for revenue recognition. Management is required to make certain estimates and assumptions about the Company’s contracts with its customers, including, among others, the nature and extent of its performance obligations, its transaction price amounts and any allocations thereof, the critical events which constitute satisfaction of its performance obligations, and when control of any promised goods or services is transferred to its customers.

The Company’s revenue from contracts with customers is reflected in the consolidated statements of operations as net sales, the vast majority of which represents product sales that consist of a single performance obligation. Product sales to customers are made under a purchase order (“PO”), or in certain cases, in accordance with the terms of a master services agreement (“MSA”) or similar arrangement, which documents the rights and obligations of each party to the contract. When a customer submits a PO for product or requests product under an MSA, a contract for a specific quantity of distinct goods at a specified price is created, and the Company’s performance obligation under the contract is satisfied when control of the product is transferred to the customer, which is indicated by shipment of the product and the transfer of title and the risk of loss to the customer. Revenue is recognized on consignment sales when control transfers to the customer, generally at the point of customer usage of the product. The transaction price for product sales is generally the amount specified in the PO or in the request under an MSA; however, as is common in Chemours’ industry, the Company offers variable consideration in the form of rebates, volume discounts, early payment discounts, pricing based on formulas or indices, price matching, and guarantees to certain customers. Such amounts are included in the Company’s estimated transaction price using either the expected value method or the most-likely amount, depending on the nature of the variable consideration included in the contract. The Company regularly assesses its customers’ creditworthiness, and product sales are made based on established credit limits. Payment terms for the Company’s invoices are typically less than 90 days.

The Company also licenses the right to access certain of its trademarks to customers under specified terms and conditions in certain arrangements, which is recognized as a component of net sales in the consolidated statements of operations. Under such arrangements, the Company may receive a royalty payment for a trademark license that is entered into on a stand-alone basis or incorporated into an overall product sales arrangement. Royalty income is generally based on customer sales and recognized under the sales-based exception as the customer sale occurs. When minimum guaranteed royalty amounts are included in the transaction price, the Company recognizes royalty income ratably over the license period for the minimum amount. When there is no consideration specified for the use of the Company’s trademark, the entire transaction price is recognized in connection with the transfer of control of product. Royalty income resulting from the right to use the Company’s technology is considered outside the scope of revenue recognition under GAAP as it is not a part of the Company’s ongoing major or central activities, and is recognized as a component of other income, net in the consolidated statements of operations in accordance with agreed-upon terms at the point or points in time that performance obligations are satisfied.

Consistent with the fact that the vast majority of the Company’s payment terms are less than 90 days from the point at which control of the promised goods or services is transferred, no adjustments have been made for the effects of a significant financing component. Additionally, the Company has elected to recognize the incremental costs associated with obtaining contracts as an expense when incurred if the amortization period of the assets that the Company would have recognized is one year or less. Amounts billed to customers for shipping and handling fees are considered a fulfillment cost and are included in net sales, and the costs incurred by the Company for the delivery of goods are classified as a component of the cost of goods sold in the consolidated statements of operations.

Research and Development Expense

Research and development (“R&D”) costs are expensed as incurred. R&D expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products, and regulatory approval of new and existing products.

Provision for (Benefit from) Income Taxes

The provision for (benefit from) income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for (benefit from) income taxes represents income taxes paid or payable for the current year, plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. The Company’s deferred tax assets and liabilities are presented on a net basis by jurisdictional filing group. Net deferred tax assets are presented as a component of other assets, while net deferred tax liabilities are presented as a component of deferred income taxes on the Company’s consolidated balance sheets. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized.

Chemours recognizes income tax positions that meet the more-likely-than-not threshold and accrues any interest related to unrecognized income tax positions as a component of other income, net in the consolidated statements of operations. Income tax-related penalties are included in the provision for (benefit from) income taxes.

Earnings Per Share

Chemours presents both basic earnings per share and diluted earnings per share. Basic earnings per share excludes dilution and is computed by dividing the total net income attributable to Chemours by the weighted-average number of shares outstanding for the period. Diluted earnings per share reflects the dilution that could occur if the Company’s outstanding stock-based compensation awards, including any unvested restricted shares, were vested and exercised, thereby resulting in the issuance of common stock as determined under the treasury stock method. In periods where the Company incurs a net loss, stock-based compensation awards are excluded from the calculation of earnings per share as their inclusion would have an anti-dilutive effect.

Cash and Cash Equivalents

Cash and cash equivalents generally include cash, time deposits, or highly-liquid investments with original maturities of three months or less.

Accounts and Notes Receivable and Allowance for Doubtful Accounts

Accounts and notes receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ accounts and notes receivable portfolio, which is determined on the basis of historical experience, specific allowances for known troubled accounts, and other available evidence. Accounts and notes receivable are written-off when management determines that they are uncollectible.

Inventories

Chemours’ U.S. inventories are valued at the lower of cost or market, as inventories held at substantially all U.S. locations are valued using the last-in, first-out (“LIFO”) method. Chemours’ non-U.S. inventories are valued at the lower of cost or net realizable value, as inventories held outside the U.S. are valued using the average cost method. The elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at the lower of cost or net realizable value. Cost is generally determined by the average cost method.

Property, Plant, and Equipment

Property, plant, and equipment is carried at cost and is depreciated using the straight-line method. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold, or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the consolidated balance sheets and are included in the determination of any gain or loss on such disposals.

Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on their extension to the asset’s useful life. Capitalized repair and maintenance costs are recorded on the consolidated balance sheets as a component of other assets.

Impairment of Long-lived Assets

Chemours evaluates the carrying value of its long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For the purposes of recognition or measurement of an impairment charge, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs, and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of the asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value, which is made based on prices of similar assets or other valuation methodologies, including present value techniques. Long-lived assets to be disposed of by means other than sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value, less the estimated cost to sell. Depreciation is discontinued for any long-lived assets classified as held for sale.

Goodwill and Other Intangible Assets

The excess of the purchase price over the estimated fair value of the net assets acquired in a business combination, including any identified intangible assets, is recorded as goodwill. Chemours tests its goodwill for impairment at least annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. An impairment exists when the carrying value of a reporting unit exceeds its fair value. The amount of impairment loss recognized in the consolidated statements of operations is equal to the excess of a reporting unit’s carrying value over its fair value, which is limited to the total amount of goodwill allocated to the reporting unit.

Chemours has the option to first qualitatively assess whether it is more-likely-than-not that an impairment exists for a reporting unit. Such qualitative factors include, among other things, prevailing macroeconomic conditions, industry and market conditions, changes in costs associated with raw materials, labor, or other inputs, the Company’s overall financial performance, and certain other entity-specific events that impact Chemours’ reporting units. When performing a quantitative test, the Company weights the results of an income-based valuation technique, the discounted cash flows method, and a market-based valuation technique, the guideline public companies method, to determine its reporting units’ fair values.

Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists, are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated.

Asset Retirement Obligations

Chemours records its asset retirement obligations at their fair value at the time the liability is incurred. Fair value is measured using the expected future cash outflows discounted at Chemours’ credit-adjusted, risk-free interest rate, which is considered to be a Level 3 input within the fair value hierarchy. Accretion expense is recognized as an operating expense within the cost of goods sold in the consolidated statements of operations using the credit-adjusted, risk-free interest rate in effect when the liability was recognized. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset and are depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 25 years.

Insurance

Chemours insures for certain risks where permitted by law or regulation, including workers’ compensation, vehicle liability, and employee-related benefits. Liabilities associated with these risks are estimated in part by considering any historical claims experience, demographic factors, and other actuarial assumptions. For certain other risks, the Company uses a combination of third-party insurance and self-insurance, reflecting its comprehensive review of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable.

Litigation

Chemours accrues for legal matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation-related liabilities and expenditures included in the consolidated financial statements include legal matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Legal costs, such as outside counsel fees and expenses, are charged to expense in the period that services are rendered.

Environmental Liabilities and Expenditures

Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more-likely than any other, the lower end of the range has been used.

Estimated liabilities are determined based on existing remediation laws and technologies. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information becomes available.

Environmental liabilities and expenditures include claims for matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements executed prior to the Separation. Accrued liabilities are undiscounted and do not include claims against third-parties, and are included in other accrued liabilities and other liabilities on the consolidated balance sheets.

Costs related to environmental remediation are charged to expense in the period incurred as a component of the cost of goods sold in the consolidated statements of operations. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized.

Treasury Stock

Chemours accounts for repurchases of the Company’s common stock as treasury stock using the cost method, whereby the entire cost of the acquired common stock is recorded as treasury stock.

Stock-based Compensation

Chemours’ stock-based compensation consists of stock options, restricted stock units (“RSUs”), and performance share units (“PSUs”) awarded to employees and non-employee directors. Stock options and PSUs are measured at their fair value on the grant date or date of modification, as applicable. RSUs are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted as a reduction in stock-based compensation expense in the period such awards are forfeited.

Derivatives

In the ordinary course of business, Chemours enters into contractual arrangements (i.e., derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management, which currently includes the following risk management strategies: (i) foreign currency forward contracts, which are used to minimize the volatility in the Company’s earnings related to foreign exchange gains and losses resulting from remeasuring its monetary assets and liabilities that are denominated in non-functional currencies; (ii) foreign currency forward contracts, which are used to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of the Company’s international subsidiaries that use the euro as their functional currency; and, (iii) euro-denominated debt, which is used to reduce the volatility in stockholders’ equity resulting from changes in foreign currency exchange rates of the euro with respect to the U.S. dollar for certain of the Company’s international subsidiaries that use the euro as their functional currency. The Company’s derivative program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program operates within Chemours’ financial risk management policies and guidelines.

The Company’s foreign currency forward contracts that are used as a net monetary assets and liabilities hedge are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. For these instruments, any gains and losses resulting from the revaluation of derivative assets and liabilities are recognized in other income, net in the consolidated statements of operations during the period in which they occurred, and any such gains or losses are intended to be offset by any gains or losses on the underlying asset or liability. For the Company’s foreign currency forward contracts that have been entered under a cash flow hedge program, any gains and losses resulting from the revaluation of derivative assets and liabilities are recognized as a component of accumulated other comprehensive loss on the consolidated balance sheets during the period in which they occurred, and are reclassified to the cost of goods sold in the consolidated statements of operations during the period in which the underlying transactions affect earnings, or when it becomes probable that the forecasted transactions will not occur. Changes in the Company’s euro-denominated debt instruments due to remeasurement, which is designated as a net investment hedge, are included in accumulated other comprehensive loss on the consolidated balance sheets. Chemours’ uses the spot method to evaluate the effectiveness of its net investment hedge.

Derivative assets and liabilities are reported on a gross basis on the consolidated balance sheets.

Foreign Currency Translation

Chemours identifies its separate and distinct foreign entities and groups them into two categories: (i) extensions of the parent (U.S. dollar functional currency); and, (ii) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated, and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances clearly indicate that the functional currency has changed.

During the periods covered by the consolidated financial statements, part of Chemours’ business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, with the exception of inventories, prepaid expenses, property, plant, and equipment, goodwill, and other intangible assets. These aforementioned assets are remeasured at historical exchange rates. Foreign currency-denominated revenue and expense amounts are measured at exchange rates in effect during the period, with the exception of expenses related to any balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the consolidated statements of operations in the period in which they occurred.

For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates, and the resulting translation adjustments are reported as a component of accumulated other comprehensive loss on the consolidated balance sheets. Assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars, and the resulting exchange gains or losses are included in other income, net in the consolidated statements of operations in the period in which they occurred. Revenues and expenses are translated into U.S. dollars at average exchange rates in effect during the period.

Defined Benefit Plans

Due to local regulations outside of the U.S., Chemours has defined benefit plans covering certain of its employees. The benefits of these plans, which primarily relate to pension, are accrued over the employees’ service periods. The Company uses actuarial methods and assumptions in the valuation of its defined benefit obligations and the determination of any net periodic pension income or expense. Any differences between actual and expected results, or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur. Rather, they are systematically recognized over subsequent periods.

Fair Value Measurement

Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established to prioritize the valuation inputs used to measure fair value. The hierarchy gives highest priority to unadjusted, quoted prices in active markets for identical assets and liabilities (i.e., Level 1 measurements) and lowest priority to unobservable inputs (i.e., Level 3 measurements). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Chemours applies the following valuation hierarchy in measuring the fair values of its assets and liabilities:

Level 1 – Quoted prices in active markets for identical assets and liabilities;

Level 2 – Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and,

Level 3 – Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability.

Recent Accounting Pronouncements

Accounting Guidance Issued and Not Yet Adopted

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU No. 2016-02”), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities.

The provisions of ASU No. 2016-02 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. The Company plans to elect the package of practical expedients included in this guidance, which allows it to not reassess whether any expired or existing contracts contain leases, the lease classification for any expired or existing leases, and the initial direct costs for existing leases. The Company does not plan to recognize short-term leases on its consolidated balance sheets, and will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term.

In July 2018, the FASB issued ASU No. 2018-11, Leases – Targeted Improvements, as an update to the previously-issued guidance. This update added a transition option which allows for the recognition of a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption without recasting the financial statements in periods prior to adoption. The Company plans to elect this transition option.

At adoption, the Company expects to recognize a material increase in total assets and total liabilities resulting from the recognition of right-of-use assets and the related lease liabilities initially measured at the present value of its future operating lease payments. The Company continues to evaluate the impacts of adopting this guidance on its financial position, results of operations, and cash flows, and is updating its systems, processes, and internal controls to meet the new reporting and disclosure requirements in ASU No. 2016-02. The Company believes the most significant impact relates to its accounting for real estate leases. The adoption of this standard will have no impact on the Company’s covenant compliance under its current debt agreements.

Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU No. 2018-15”), which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Pursuant to the amendments, the Company, when acting as a customer to a cloud computing arrangement that is a service contract, is required to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU No. 2018-15 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. Upon adoption, the Company will have the option to elect whether it applies the amendments under ASU No. 2018-15 retrospectively, or prospectively to all implementation costs incurred after the date of adoption. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows.

Recently Adopted Accounting Guidance

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). The objective of this standard is to remove inconsistent practices with regard to revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard (collectively, “Topic 606”).

Effective January 1, 2018, Chemours adopted the new revenue recognition guidance contained in Topic 606 using the modified retrospective transition method. The Company elected to utilize a practical expedient allowed under the modified retrospective transition method to apply the new standard only to contracts that are not completed on the date of initial adoption. In applying this guidance, the Company evaluated its population of open contracts with customers on January 1, 2018 and determined that the impact of adopting Topic 606 was not material to its consolidated financial statements. No cumulative adjustment to the Company’s opening retained earnings balance was required. As a result of applying this new guidance, there are changes to the classification of certain amounts in the consolidated statements of operations. Certain royalty income amounts for trademark licensing arrangements that were previously reflected as a component of other income, net in the consolidated statements of operations are now reflected as a component of net sales, which amounted to $4 for the year ended December 31, 2018. Additionally, certain expenses related to the Company’s provision of technical services to customers that were previously reflected as a component of selling, general, and administrative expense in the consolidated statements of operations will now be reflected as a component of the cost of goods sold, which amounted to $2 for the year ended December 31, 2018. Under the modified retrospective transition method, the Company’s comparative financial information as of and for the years ended December 31, 2017 and 2016 has not been restated, and as such, continues to be reported using the accounting standards in effect during those time periods.

The following table sets forth the impacts of the adoption of Topic 606 on the Company’s consolidated statements of operations for the year ended December 31, 2018.

	Year Ended December 31, 2018
	Without			Topic 606
	Topic 606			Adjustments			As Reported
Net sales	$	6,634		$	4		$	6,638
Cost of goods sold		4,665			2			4,667
Gross profit		1,969			2			1,971
Selling, general, and administrative expense		659			(2	)		657
Research and development expense		82			—			82
Restructuring, asset-related, and other charges		49			—			49
Total other operating expenses		790			(2	)		788
Equity in earnings of affiliates		43			—			43
Interest expense, net		(195	)		—			(195	)
Loss on extinguishment of debt		(38	)		—			(38	)
Other income, net		166			(4	)		162
Income before income taxes		1,155			—			1,155
Provision for income taxes		159			—			159
Net income		996			—			996
Less: Net income attributable to non-controlling interests		1			—			1
Net income attributable to Chemours	$	995		$	—		$	995

Classification of Certain Cash Receipts and Cash Payments

In August 2016, the FASB issued various updates to ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU No. 2016-15”), which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The provisions of ASU No. 2016-15 are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and are to be applied using a retrospective transition method. The Company adopted ASU No. 2016-15 on January 1, 2018, the impact of which was not material to its cash flows. There were no adjustments to prior periods resulting from the retrospective application of this guidance.

Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU No. 2017-01”), which changes the definition of a business to assist entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. ASU No. 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2018, the result of which did not have a significant impact on its financial position, results of operations, or cash flows.

Retirement Benefits

In March 2017, the FASB issued ASU No. 2017-07, Compensation – Retirement Benefits (Topic 715) (“ASU No. 2017-07”), which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The provisions of ASU No. 2017-07 are effective for fiscal years beginning after December 31, 2017, as well as interim periods within those fiscal years, and should be applied (i) retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and (ii) prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. The Company adopted this guidance on January 1, 2018, which resulted in a reclassification of non-operating pension income from the operating expense captions of the consolidated statements of operations to other income, net for the years ended December 31, 2017 and 2016.

The following table sets forth a reclassification of the Company’s non-operating pension and other post-retirement employee benefit income for the years ended December 31, 2017 and 2016.

	Year Ended December 31, 2017									Year Ended December 31, 2016
	As Reported			Adjustments			As Reclassified			As Reported			Adjustments			As Reclassified
Net sales	$	6,183		$	—		$	6,183		$	5,400		$	—		$	5,400
Cost of goods sold		4,429			9			4,438			4,290			7			4,297
Gross profit		1,754			(9	)		1,745			1,110			(7	)		1,103
Selling, general, and administrative expense		602			24			626			934			12			946
Research and development expense		80			1			81			80			1			81
Restructuring, asset-related, and other charges		57			—			57			170			—			170
Total other operating expenses		739			25			764			1,184			13			1,197
Equity in earnings of affiliates		33			—			33			29			—			29
Interest expense, net		(214	)		—			(214	)		(219	)		—			(219	)
(Loss) gain on extinguishment of debt		(1	)		—			(1	)		6			—			6
Other income, net		79			34			113			247			20			267
Income (loss) before income taxes		912			—			912			(11	)		—			(11	)
Provision for (benefit from) income taxes		165			—			165			(18	)		—			(18	)
Net income		747			—			747			7			—			7
Less: Net income attributable to non-controlling interests		1			—			1			—			—			—
Net income attributable to Chemours	$	746		$	—		$	746		$	7		$	—		$	7

Derivatives and Hedging

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) (“ASU No. 2017-12”), which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The provisions of ASU No. 2017-12 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early adoption is permitted in any interim period. The amendments in this update are applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. The Company elected to adopt this guidance during the second quarter of 2018, the result of which did not have an impact on its financial position, results of operations, or cash flows.

Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU No. 2018-02”), which allows for a reclassification from accumulated other comprehensive income or loss to retained earnings for any stranded tax effects resulting from U.S. tax reform. The amendments in this update also require certain disclosures about stranded tax effects. ASU No. 2018-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted this guidance during the fourth quarter of 2018, which resulted in a reclassification of $9 from accumulated other comprehensive loss to retained earnings on the consolidated balance sheets.

Significant Transactions and Events

12 Months Ended

Dec. 31, 2018

Significant Transactions And Events [Abstract]

Significant Transactions and Events

Note 4. Significant Transactions and Events

Chemical Solutions Portfolio Optimization

In June 2016, the Company entered into an asset purchase agreement with Veolia North America, Inc. (“Veolia”), whereby Veolia agreed to acquire the Sulfur business of Chemours’ Chemical Solutions segment for a purchase price of $325 in cash, subject to customary working capital and other adjustments. $10 of the proceeds were received in May 2016. The Company completed the sale and, in July 2016, received the remaining proceeds of $311, net of working capital adjustments. Prior to the completion of the sale, in the second quarter of 2016, the Company recorded a pre-tax impairment loss of $58 as a component of restructuring, asset-related, and other charges in the consolidated statements of operations. Upon completion of the sale, the Company also recorded an additional pre-tax loss on sale of $4, net of a benefit from contractual adjustments in other income, net in the consolidated statements of operations.

In April 2016, the Company entered into a stock and asset purchase agreement with LANXESS Corporation (“LANXESS”), whereby LANXESS agreed to acquire the Clean & Disinfect (“C&D”) business of Chemours’ Chemical Solutions segment by acquiring certain of Chemours’ subsidiaries and assets for a purchase price of $230 in cash, subject to customary working capital and other adjustments. The Company completed the sale and, in August 2016, received proceeds of $223, net of working capital adjustments and $2 of cash transferred. For the year ended December 31, 2016, in connection with this sale, the Company recorded a pre-tax gain of $169 in other income, net in the consolidated statements of operations. The Company incurred $9 of transaction and other charges in connection therewith.

In November 2015, the Company signed a definitive agreement to sell its Aniline facility in Beaumont, Texas to Dow. The transaction closed in March 2016, and Chemours received $140 in cash from Dow. The Company incurred $11 of transaction and other charges in connection with this sale, and recognized a pre-tax gain of $89 for the year ended December 31, 2016, which was recorded in other income, net in the consolidated statements of operations.

Sale of Land in Linden, New Jersey

In March 2016, the Company entered into an agreement to sell a 210-acre plot of land that formerly housed a DuPont manufacturing site located in Linden, New Jersey. The land was assigned to Chemours in connection with the Separation, and the Company completed the sale in March 2018 for a gain of $42 and net cash proceeds of $39. As part of the sales agreement, the buyer agreed to assume certain costs associated with ongoing environmental remediation activities at the site amounting to $3, which have been reflected as a component of prepaid expenses and other on the consolidated balance sheets. Chemours remains responsible for certain other ongoing environmental remediation activities at the site, which were previously accrued as a component of other liabilities on the consolidated balance sheets.

Acquisition of ICOR International, Inc.

In April 2018, the Company, through its wholly-owned subsidiary, The Chemours Company FC, LLC, entered into a Stock Purchase Agreement (“SPA”) to acquire all of the outstanding stock of ICOR International, Inc. (“ICOR”), a closely-held private company that produces, sells, and distributes replacement refrigerant gases for use in commercial, industrial, and automotive refrigerant applications. Pursuant to the terms of the SPA, the Company paid $37 in total consideration at closing in the all-cash acquisition, which included customary working capital and other adjustments made within a specified time period. The acquisition of ICOR complements the Company’s existing portfolio of product offerings within the Fluoroproducts segment, as well as provides the Company with access to ICOR’s established customer base and assembled workforce.

The Company accounted for the acquisition of ICOR as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the consideration transferred over the fair value of the identifiable net assets acquired was recorded as goodwill within the Fluoroproducts segment, which represents the expected future benefits arising from the assembled workforce and other synergies to be realized from the acquisition of ICOR. The Company elected to treat the acquisition of ICOR as an asset acquisition under the Internal Revenue Code, and as such, expects that all of the related goodwill will be deductible for federal income tax purposes.

The following table sets forth the Company’s fair value estimates of the assets acquired and liabilities assumed in the acquisition of ICOR, which were finalized during the fourth quarter of 2018.

	Fair Value At Acquisition Date		Measurement Period Adjustments			Adjusted Fair Value		Weighted-average Useful Life (in Years)
Assets acquired:
Accounts receivable - trade	$	4	$	—		$	4
Inventories		8		—			8
Property, plant, and equipment		1		—			1
Identifiable intangible asset:
Customer relationships (1)		20		2			22		5
Total assets acquired		33		2			35
Liabilities assumed:
Accounts payable		1		—			1
Other accrued liabilities		1		—			1
Total liabilities assumed		2		—			2
Total identifiable net assets acquired		31		2			33
Goodwill (1)		6		(2	)		4
Net assets acquired	$	37	$	—		$	37

(1)

During the third quarter of 2018, the Company recorded a measurement period adjustment to its customer relationships based on an ongoing analysis associated with the preparation of a third-party appraisal.

The fair value of ICOR’s customer relationships was determined using the excess earnings method, which is a discounted cash flows approach. This method takes into account significant unobservable inputs and is a Level 3 fair value measurement within the fair value hierarchy. The use of this valuation methodology requires management to make various assumptions, including, but not limited to, assumptions about future profitability, cash flows, and discount rates applicable to the acquired business and, where applicable, market participants. These assumptions are based on management’s best estimates and include considerations related to management’s knowledge and experience, historical trends, general economic conditions, and other situational factors.

The Company’s consolidated financial statements include ICOR’s results of operations from April 2, 2018, the date of acquisition, through December 31, 2018. Net sales and net income attributable to Chemours contributed by ICOR during this period were not material to the Company’s or its Fluoroproducts segment’s results of operations. Acquisition-related expenses amounted to less than $1 at December 31, 2018, and are included as a component of selling, general, and administrative expense in the consolidated statements of operations.

Net Sales

12 Months Ended

Dec. 31, 2018

Revenue From Contract With Customer [Abstract]

Net Sales

Note 5. Net Sales

Disaggregation of Net Sales

The following table sets forth a disaggregation of the Company’s net sales by geographic region, product group, and segment for the year ended December 31, 2018.

	Year Ended December 31, 2018
			Chemical		Titanium
	Fluoroproducts		Solutions		Technologies		Total
Net sales by geographic region (1)
North America	$	1,143	$	341	$	894	$	2,378
Asia Pacific		675		81		964		1,720
Europe, the Middle East, and Africa		825		18		842		1,685
Latin America (2)		219		162		474		855
Total net sales	$	2,862	$	602	$	3,174	$	6,638

Net sales by product group
Fluorochemicals	$	1,497	$	—	$	—	$	1,497
Fluoropolymers		1,365		—		—		1,365
Mining solutions		—		289		—		289
Performance chemicals and intermediates		—		313		—		313
Titanium dioxide and other minerals		—		—		3,174		3,174
Total net sales	$	2,862	$	602	$	3,174	$	6,638

(1)

Net sales are attributable to countries based on customer location.

(2)

Latin America includes Mexico.

Substantially all of the Company’s net sales are derived from goods and services transferred at a point in time.

Contract Balances

The Company’s assets and liabilities from contracts with customers constitute accounts receivable - trade, deferred revenue, and customer rebates. An amount for accounts receivable - trade is recorded when the right to consideration under a contract becomes unconditional. An amount for deferred revenue is recorded when consideration is received prior to the conclusion that a contract exists, or when a customer transfers consideration prior to the Company satisfying its performance obligations under a contract. Customer rebates represent an expected refund liability to a customer based on a contract. In contracts with customers where a rebate is offered, it is generally applied retroactively based on the achievement of a certain sales threshold. As revenue is recognized, the Company estimates whether or not the sales threshold will be achieved to determine the amount of variable consideration to include in the transaction price.

The following table sets forth the Company’s contract balances from contracts with customers for the year ended December 31, 2018 and 2017.

	Year Ended December 31,
	2018		2017
Accounts receivable - trade, net (1)	$	790	$	847
Customer rebates		79		83

(1)

Accounts receivable - trade, net includes trade notes receivable, and is net of allowances for doubtful accounts of $5 at December 31, 2018 and 2017. Such allowances are equal to the estimated uncollectible amounts.

The Company’s deferred revenue balances at December 31, 2018 and 2017 were not significant. Additionally, changes in the Company’s deferred revenue balances resulting from additions for advance payments and deductions for amounts recognized in net sales during the year ended December 31, 2018 were not significant. For the year ended December 31, 2018, the amount of revenue recognized from performance obligations satisfied in prior periods (e.g., due to changes in transaction price) was not significant.

There were no other contract asset balances or capitalized costs associated with obtaining or fulfilling customer contracts at December 31, 2018.

Remaining Performance Obligations

Certain of the Company’s MSA or other arrangements contain take-or-pay clauses, whereby customers are required to purchase a fixed minimum quantity of product during a specified period, or pay the Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding performance obligations on contracts with an original expected duration greater than one year. At December 31, 2018, Chemours had $119 of remaining performance obligations. The Company expects to recognize approximately 35% of its remaining performance obligations as revenue in 2019, an approximate additional 45% in 2020, and the balance thereafter. The Company applies the practical expedient in Topic 606 and does not include remaining performance obligations that have original expected durations of one year or less, or amounts for variable consideration allocated to wholly-unsatisfied performance obligations or wholly-unsatisfied distinct goods that form part of a single performance obligation, if any. Amounts for contract renewals that are not yet exercised by December 31, 2018 are also excluded.

Research and Development Expense

12 Months Ended

Dec. 31, 2018

Research And Development [Abstract]

Research and Development Expense

Note 6. Research and Development Expense

The following table sets forth the Company’s R&D expense by segment for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Fluoroproducts	$	50	$	48	$	46
Chemical Solutions		2		3		7
Titanium Technologies		28		29		27
Corporate and Other		2		1		1
Total research and development expense	$	82	$	81	$	81

Restructuring, Asset-Related, and Other Charges

12 Months Ended

Dec. 31, 2018

Restructuring And Related Activities [Abstract]

Restructuring, Asset-Related, and Other Charges

Note 7. Restructuring, Asset-related, and Other Charges

The following table sets forth the components of the Company’s restructuring, asset-related, and other charges by category for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Restructuring and other charges:
Employee separation charges	$	14	$	23	$	4
Decommissioning and other charges		31		33		47
Total restructuring and other charges		45		56		51
Asset-related charges (1)		4		1		119
Total restructuring, asset-related, and other charges	$	49	$	57	$	170

(1)

Asset-related charges for the year ended December 31, 2018 included $4 for a pre-tax goodwill impairment charge in the Company’s Chemical Solutions segment. Asset-related charges for the year ended December 31, 2016 included $13 and $58 in pre-tax impairment charges related to the sales of the Company’s corporate headquarters building located in Wilmington, Delaware and its Sulfur business, respectively, and $48 in pre-tax impairment charges related to the Company’s Aniline facility in Pascagoula, Mississippi.

The following table sets forth the impacts of the Company’s restructuring, asset-related, and other charges to segment earnings for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Restructuring and other charges:
Plant and product line closures:
Fluoroproducts	$	—	$	3	$	7
Chemical Solutions		4		17		8
Titanium Technologies		—		4		30
Corporate and Other		9		—		—
Total plant and product line closures		13		24		45
2015 Global Restructuring Program:
Fluoroproducts		—		—		4
Titanium Technologies		—		—		2
Total 2015 Global Restructuring Program		—		—		6
2017 Restructuring Program:
Fluoroproducts		9		—		—
Chemical Solutions		2		—		—
Titanium Technologies		1		—		—
Corporate and Other		15		32		—
Total 2017 Restructuring Program		27		32		—
2018 Restructuring Program		5		—		—
Total restructuring and other charges		45		56		51
Asset-related charges:
Chemical Solutions		4		—		106
Corporate and Other		—		1		13
Total asset-related charges		4		1		119
Total restructuring, asset-related, and other charges	$	49	$	57	$	170

Plant and Product Line Closures

Fluoroproducts

In August 2015, in an effort to improve the profitability of the Company’s Fluoroproducts segment, management approved the closure of certain production lines in the segment’s U.S. manufacturing plants. For the years ended December 31, 2017 and 2016, the Company recorded additional decommissioning and dismantling-related charges of $3 and $7, respectively, for certain of these production lines. At December 31, 2017, the Company had substantially completed all actions related to the restructuring activities for certain of its production lines, which amounted to $17 in the aggregate, excluding asset-related charges.

Chemical Solutions

In the fourth quarter of 2015, the Company announced the completion of the strategic review of its Reactive Metals Solutions (“RMS”) business and management’s decision to stop production at its Niagara Falls, New York manufacturing plant. The RMS plant had approximately 200 employees and contractors impacted by this action, and production stopped at the plant in September 2016, when the Company immediately began actions to decommission the plant. The Company recorded additional decommissioning and dismantling-related charges of $4, $17, and $8 for the years ended December 31, 2018, 2017, and 2016, respectively. The Company expects to incur approximately $10 in additional restructuring charges for similar activities through 2021, which will be expensed as incurred. As of December 31, 2018, the Company incurred, in the aggregate, $35 in restructuring charges related to these activities, excluding asset-related charges.

Titanium Technologies

In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing plant. The Edge Moor plant produced TiO₂ pigment for use in the paper industry and certain other applications where demand had steadily declined, resulting in under-used capacity at the plant. In addition, the Company permanently closed one under-used TiO₂ pigment production line at its New Johnsonville, Tennessee plant. The Company stopped production at its Edge Moor plant in September 2015, and immediately began decommissioning the plant. For the years ended December 31, 2017 and 2016, the Company recorded additional decommissioning and dismantling-related charges of $4 and $30, respectively. The Company completed these activities in 2017, which amounted to $60 in the aggregate, excluding asset-related charges. The Company sold the land where the plant was located for $10 in the first quarter of 2017.

Corporate and Other

In the first quarter of 2018, the Company began a project to demolish and remove several dormant, unused buildings at its Chambers Works site in Deepwater, New Jersey, which were assigned to Chemours in connection with the Separation. For the year ended December 31, 2018, the Company incurred $9 in decommissioning and dismantling-related charges associated with these efforts. The Company expects to incur approximately $20 to $25 in additional restructuring charges related to its Chambers Works site through the end of 2020, which will be reflected in Corporate and Other, and will be expensed as incurred.

2015 Global Restructuring Program

In the fourth quarter of 2015, the Company announced a global workforce reduction impacting approximately 430 positions. This action was part of the Company’s efforts to streamline and simplify the structure of its worldwide organization, and to reduce costs. The associated headcount reductions were completed during the year ended December 31, 2016, and the Company recognized an additional $6 in employee separation charges for these efforts.

2017 Restructuring Program

In 2017, the Company initiated certain restructuring activities designed to further the cost savings and productivity improvements outlined under management’s transformation plan. These activities include, among other efforts: (i) outsourcing and further centralizing certain business process activities; (ii) consolidating existing, outsourced third-party information technology (“IT”) providers; and, (iii) implementing various upgrades to the Company’s current IT infrastructure. In connection with these corporate function efforts, the Company recorded $18 and $14 in restructuring-related charges for years ended December 31, 2018 and 2017, respectively.

In October 2017, the Company also announced a voluntary separation program (“VSP”) for certain eligible U.S. employees in an effort to better manage the anticipated future changes to its workforce. Employees who volunteered for and were accepted under the VSP were entitled to receive certain financial incentives above the Company’s customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Approximately 300 employees separated from the Company through the end of 2018. An accrual representing the majority of these termination benefits, amounting to $18, was recognized in the fourth quarter of 2017. The remaining incremental, one-time financial incentives under the VSP were recognized over the period each participating employee continued to provide service to Chemours, and amounted to $9.

The Company recorded charges of $27 and $32 for the years ended December 31, 2018 and 2017, respectively, for its 2017 program. The cumulative amount incurred, in the aggregate, for the Company’s 2017 program amounted to $59 at December 31, 2018. The Company has substantially completed all actions related to this program, and the remaining amounts accrued as of December 31, 2018 are expected to be paid out in the first half of 2019.

2018 Restructuring Program

In the fourth quarter of 2018, management initiated a restructuring program of the Company’s corporate functions and recorded the related estimated severance costs of $5. The program is expected to be completed in the first half of 2019.

The following table sets forth the change in the Company’s employee separation-related liabilities associated with its restructuring programs for the years ended December 31, 2018 and 2017.

	Fluoroproducts Line Shutdown			Chemical Solutions Site Closures			Titanium Technologies Site Closures			2015 Global Restructuring Program			2017 Restructuring Program			2018 Restructuring Program		Total
Balance at January 1, 2017	$	1		$	8		$	4		$	21		$	—		$	—	$	34
Charges to income		—			—			—			1			23			—		24
Payments		(1	)		(6	)		(3	)		(21	)		—			—		(31	)
Balance at December 31, 2017		—			2			1			1			23			—		27
Charges to income		—			—			—			—			9			5		14
Payments		—			(2	)		(1	)		—			(22	)		—		(25	)
Balance at December 31, 2018	$	—		$	—		$	—		$	1		$	10		$	5	$	16

At December 31, 2018 and 2017, there are no significant outstanding liabilities related to the Company’s decommissioning and other restructuring-related charges.

Other Income, Net

12 Months Ended

Dec. 31, 2018

Other Income And Expenses [Abstract]

Other Income, Net

Note 8. Other Income, Net

The following table sets forth the components of the Company’s other income, net for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Leasing, contract services, and miscellaneous income (1)	$	79	$	30	$	35
Royalty income (2)		10		24		15
Gain on sales of assets and businesses (3)		45		22		254
Exchange gains (losses), net (4)		1		3		(57	)
Non-operating pension and other post-retirement employee benefit income		27		34		20
Total other income, net	$	162	$	113	$	267

(1)

Leasing, contract services, and miscellaneous income includes European Union fluorinated greenhouse gas quota authorization sales of $67, $15, and $6 for the years ended December 31, 2018, 2017, and 2016, respectively.

(2)

Royalty income for the year ended December 31, 2018 is primarily from technology licensing. Royalty income for the years ended December 31, 2017 and 2016 is primarily from technology and trademark licensing.

(3)

For the year ended December 31, 2018, gain on sale includes a $3 gain and a $42 gain associated with the sales of the Company’s East Chicago, Indiana and Linden, New Jersey sites, respectively. For the year ended December 31, 2017, gain on sale includes a gain of $13 associated with the sale of the Company’s land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, and a $12 gain associated with the sale of the Company’s Edge Moor, Delaware plant site, net of certain losses on other disposals. For the year ended December 31, 2016, gain on sale includes gains of $169 and $89 associated with the sales of the Company’s C&D business and its Aniline facility in Beaumont, Texas, respectively.

(4)

Exchange gains (losses), net includes gains and losses on the Company’s foreign currency forward contracts that have not been designated as a cash flow hedge.

Income Taxes

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Income Taxes

Note 9. Income Taxes

The following table sets forth the components of the Company’s provision for (benefit from) income taxes for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Current tax expense (benefit):
U.S. federal	$	23		$	(8	)	$	—
U.S. state and local		4			1			—
International		110			89			93
Total current tax expense		137			82			93
Deferred tax expense (benefit):
U.S. federal		20			60			(101	)
U.S. state and local		3			6			(17	)
International		(1	)		17			7
Total deferred tax expense (benefit)		22			83			(111	)
Total provision for (benefit from) income taxes	$	159		$	165		$	(18	)

The following table sets forth the components of the Company’s deferred tax assets and liabilities at December 31, 2018 and 2017.

	December 31,
	2018			2017
Deferred tax assets:
Environmental and other reserves	$	80		$	89
Litigation reserves		28			14
Stock-based compensation and accrued employee benefits		28			26
Other assets and other accrued liabilities		8			8
Tax attribute carryforwards		29			27
Foreign tax credit carryforwards		18			17
Total deferred tax assets		191			181
Less: Valuation allowance		(2	)		(17	)
Total deferred tax assets, net		189			164
Deferred tax liabilities:
Pension and other liabilities		(35	)		(55	)
Property, plant, and equipment		(313	)		(274	)
Inventories and other assets		(12	)		(4	)
Total deferred tax liabilities		(360	)		(333	)
Deferred tax liability, net	$	(171	)	$	(169	)

The following table sets forth an analysis of the Company’s effective tax rates for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018						2017						2016
	$			%			$			%			$			%
Statutory U.S. federal income tax rate	$	243			21.0	%	$	319			35.0	%	$	(4	)		35.0	%
State income taxes, net of federal benefit		7			0.6	%		7			0.7	%		(16	)		150.4	%
Lower effective tax rate on international operations, net		(44	)		(3.8	)%		(149	)		(16.3	)%		(61	)		552.5	%
Depletion		(6	)		(0.5	)%		(8	)		(0.9	)%		(6	)		51.2	%
Goodwill		—			—	%		—			—	%		5			(47.9	)%
Exchange losses (gains)		(4	)		(0.3	)%		5			0.6	%		4			(39.1	)%
Provision to return and other adjustments		(9	)		(0.8	)%		6			0.6	%		6			(57.9	)%
Permanent items		12			1.0	%		9			1.0	%		3			(27.3	)%
Valuation allowance		(15	)		(1.3	)%		(33	)		(3.6	)%		50			(451.6	)%
Net impact of U.S. tax reform		(10	)		(0.9	)%		39			4.3	%		—			(—	)%
Stock-based compensation		(14	)		(1.2	)%		(20	)		(2.2	)%		—			(—	)%
Other, net		(1	)		—	%		(10	)		(1.1	)%		1			(1.7	)%
Total effective tax rate	$	159			13.8	%	$	165			18.1	%	$	(18	)		163.6	%

The following table sets forth the Company’s income (loss) before income taxes for its U.S. and international operations for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017			2016
U.S. operations (including exports)	$	114	$	(306	)	$	(481	)
International operations		1,041		1,218			470
Total income (loss) before income taxes	$	1,155	$	912		$	(11	)

U.S. Tax Reform

On December 22, 2017, the U.S. government enacted comprehensive tax legislation, commonly referred to as U.S. tax reform. U.S. tax reform makes broad and complex changes to the U.S. tax code, including, but not limited to: (i) reducing the U.S. federal corporate tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (vi) creating the Base Erosion Anti-abuse Tax (“BEAT”), a new minimum tax; (vi) creating a new limitation on the deductible interest expense; and, (vii) the creation of the Global Intangibles Low-taxed Income (“GILTI”) inclusions.

The Deemed Repatriation Transition Tax (the “Transition Tax”) is a tax on previously untaxed accumulated and current earnings and profits (“E&P”) of certain of the Company’s foreign subsidiaries. The Company has determined, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings in order to compute its one-time Transition Tax.

U.S. tax reform created a new requirement that certain income (i.e., GILTI) earned by controlled foreign corporations (“CFCs”) must be included currently in the gross income of the CFCs’ U.S. shareholder. GILTI is the excess of the shareholder’s net CFC-tested income over the net deemed tangible income return, which is currently defined as the excess of (i) 10% of the aggregate of the U.S. shareholder’s pro rata share of the qualified business asset investment of each CFC “routine return” with respect to which it is a U.S. shareholder over, (ii) the amount of certain interest expense taken into account in the determination of net CFC-tested income. The Company has elected to treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (i.e., the period cost method).

In 2017, the Company recorded provisional estimates for U.S. tax reform in its provision for income taxes, which amounted to a net benefit of $3. Staff Accounting Bulletin No. 118 (“SAB No. 118”) issued by the U.S. Securities and Exchange Commission (“SEC”) allowed registrants to record provisional estimates for U.S. tax reform during a measurement period not to exceed one year from the enactment date, which was December 22, 2017. In September 2018, the Company recorded a $10 tax benefit to adjust its initial provisional estimates for U.S. tax reform in its provision for income taxes, which reduced the effective tax rate by 1% for the year ended December 31, 2018. The adjustment was specifically related to changes to certain deferred tax assets and liabilities upon filing of the Company’s 2017 tax return, which impacted the Company’s initial estimate of the revaluation of these deferred tax assets and liabilities as a result of the reduced corporate tax rate, the Transition Tax on previously untaxed accumulated and current E&P of certain of the Company’s foreign subsidiaries, and the associated foreign tax credits.

While management has completed its analysis within the applicable measurement period, pursuant to SAB No. 118, the Company is accounting for the tax impact of U.S. tax reform’s provisions based on an interpretation of existing statutory law, including guidance issued by the U.S. Treasury and the Internal Revenue Service (“IRS”). During the second half of 2018, the U.S. Treasury and the IRS issued certain proposed regulations addressing new provisions such as GILTI, BEAT, Limitation of Deduction of Business Interest, Foreign Tax Credit, and the Anti-hybrid Regulations. On January 15, 2019, the final Section 965 Toll Charge regulations were issued. While there can be no assurances as to the effect of any final regulations on the Company’s income tax provision, management will continue to evaluate the impact as any regulations issued become final.

At December 31, 2018, management believed that sufficient liquidity was available in the U.S. As a result, the Company is indefinitely reinvested with respect to the historical unremitted pre-2018 E&P of its foreign subsidiaries, which was approximately $550 at December 31, 2018. Management asserts that it is indefinitely reinvested with respect to current year earnings from several foreign subsidiaries, and therefore, has not recorded deferred tax liabilities with respect to those earnings. At December 31, 2018, deferred tax liabilities for foreign subsidiaries that are not indefinitely reinvested were not material to the Company’s consolidated financial statements. The potential tax implications of the repatriation of unremitted E&P are driven by the facts at the time of distribution; however, due to U.S. tax reform and the U.S. Transition Tax, the incremental cost to repatriate E&P is not expected to be material if a distribution is made in the future as there are minimal foreign withholding taxes in the applicable foreign jurisdictions.

Other Matters

For the year ended December 31, 2018, the Company released $15 of valuation allowance on its foreign tax credits, which was the result of additional guidance issued by the U.S. Treasury during 2018 with respect to foreign tax credits. The valuation allowance release represents the amount of foreign tax credit carryforwards that are expected to be utilized before they begin to expire in 2026.

Under the tax laws of various jurisdictions in which the Company operates, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward or back, subject to statutory limitations, to reduce taxable income or taxes payable in future or prior years. At December 31, 2018, the Company’s U.S federal and state tax losses amounted to $6, which substantially expire between 2036 and 2038. The Company also had U.S. foreign tax credit carryforwards of $18, which expire in 2026, and $13 in R&D tax credits, which expire in 2035. Lastly, the Company had foreign net operating losses of $3, which substantially expire between 2026 and 2029.

Each year, Chemours and/or its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions.

The following table sets forth the Company’s significant jurisdictions’ tax returns that are subject to examination by their respective taxing authorities for the open years listed.

Jurisdiction		Open Years
China		2014 through 2018
Mexico		2012 through 2018
Netherlands		2015 through 2018
Singapore		2015 through 2018
Switzerland		2015 through 2018
Taiwan		2015 through 2018
U.S.		2015 through 2018

Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the tax matters agreement. As a result, income tax uncertainties are recognized in the Company’s consolidated financial statements in accordance with accounting for income taxes, when applicable.

The following table sets forth the change in the Company’s unrecognized tax benefits for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017			2016
Balance at January 1,	$	—	$	6		$	7
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		—		(6	)		(1	)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		2		—			—
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations		—		—			—
Balance at December 31,	$	2	$	—		$	6

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	2	$	—		$	—
Total amount of interest and penalties recognized in the consolidated statements of operations		—		—			—
Total amount of interest and penalties recognized in the consolidated balance sheets		—		—			—

The following table sets forth a rollforward of the Company’s deferred tax asset valuation allowance for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Balance at January 1,	$	17		$	50		$	—
Net charges to income tax expense		—			—			50
Release of valuation allowance		(15	)		(33	)		—
Balance at December 31,	$	2		$	17		$	50

Earnings Per Share of Common Stock

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

Note 10. Earnings Per Share of Common Stock

The following table sets forth reconciliations of the numerators and denominators for the Company’s basic and diluted earnings per share calculations for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Numerator:
Net income attributable to Chemours	$	995	$	746	$	7
Denominator:
Weighted-average number of common shares outstanding - basic		176,968,554		184,844,106		181,621,422
Dilutive effect of the Company’s employee compensation plans		5,603,467		6,139,885		1,795,078
Weighted-average number of common shares outstanding - diluted		182,572,021		190,983,991		183,416,500

Basic earnings per share of common stock	$	5.62	$	4.04	$	0.04
Diluted earnings per share of common stock		5.45		3.91		0.04

The following table sets forth the average number of stock options that were anti-dilutive and, therefore, were not included in the Company’s diluted earnings per share calculations for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Average number of stock options		393,016		43,072		5,820,499

Accounts and Notes Receivable, Net

12 Months Ended

Dec. 31, 2018

Receivables [Abstract]

Accounts and Notes Receivable, Net

Note 11. Accounts and Notes Receivable, Net

The following table sets forth the components of the Company’s accounts and notes receivable, net at December 31, 2018 and 2017.

	December 31,
	2018		2017
Accounts receivable - trade, net (1)	$	790	$	847
VAT, GST, and other taxes (2)		56		54
Other receivables (3)		15		18
Total accounts and notes receivable, net	$	861	$	919

(1)

Accounts receivable - trade, net includes trade notes receivable of $2 and less than $1 at December 31, 2018 and 2017, respectively, and is net of allowances for doubtful accounts of $5 at December 31, 2018 and 2017. Such allowances are equal to the estimated uncollectible amounts.

(2)

Value added tax (“VAT”) and goods and services tax (“GST”) for various jurisdictions.

(3)

Other receivables consist of notes receivable, advances, the fair value of derivative assets, and other deposits.

Accounts and notes receivable are carried at amounts that approximate their fair values. Bad debt expense amounted to less than $1, $1, and $7 for the years ended December 31, 2018, 2017, and 2016, respectively.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2018

Inventory Net [Abstract]

Inventories

Note 12. Inventories

The following table sets forth the components of the Company’s inventories at December 31, 2018 and 2017.

	December 31,
	2018			2017
Finished products	$	701		$	648
Semi-finished products		195			164
Raw materials, stores, and supplies		476			313
Inventories before LIFO adjustment		1,372			1,125
Less: Adjustment of inventories to LIFO basis		(225	)		(190	)
Total inventories	$	1,147		$	935

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all U.S. locations, which comprised $622 and $509 (or 45%) of inventories before the LIFO adjustments at December 31, 2018 and 2017. The remainder of the Company’s inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment, Net

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Property, Plant, and Equipment, Net

Note 13. Property, Plant, and Equipment, Net

The following table sets forth the components of the Company’s property, plant, and equipment, net at December 31, 2018 and 2017.

	December 31,
	2018			2017
Equipment	$	7,344		$	6,961
Buildings		914			875
Construction-in-progress		579			520
Land		119			119
Mineral rights		36			36
Property, plant, and equipment		8,992			8,511
Less: Accumulated depreciation		(5,701	)		(5,503	)
Total property, plant, and equipment, net	$	3,291		$	3,008

Depreciation expense amounted to $276, $269, and $281 for the years ended December 31, 2018, 2017, and 2016, respectively. Property, plant, and equipment, net included gross assets under capital leases of $7 at December 31, 2018 and 2017, and a build-to-suit lease asset of $55 and $8 at December 31, 2018 and 2017, respectively. Interest expense capitalized as part of property, plant, and equipment, net amounted to $17, $9, and $18 for the years ended December 31, 2018, 2017, and 2016, respectively.

See “Note 19 – Debt” for further discussion regarding the Company’s build-to-suit lease arrangement.

Goodwill and Other Intangible Assets, Net

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

Note 14. Goodwill and Other Intangible Assets, Net

Goodwill

The following table sets forth the changes in the carrying amount of the Company’s goodwill by segment for the years ended December 31, 2018 and 2017.

	December 31,
	2018			2017
Fluoroproducts:
Balance at January 1,	$	85		$	85
Acquisition of business		4			—
Balance at December 31,		89			85
Chemical Solutions:
Balance at January 1,		55			55
Goodwill impairment		(4	)		—
Balance at December 31,		51			55
Titanium Technologies:
Balance at January 1,		13			13
Balance at December 31,		13			13
Total goodwill	$	153		$	153

Chemours consists of three operating segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Company defines its reporting units as one level below these operating segments, with the exception of the Titanium Technologies segment, which is both an operating segment and a reporting unit. The Company tested the goodwill balances attributable to each of its reporting units for potential impairment on October 1, 2018 and 2017, the dates of Chemours’ annual goodwill assessment, and concluded that $4 of goodwill associated with the Performance Chemicals and Intermediates reporting unit in the Chemical Solutions segment was impaired at October 1, 2018. No further goodwill impairments were recorded for the years ended December 31, 2018 and 2017, as the fair values of the Company’s other reporting units that carry goodwill exceeded each respective reporting unit’s carrying amount on October 1, 2018 and 2017.

The total accumulated impairment losses included in the Company’s goodwill balance at December 31, 2018 amounted to $4. There were no accumulated impairment losses included in the Company’s goodwill balance at December 31, 2017.

Other Intangible Assets, Net

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s other intangible assets by major class at December 31, 2018 and 2017.

	December 31, 2018							December 31, 2017
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(8	)	$	1	$	9	$	(8	)	$	1
Customer relationships		22		(3	)		19		—		—			—
Patents		19		(19	)		—		19		(18	)		1
Purchased trademarks		5		(3	)		2		5		(2	)		3
Purchased and licensed technology		3		(3	)		—		3		(2	)		1
Other (1)		10		(4	)		6		10		(3	)		7
Total other intangible assets, net	$	68	$	(40	)	$	28	$	46	$	(33	)	$	13

(1)

Represents non-cash favorable supply contracts acquired in connection with the sale of the Sulfur business and recognized during the third quarter of 2016 based on the present value of the difference between their contractual cash flows and estimated cash flows had the contracts been executed at a determinable market price. These contract intangibles will be amortized to cost of goods sold over the remaining life of the supply contracts through 2021.

The aggregate pre-tax amortization expense for definite-lived intangible assets was $6, $4, and $3 for the years ended December 31, 2018, 2017, and 2016, respectively. The estimated aggregate pre-tax amortization expense for 2019, 2020, 2021, 2022, and 2023 is $7, $7, $7, $5, and $1, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. The Company does not have any indefinite-lived intangible assets.

Investments in Affiliates

12 Months Ended

Dec. 31, 2018

Equity Method Investments And Joint Ventures [Abstract]

Investments in Affiliates

Note 15. Investments in Affiliates

The Company holds investments in companies where it, directly or indirectly, owns 20% to 50% of the voting stock, or has the ability to exercise significant influence over the operating and financial policies of the investee.

The following table sets forth the carrying value, jurisdiction, and ownership percentages of the Company’s investments in affiliates at December 31, 2018 and 2017.

		December 31, 2018			December 31, 2017
Investee	Jurisdiction	Carrying Value		Ownership	Carrying Value		Ownership
Chemours-Mitsui Fluorochemicals Company, Ltd.	Japan	$	94	50.0%	$	112	50.0%
The Chemours Chenguang Fluoromaterials Company Limited	China		36	50.0%		36	50.0%
Changshu 3F Zhonghao New Chemical Materials Co., Ltd.	China		30	10.0%		25	10.0%
		$	160		$	173

The following table sets forth the changes in the Company’s investments in affiliates for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017		2016
Balance at January 1,	$	173		$	136	$	136
Equity in earnings of affiliates		43			33		29
Investments in affiliates		—			—		1
Dividends		(58	)		—		(18	)
Divestment		—			—		(12	)
Currency translation and other		2			4		—
Balance at December 31,	$	160		$	173	$	136

The Company engages in transactions with its equity method investees in the ordinary course of business. For the years ended December 31, 2018, 2017, and 2016, net sales to the Company’s equity method investees amounted to $143, $99, and $70, respectively, and purchases from the Company’s equity method investees amounted to $125, $87, and $97, respectively.

Other Assets

12 Months Ended

Dec. 31, 2018

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Assets

Note 16. Other Assets

The following table sets forth the components of the Company’s other assets at December 31, 2018 and 2017.

	December 31,
	2018		2017
Capitalized repair and maintenance costs	$	178	$	117
Pension assets (1)		174		260
Deferred income taxes		46		40
Miscellaneous		39		36
Total other assets	$	437	$	453

(1)

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

Accounts Payable

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Accounts Payable

Note 17. Accounts Payable

The following table sets forth the components of the Company’s accounts payable at December 31, 2018 and 2017.

	December 31,
	2018		2017
Trade payables	$	1,111	$	1,008
Dividends payable		—		31
VAT and other payables		26		36
Total accounts payable	$	1,137	$	1,075

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Other Accrued Liabilities

Note 18. Other Accrued Liabilities

The following table sets forth the components of the Company’s other accrued liabilities at December 31, 2018 and 2017.

	December 31,
	2018		2017
Compensation and other employee-related costs	$	108	$	174
Employee separation costs (1)		16		27
Accrued litigation (2)		76		13
Environmental remediation (2)		74		66
Income taxes		87		58
Customer rebates		79		83
Deferred income		6		8
Accrued interest		21		24
Miscellaneous (3)		92		105
Total other accrued liabilities	$	559	$	558

(1)

Represents the current portion of accrued employee separation costs related to the Company’s restructuring and other activities.

(2)

Represents the current portion of accrued litigation and environmental remediation, which are discussed further in “Note 21 – Commitments and Contingent Liabilities.”

(3)

Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, the current portion of the Company’s asset retirement obligations, and other miscellaneous expenses.

Debt

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Debt

Note 19. Debt

The following table sets forth the components of the Company’s debt at December 31, 2018 and 2017.

	December 31,
	2018			2017
Senior secured term loans:
Tranche B-1 Dollar Term Loan due May 2022	$	—		$	923
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		—			469
Tranche B-2 Dollar Term Loan due May 2025		893			—
Tranche B-2 Euro Term Loan due May 2025 (€347 at December 31, 2018)		396			—
Senior unsecured notes:
6.625% due May 2023		908			1,158
7.000% due May 2025		750			750
6.125% due May 2023 (€295 at December 31, 2017)		—			350
4.000% due May 2026 (€450 at December 31, 2018)		513			—
5.375% due May 2027		500			500
Capital lease obligations		2			3
Build-to-suit lease obligation		55			8
Total debt		4,017			4,161
Less: Unamortized issue discounts		(10	)		(8	)
Less: Unamortized debt issuance costs		(35	)		(41	)
Less: Current maturities of long-term debt		(13	)		(15	)
Total long-term debt, net	$	3,959		$	4,097

Senior Secured Credit Facilities

On April 3, 2017, the Company completed an amendment to its then-existing credit agreement which provided for a seven-year, senior secured term loan facility and a five-year, $750 senior secured revolving credit facility (“Prior Revolving Credit Facility”) (collectively, the “Prior Senior Secured Credit Facilities”). The senior secured term loan facility under the Prior Senior Secured Credit Facilities provided for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of $940 (“Prior Dollar Term Loan”) and a class of term loans, denominated in euros, in an aggregate principal amount of €400 (“Prior Euro Term Loan”) (collectively, the “Prior Term Loans”). On April 3, 2018, the Company entered into an amended and restated credit agreement that provides for a seven-year, senior secured term loan facility and a five-year, $800 senior secured revolving credit facility (“New Revolving Credit Facility”) (collectively, the “New Senior Secured Credit Facilities”). The New Senior Secured Credit Facilities replaced, in full, the Company’s obligations under the Prior Senior Secured Credit Facilities, and is subject to a springing maturity in the event that the senior unsecured notes due in May 2023 are not redeemed, repaid, modified, and/or refinanced within the 91-day period prior to their maturity date.

The senior secured term loan facility under the New Senior Secured Credit Facilities provides for a class of term loans, denominated in U.S. dollars, in an aggregate principal amount of $900 (“New Dollar Term Loan”) and a class of term loans, denominated in euros, in an aggregate principal amount of €350 (“New Euro Term Loan”) (collectively, the “New Term Loans”). The proceeds of the New Term Loans, together with cash on hand, were primarily used to prepay, in full, all outstanding amounts under the Prior Senior Secured Credit Facilities, which amounted to $921 for the Prior Dollar Term Loan and €393 for the Prior Euro Term Loan. The New Dollar Term Loan bears a variable interest rate equal to, at the election of the Company, adjusted LIBOR plus 1.75% or adjusted base rate plus 0.75%, subject to an adjusted LIBOR or an adjusted base rate floor of 0.00% or 1.00%, respectively. The New Euro Term Loan bears a variable interest rate equal to adjusted EURIBOR plus 2.00%, subject to an adjusted EURIBOR floor of 0.50%. The New Term Loans will mature on April 3, 2025, and are subject to acceleration in certain circumstances.

The proceeds of any loans made under the New Revolving Credit Facility can be used for working capital needs and other general corporate purposes, including permitted acquisitions, as defined in the amended and restated credit agreement. The New Revolving Credit Facility bears a variable interest rate range based on the Company’s total net leverage ratio, as defined in the amended and restated credit agreement, between (i) a 0.25% and a 1.00% spread for adjusted base rate loans, and (ii) a 1.25% and a 2.00% spread for LIBOR and EURIBOR loans. In addition, the Company is required to pay a commitment fee on the average daily unused amount of the New Revolving Credit Facility within an interest rate range based on its total net leverage ratio, between 0.10% and 0.25%. The New Revolving Credit Facility will mature on April 3, 2023, and is subject to acceleration in certain circumstances.

There were no borrowings under the New Revolving Credit Facility at December 31, 2018 or under the Prior Revolving Credit Facility at December 31, 2017. Issued and outstanding letters of credit under the New Revolving Credit Facility amounted to $104 at December 31, 2018. Issued and outstanding letters of credit under the Prior Revolving Credit Facility amounted to $101 at December 31, 2017. At December 31, 2018, the effective interest rates on the New Dollar Term Loan and the New Euro Term Loan were 4.28% and 2.50%, respectively, and commitment fees on the New Revolving Credit Facility were assessed at a rate of 0.10% per annum. In connection with the issuance of the New Senior Secured Credit Facilities, the Company incurred a loss on debt extinguishment of $3 for the year ended December 31, 2018.

The amended and restated credit agreement also modified or eliminated certain provisions of the Company’s prior credit agreement, including the interest coverage ratio financial covenant and certain other negative covenants to allow for further flexibility. Under the amended and restated credit agreement, solely with respect to the New Revolving Credit Facility, the Company is required to not exceed a maximum senior secured net leverage ratio of (i) 2.25 to 1.00 for the quarter December 31, 2018, and (ii) 2.00 to 1.00 in each quarter beginning January 1, 2019, through the date of maturity. In addition, the amended and restated credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict the Company’s and its subsidiaries’ ability, subject to certain exceptions, to incur additional indebtedness or liens, pay dividends, and engage in certain transactions, including mergers, acquisitions, asset sales, or investments, outside of specified carve-outs. The amended and restated credit agreement also contains customary representations and warranties and events of default, which are substantially similar to those in the prior credit agreement. The Company was in compliance with its debt covenants at December 31, 2018 and 2017.

The Company’s obligations under the New Senior Secured Credit Facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, which are also guarantors of the Company’s outstanding notes, subject to certain exceptions. The obligations under the New Senior Secured Credit Facilities are also, subject to certain exceptions, secured by a first priority lien on substantially all of the Company’s assets and substantially all of the assets of its wholly-owned, material domestic subsidiaries, including 100% of the stock of certain of its domestic subsidiaries and 65% of the stock of certain of its foreign subsidiaries.

Senior Unsecured Notes

Senior Unsecured Notes due May 2023 and May 2025

On May 12, 2015, Chemours issued an aggregate principal amount of $2,503 in senior unsecured notes consisting of an aggregate principal amount of $1,350 6.625% senior unsecured notes due May 2023, denominated in U.S. dollars (the “2023 Dollar Notes”), an aggregate principal amount of €360 6.125% senior unsecured notes due May 2023, denominated in euros (the “2023 Euro Notes”), and an aggregate principal amount of $750 7.000% senior unsecured notes due May 2025, denominated in U.S dollars (the “2025 Notes) (collectively, the “Original Notes”). As discussed in more detail below, the Company purchased or redeemed, as applicable, all of the outstanding 2023 Euro Notes and a $250 aggregate principal amount of the 2023 Dollar Notes. The Original Notes required or require, as applicable, payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and September 15 of each year. The proceeds from the Original Notes were issued to fund a cash distribution to DuPont in connection with the Separation.

The Original Notes were or are, as applicable, fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, by each of Chemours’ existing and future direct or indirect domestic restricted subsidiaries that (i) incurs or guarantees indebtedness under the New Senior Secured Credit Facilities, or (ii) guarantees certain other indebtedness of the Company or any guarantor in an aggregate principal amount in excess of $75. The Original Notes were or are, as applicable, unsecured and unsubordinated by Chemours and its guarantor subsidiaries. The Original Notes ranked or rank, as applicable, equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and senior in right of payment to all of its existing and future debt that is by its terms expressly subordinated in right of payment to the Original Notes. The Original Notes were or are, as applicable, subordinated to indebtedness under the New Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt.

Pursuant to the terms of the indenture governing the Original Notes, the Company was or is, as applicable, obligated to offer to purchase the Original Notes at a price of (i) 101% of their principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events, and (ii) 100% of their principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, with the proceeds from certain asset dispositions. These restrictions and prohibitions were or are, as applicable, subject to certain qualifications and exceptions set forth in the indenture governing the Original Notes, including without limitation, reinvestment rights with respect to the proceeds of asset dispositions.

Chemours is permitted to currently redeem some or all of the 2023 Dollar Notes at specified redemption prices, and may redeem some or all of the 2025 Notes on or after May 15, 2020 at specified redemption prices. Chemours may also redeem some or all of the 2023 Dollar Notes or the 2025 Notes by means other than a redemption, including tender offer or open market purchases. Pursuant to the terms of the tax matters agreement entered into at the time of the Separation, the Company’s ability to pre-pay, pay down, redeem, retire, or otherwise acquire the 2025 Notes is limited in the absence of obtaining certain tax opinions.

Senior Unsecured Notes Due May 2027

On May 23, 2017, Chemours issued a $500 aggregate principal amount of 5.375% senior unsecured notes due May 2027 (the “2027 Notes”). The 2027 Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year. The Company received proceeds of $489, net of an original issue discount of $5 and underwriting fees and other related expenses of $6, which are deferred and amortized to interest expense using the effective interest method over the term of the 2027 Notes. A portion of the net proceeds from the 2027 Notes was used to pay the $335 accrued for the global settlement of the multi-district “PFOA MDL Settlement,” as discussed in “Note 21 – Commitments and Contingent Liabilities.” The remaining proceeds from the 2027 Notes were available for general corporate purposes.

The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis by each of Chemours’ existing and future direct and indirect domestic restricted subsidiaries that (i) incurs or guarantees indebtedness under the New Senior Secured Credit Facilities, or (ii) guarantees certain other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $100. The guarantees of the 2027 Notes will rank equally with all other senior indebtedness of the guarantors. The 2027 Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and are senior in right of payment to all of its existing and future debt that is by its terms expressly subordinated in right of payment to the 2027 Notes. The 2027 Notes are subordinated to indebtedness under the New Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt, and structurally subordinated to the liabilities of any non-guarantor subsidiaries.

Pursuant to the terms of the indenture governing the 2027 Notes, Chemours may redeem the 2027 Notes, in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium and accrued and unpaid interest, if any, to the date of purchase prior to February 15, 2027. Chemours may also redeem some or all of the 2027 Notes by means other than a redemption, including tender offer and open market repurchases. Chemours is obligated to offer to purchase the 2027 Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events.

Senior Unsecured Notes due May 2026

On June 6, 2018, the Company issued an aggregate principal amount of €450 4.000% senior unsecured notes due May 2026, denominated in euros (the “2026 Euro Notes”). The 2026 Euro Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, by each of the Company’s existing and future direct and indirect domestic restricted subsidiaries that (i) incurs or guarantees indebtedness under the New Senior Secured Credit Facilities, or (ii) guarantees certain other indebtedness of the Company or any guarantor in an aggregate principal amount in excess of $100. The 2026 Euro Notes require payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and November 15 of each year.

Pursuant to the terms of the indenture governing the 2026 Euro Notes, the Company is obligated to offer to purchase the 2026 Euro Notes at a price of 101% of the principal amount, together with accrued and unpaid interest, if any, up to, but not including, the date of purchase, upon the occurrence of certain change of control events. Prior to May 15, 2021, the Company may redeem the 2026 Euro Notes (i) in whole or in part, at an amount equal to 100% of the aggregate principal amount plus a specified “make-whole” premium, and (ii) on one or more occasions, up to 35% of the aggregate principal amount of the notes, with the net cash proceeds of one or more equity offerings at a price equal to 104% of the principal amounts of such notes, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date. The guarantees of the 2026 Euro Notes will rank equally with all other senior indebtedness of the guarantors. The 2026 Euro Notes rank equally in right of payment to all of the Company’s existing and future unsecured unsubordinated debt and are senior in right of payment to all of its existing and future debt that is, by its terms, expressly subordinated in right of payment to the 2026 Euro Notes. The 2026 Euro Notes are subordinated to indebtedness under the New Senior Secured Credit Facilities, as well as any future secured debt to the extent of the value of the assets securing such debt, and are structurally subordinated to the liabilities of any non-guarantor subsidiaries.

The Company received net proceeds of €445 from the offering of the 2026 Euro Notes, which, together with cash on hand, were used to purchase or redeem, as the case may be, all of the outstanding 2023 Euro Notes and a $250 aggregate principal amount of the 2023 Dollar Notes pursuant to the Tender Offers (defined below) and the redemption of the 2023 Euro Notes, as well as pay for any fees and expenses in connection therewith. In connection with the concurrent redemption of the 2023 Euro Notes and issuance of the 2026 Euro Notes, the Company incurred a loss on extinguishment of $35 for the year ended December 31, 2018.

2023 Notes Tender Offers and Redemption of the 2023 Euro Notes

On May 21, 2018, the Company commenced two all-cash tender offers to purchase: (i) up to $250 of the outstanding 2023 Dollar Notes, for a purchase price of $1,052.50 per $1,000.00 of principal amount through an early tender deadline of June 4, 2018, and $1,022.50 per $1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (the “Dollar Tender Offer”); and, (ii) any and all of the outstanding 2023 Euro Notes (collectively, the “2023 Notes”), for a purchase price of €1,048.75 per €1,000.00 of principal amount through an early tender deadline of June 4, 2018, and €1,018.75 per €1,000.00 of principal amount thereafter, through June 18, 2018, the tender expiration date, plus any accrued and unpaid interest thereon (the “Euro Tender Offer”) (collectively, the “Tender Offers”).

The Company completed the Dollar Tender Offer on June 6, 2018 for an aggregate purchase price of $264, inclusive of an early participation premium of $13 and accrued interest of $1. The Company completed the Euro Tender Offer on June 8, 2018 for an aggregate purchase price of €310, inclusive of an early participation premium of €14 and accrued interest of €1. In connection with the Euro Tender Offer, the Company received consents from the holders of a majority of the aggregate principal amount of the 2023 Euro Notes to amend certain provisions of the indenture governing the 2023 Euro Notes, thereby allowing the Company to call and redeem the remaining 2023 Euro Notes outstanding upon two business days’ notice to the noteholders. On June 8, 2018, the Company completed the redemption of the remaining outstanding 2023 Euro Notes that were not purchased pursuant to the Euro Tender Offer. The Tender Offers and the redemption of the 2023 Euro Notes were funded with the proceeds from the offering of the 2026 Euro Notes and cash on hand.

Build-to-suit Lease Obligation

In October 2017, Chemours executed a build-to-suit lease agreement to construct a new 312,000-square-foot R&D facility on the Science, Technology, and Advanced Research campus of the University of Delaware (“UD”) in Newark, Delaware (“The Chemours Discovery Hub”). The land on which The Chemours Discovery Hub will be located is leased to a third-party owner-lessor by UD, and Chemours will act as the construction agent and ultimate lessee of the facility based on the Company’s agreement with the owner-lessor. Project costs paid by the owner-lessor are reflected in the Company’s consolidated balance sheets as construction-in-progress within property, plant, and equipment, and a corresponding build-to-suit lease liability within long-term debt. Through December 31, 2018 and 2017, project costs paid by the owner-lessor amounted to $55 and $8, respectively. Construction of The Chemours Discovery Hub is expected to be completed by the end of 2019.

Maturities

The Company has required quarterly principal payments related to the New Senior Secured Credit Facilities equivalent to 1.00% per annum through December 2024, with the balance due at maturity. Also, following the end of each fiscal year commencing on the year ended December 31, 2019, on an annual basis, the Company is required to make additional principal payments depending on leverage levels, as defined in the amended and restated credit agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.50 to 1.00 leverage target.

The following table sets forth the Company’s debt principal maturities for the next five years and thereafter.

	Year Ended
	December 31,
2019	$	13
2020		13
2021		13
2022		13
2023		921
Thereafter		2,987
Total principal maturities on senior debt	$	3,960

Debt Fair Value

The following table sets forth the estimated fair values of the Company’s senior debt issues, which are based on quotes received from third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy.

	December 31, 2018					December 31, 2017
	Carrying Value			Fair Value		Carrying Value			Fair Value
Senior secured term loans:
Tranche B-1 Dollar Term Loan due May 2022	$	—		$	—	$	923		$	928
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		—			—		469			471
Tranche B-2 Dollar Term Loan due May 2025		893			862		—			—
Tranche B-2 Euro Term Loan due May 2025 (€347 at December 31, 2018)		396			394		—			—
Senior unsecured notes:
6.625% due May 2023		908			918		1,158			1,228
7.000% due May 2025		750			761		750			816
6.125% due May 2023 (€295 at December 31, 2017)		—			—		350			373
4.000% due May 2026 (€450 at December 31, 2018)		513			487		—			—
5.375% due May 2027		500			454		500			521
Total senior debt		3,960		$	3,876		4,150		$	4,337
Less: Unamortized issue discounts		(10	)				(8	)
Less: Unamortized debt issuance costs		(35	)				(41	)
Total senior debt, net	$	3,915				$	4,101

Other Liabilities

12 Months Ended

Dec. 31, 2018

Other Liabilities Disclosure [Abstract]

Other Liabilities

Note 20. Other Liabilities

The following table sets forth the components of the Company’s other liabilities at December 31, 2018 and 2017.

	December 31,
	2018		2017
Environmental remediation (1)	$	152	$	187
Employee-related costs (2)		130		123
Accrued litigation (1)		53		48
Asset retirement obligations		51		43
Deferred revenue		7		6
Miscellaneous (3)		64		68
Total other liabilities	$	457	$	475

(1)

The Company’s accrued environmental remediation and accrued litigation liabilities are discussed further in “Note 21 – Commitments and Contingent Liabilities.”

(2)

Employee-related costs primarily represent liabilities associated with the Company’s long-term employee benefits plans.

(3)

Miscellaneous primarily includes an accrued indemnification liability of $46 and $52 at December 31, 2018 and 2017, respectively.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

Note 21. Commitments and Contingent Liabilities

Operating Leases

Chemours uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the lease agreement. Future minimum lease payments (including residual value guarantee amounts) under non-cancelable operating leases are $68, $48, $41, $36, and $31 for the years ended December 31, 2019, 2020, 2021, 2022, and 2023, respectively, and $134 for the years thereafter. Net rental expense under the Company’s operating leases was $81, $76, and $68 for the years ended December 31, 2018, 2017, and 2016, respectively.

Asset Retirement Obligations

Chemours has recorded asset retirement obligations, which are inclusive of costs related to closure, reclamation, and removal for mining operations in the production of TiO₂ in the Titanium Technologies segment; cap, cover, and post-closure maintenance of landfills in all segments; and, shipment and disposal of stored waste in all segments.

The following table sets forth the activity in the Company’s asset retirement obligations for the years ended December 31, 2018 and 2017.

	Year Ended December 31,
	2018			2017
Balance at January 1,	$	48		$	43
Accretion expense		10			6
Settlements and payments		(1	)		(1	)
Balance at December 31,	$	57		$	48

Current portion	$	6		$	5
Non-current portion		51			43

Litigation

In addition to the matters discussed below, the Company and certain of its subsidiaries, from time to time, are subject to various lawsuits, claims, assessments, and proceedings with respect to product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. In addition, Chemours, by virtue of its status as a subsidiary of DuPont prior to the Separation, is subject to or required under the Separation-related agreements executed prior to the Separation to indemnify DuPont against various pending legal proceedings. It is not possible to predict the outcomes of these various lawsuits, claims, assessments, or proceedings. While management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

Asbestos

In the Separation, DuPont assigned its asbestos docket to Chemours. At December 31, 2018 and 2017, there were approximately 1,300 and 1,600 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside of the U.S. Most of the actions were brought by contractors who worked at sites between the 1950s and the 1990s. A small number of cases involve similar allegations by DuPont employees or household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At December 31, 2018 and 2017, Chemours had an accrual of $37 and $38 related to these matters, respectively.

Benzene

In the Separation, DuPont assigned its benzene docket to Chemours. At December 31, 2018 and 2017 there were 19 and 17 cases pending against DuPont alleging benzene-related illnesses, respectively. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products such as paints, thinners, and reducers.

Management believes that a loss is reasonably possible as to the docket as a whole; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

PFOA

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) at its Fayetteville, North Carolina plant and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites, including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and, Shimizu, Japan. These sites are now owned and/or operated by Chemours.

Chemours maintained accruals of $22 and $14 related to the PFOA matters discussed below at December 31, 2018 and 2017, respectively. These accruals relate to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (“EPA”) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the state or the national health advisory. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

Drinking Water Actions

In 2004, DuPont settled a class action captioned Leach v. DuPont, filed in West Virginia state court, alleging that approximately 80,000 residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. Among the settlement terms, DuPont funded a series of health studies by an independent science panel of experts (“C8 Science Panel”) to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol. Under the terms of the settlement, DuPont is obligated to fund up to $235 for a medical monitoring program for eligible class members and pay the administrative cost associated with the program, including class counsel fees. The court-appointed Director of Medical Monitoring implemented the program and testing is ongoing with associated payments to service providers disbursed from an escrow account which the Company replenishes pursuant to the settlement agreement. As of December 31, 2018, approximately $1.5 has been disbursed from escrow related to medical monitoring. While it is reasonably possible that the Company will incur additional costs related to the medical monitoring program, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At Separation, this obligation was assigned to Chemours and is included in the accrual amounts recorded as of December 31, 2018.

Further, under the Leach settlement, class members may pursue personal injury claims against DuPont only for those diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were subsequently filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (“MDL”) in Ohio federal court. These were resolved in March 2017 when DuPont entered into an agreement settling all MDL cases and claims, including all filed and unfiled personal injury cases and claims that were part of the plaintiffs’ counsel’s claim inventory, as well as cases tried to a jury verdict (the “MDL Settlement”) for $670.7 in cash, with half paid by Chemours, and half paid by DuPont.

Concurrently with the MDL Settlement, DuPont and Chemours agreed to a limited sharing of potential future PFOA costs (indemnifiable losses, as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours will annually pay future PFOA costs up to $25 and, if such amount is exceeded, DuPont will pay any excess amount up to the next $25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties, or attorneys’ fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

While all MDL lawsuits were dismissed or resolved through the MDL Settlement, the MDL Settlement did not resolve PFOA personal injury claims of plaintiffs who did not have cases or claims in the MDL or personal injury claims based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, approximately 40 personal injury cases have been filed and are pending in West Virginia or Ohio courts alleging status as a Leach class member.

DuPont has also been named in approximately 25 lawsuits pending in New York courts, which are not part of the Leach class, brought by individual plaintiffs alleging negligence and other claims in the release of perfluorinated compounds, including PFOA, into drinking water, and seeking medical monitoring, compensatory, and punitive damages against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York. Two other lawsuits in New York have been filed by a business seeking to recover its losses and by nearby property owners and residents, in a putative class action, seeking medical monitoring, compensatory and punitive damages, and injunctive relief.

Water District Actions

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance, and trespass in the release of perfluorinated compounds, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages.

In February 2018, the New Jersey-American Water Company, Inc. (“NJAW”) filed suit against DuPont and Chemours in New Jersey federal court alleging that discharges of perfluorochemicals, in violation of the New Jersey Compensation and Control Act, were made into groundwater utilized in the NJAW Penns Grove water system. NJAW alleges that damages include costs associated with remediating, operating, and maintaining its system, and attorney fees.

In January 2019, the Town of East Hampton (the “Town”) filed a lawsuit against DuPont, Chemours and numerous other defendants in New York state court alleging that it has and will incur costs for assessment, remediation, and response to address PFOA and “PFOS” (perfluorooctane sulfonic acid) contamination in drinking water and the environment. As to DuPont and Chemours, the Town alleges that PFOA and/or PFOS washed from clothing or cleaning supplies to cesspools and then subsurface water. In addition to cost recovery, the Town seeks natural resource damages, compensatory, and punitive damages and injunctive relief.

Other PFOA Actions

In February 2018, the State of Ohio initiated litigation against DuPont regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and seeks damages including remediation and other costs and punitive damages.

In October 2018, a putative class action was filed in Ohio federal court against 3M Company (“3M”), DuPont, Chemours, and other defendants seeking class action status for U.S. residents having a detectable level of “PFAS” (perfluoroalkyl and polyfluoroalkyl substances) in their blood serum. The complaint seeks declaratory and injunctive relief, including the establishment of a PFAS Science Panel.

In October 2018, a putative class action was filed in New Jersey federal court against 3M, DuPont, and Chemours alleging causes of action, including negligence, nuisance, and trespass and seeking damages including property diminution, remediation, treatment, and abatement with compensatory and punitive damages. The purported class includes private drinking water and well owner-occupants within two to five miles of the Company’s Chambers Works, New Jersey site containing any detectable level of PFOA or PFOS.

In December 2018, the owners of a dairy farm filed a lawsuit in Maine state court against numerous defendants including DuPont and Chemours alleging that their dairy farm was contaminated by PFOS and PFOA present in treated municipal sewer sludge was used in agricultural spreading applications on their farm. The complaint asserts negligence, trespass, and other tort and state statutory claims and seeks damages.

PFOA Summary

There may be additional lawsuits filed related to DuPont’s use of PFOA, its manufacture of PFOA, or its customers’ use of DuPont products. Any such litigation could result in Chemours incurring additional costs and liabilities. Management believes that it is reasonably possible that the Company could incur losses related to other PFOA matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

U.S. Smelter and Lead Refinery, Inc.

There are six lawsuits, including one putative class action, pending against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Several of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and damages under the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA”, often referred to as “Superfund”). At Separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in early stages and have significant factual issues to be resolved.

GenX and Other Perfluorinated and Polyfluorinated Compounds

At its Fayetteville, North Carolina facility, the Company continues to capture and separately dispose of process waste water containing the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”) and other perfluorinated and polyfluorinated compounds. The Company believes that discharges to the Cape Fear River, site surface water, groundwater, and air emissions have not impacted the safety of drinking water in North Carolina and is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities, including an ongoing investigation being conducted by the U.S. Attorney’s Office for the Eastern District of North Carolina and the Environment and Natural Resources Division of the U.S. Department of Justice.

In September 2017, the North Carolina Department of Environmental Quality (“NC DEQ”) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief, including abatement and site correction. A partial Consent Order was entered partially resolving the State’s action in return for the Company’s agreement to continue and supplement the voluntary waste water disposal measures it had previously commenced and to provide certain information. In November 2017, the NC DEQ informed the Company that it was suspending the process waste water discharge permit for the Fayetteville facility. The Company thereafter commenced the capture and separate disposal of all process waste water from the Fayetteville facility related to the Company’s own operations. In addition, in June 2018, the North Carolina Legislature enacted legislation (i) granting the governor the authority, in certain circumstances, to require a facility with unauthorized PFAS discharges to cease operations, and (ii) granting the governor the authority, in certain circumstances, to direct the NC DEQ secretary to order a PFAS discharger to establish permanent replacement water supplies for parties whose water was contaminated by the discharge.

On July 13, 2018, Cape Fear River Watch (“CFRW”), a non-profit organization, sued the NC DEQ in North Carolina state court, seeking to require the NC DEQ to take additional actions as to the Fayetteville facility. On August 29, 2018, CFRW sued the Company in North Carolina federal court for alleged violations of the Clean Water Act and the Toxic Substances Control Act (“TSCA”), seeking declaratory and injunctive relief and penalties.

On November 21, 2018, the NC DEQ, CFRW, and the Company reached a proposed Consent Order that would resolve the State’s and CFRW’s lawsuits and other matters (including issues regarding the legislation referenced above and Notices of Violation issued by the State) and would also resolve litigation brought by CFRW. Under its terms, Chemours will agree to pay $13 to cover a civil penalty and investigative costs and will take additional actions to address site surface water, groundwater, and air emissions, including installing technology to abate future emissions by specified dates and meeting specified emissions reductions (with stipulated penalties for failures to do so). As a result of the proposed Consent Order, as of December 31, 2018, the Company had total accrued liabilities of $75 for this matter, of which, $65 is treated as accrued litigation costs. The Company’s estimated liability is based on management’s assessment of the current facts and circumstances for this matter, which are subject to various assumptions that include, but are not limited to, the number of affected properties, the type of water treatment system required, the cost of proposed water treatment systems and any related operation, maintenance, and monitoring (“OM&M”) requirements, assessed fines and penalties, and other charges contemplated by the proposed Consent Order.

The proposed Consent Order was subject to public comment ending in January 2019. The proposed Consent Order provides that the NC DEQ reserves the right, based on the public comments, to withdraw or withhold its consent to the order. The NC DEQ may also request that the Company agree to modifications to the proposed Consent Order as a condition to the NC DEQ’s continued consent to it, although the Company is under no obligation to agree to any modifications. The proposed Consent Order, either as originally agreed or as modified, must be approved by the court.

Numerous public comments were submitted on the proposed Consent Order. In addition, a public water authority has filed a motion to intervene in the State’s case to oppose court approval of the proposed Consent Order. The NC DEQ is currently reviewing the public comments. At this time, there is no assurance: (i) that the NC DEQ will continue to consent to the order, including with modifications; (ii) what the full scope of any modifications would be; or, (iii) whether the court will approve the order.

On February 14, 2019, the Company received a Notice of Violation (“NOV”) from the EPA alleging certain TSCA violations at its Fayetteville site. Matters raised in the NOV could have the potential to affect operations at the Fayetteville site; however, based on the Company’s review, management believes that it has appropriate responses to the allegations that it intends to address with the EPA. At this time, management does not believe that a loss is probable related to the matters in this NOV.

It is also possible that issues relating to site discharges could result in further litigation or regulatory demands with regard to the Fayetteville facility, including potential permit modifications. If such issues arise, if the proposed Consent Order is modified or not approved by the court, or as implementation of the obligations under the Consent Order proceed, an additional loss is reasonably possible but not estimable at this time.

The Company has responded to grand jury subpoenas, produced witnesses before a grand jury and for interviews with government investigators and attorneys, and met with the U.S. Attorney’s Office for the Eastern District of North Carolina and the Environmental Natural Resources Division of the U.S. Department of Justice regarding their investigation into a potential violation of the Clean Water Act. Although the Company is not able at this point to predict the outcome of that investigation, it is reasonably possible that it could result in a criminal or civil proceeding, the imposition of fines and penalties, and/or other remedies.

Civil actions have been filed against DuPont and Chemours in North Carolina federal court relating to discharges from the Fayetteville site. These actions include a consolidated action brought by public water suppliers seeking damages and injunctive relief, a consolidated purported class action seeking medical monitoring, and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River, an action by private well owners seeking compensatory and punitive damages and the above mentioned action filed by Cape Fear River Watch, which alleges violation of the Clean Water Act and/or the TSCA seeking declaratory and injunctive relief and penalties. It is possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges.

It is not possible at this point to predict the timing, course, or outcome of governmental and regulatory inquiries and notices, the action brought by North Carolina, the actions brought by CFRW, and other litigation, and it is possible that these matters could materially affect the Company’s financial results and operations. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid and other perfluorinated and polyfluorinated compounds at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

Mining Solutions Facility Construction Stoppage

In March 2018, a civil association in Mexico filed a complaint against the government authorities involved in the permitting process of the Company’s new Mining Solutions facility under construction in Gomez Palacio, Durango, Mexico. The claimant sought and obtained a suspension from the district judge to stop the Company’s construction work while the claim is studied and reviewed. Chemours, as the third-party affected, has filed an appeal. The Company has declared force majeure with its vendors while plant construction is idled. Chemours’ project permits fully comply with the laws and regulations at the federal, state, and municipal levels, and the Company is working with local and federal authorities, along with community leaders, to address the complaint.

Environmental

Chemours, due to the terms of its Separation-related agreements with DuPont, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Much of this liability results from CERCLA, the Resource Conservation and Recovery Act, and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation, and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At December 31, 2018 and 2017, the consolidated balance sheets included liabilities relating to these matters of $226 and $253, respectively, which, in management’s opinion, are appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the Separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $450 above the amount accrued at December 31, 2018.

For the years ended December 31, 2018, 2017, and 2016, Chemours incurred environmental remediation expenses of $36, $48, and $44, respectively. In addition, during the fourth quarter of 2018, the Company reclassified $2 of its environmental liabilities to accrued litigation in connection with the ongoing matters at its Fayetteville, North Carolina facility.

Sale of East Chicago, Indiana

On June 29, 2018, the Company sold its East Chicago, Indiana site to a third-party for $1. In connection with the sale, the buyer has agreed to assume all costs associated with environmental remediation activities at the site in excess of $21, which will remain the responsibility of Chemours. At the time of the sale, the Company had accrued the full $21, and will reimburse the buyer through a series of progress payments to be made at defined intervals as certain tasks are completed. The Company recognized a gain of $3 on the sale, which includes the purchase price of $1, plus $2 in environmental remediation liabilities that were assumed by the buyer on the occurrence of the sale.

Sale of Potomac River, West Virginia

On September 27, 2018, the Company sold its Potomac River, West Virginia site to a third-party for $4. In connection with the sale, the buyer has agreed to assume certain future environmental remediation costs, and Chemours has retained $4 in existing environmental remediation liabilities. The Company recognized a $3 gain on the sale, which was deferred and will be recognized as the Company completes certain environmental remediation activities at the site.

Equity

12 Months Ended

Dec. 31, 2018

Stockholders Equity Note [Abstract]

Equity

Note 22. Equity

Share Repurchase Program

On November 30, 2017, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $500, plus any associated fees or costs in connection with the Company’s share repurchase activity (the “2017 Share Repurchase Program”). Under the 2017 Share Repurchase Program, shares of Chemours’ common stock were purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s 2017 Share Repurchase Program became effective on November 30, 2017. On May 31, 2018, the Company completed the aggregate $500 in authorized purchases of Chemours’ issued and outstanding common stock under the 2017 Share Repurchase Program, which amounted to a cumulative 10,085,647 shares purchased at an average share price of $49.58 per share. All common shares purchased under the 2017 Share Repurchase Program are held as treasury stock and are accounted for using the cost method.

On August 1, 2018, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $750, plus any associated fees or costs in connection with the Company’s share repurchases activity (the “2018 Share Repurchase Program”). Under the 2018 Share Repurchase Program, shares of Chemours’ common stock can be purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s 2018 Share Repurchase Program became effective on August 1, 2018 and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

During 2018, the Company purchased an aggregate 6,350,857 shares of Chemours’ issued and outstanding common stock under the 2018 Share Repurchase Program, which amounted to $250 at an average share price of $39.31 per share. The aggregate amount of Chemours’ common stock that remained available for purchase under this program at December 31, 2018 was $500.

Dividends Payable

On November 30, 2017, the Company’s board of directors declared a cash dividend of $0.17 per share, payable to the record holders of Chemours’ issued and outstanding common stock as of the close of business on February 15, 2018. This dividend was paid on March 15, 2018, and accordingly, the Company had accrued a dividend payable amounting to $31 at December 31, 2017.

Stock-based Compensation

12 Months Ended

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

Note 23. Stock-based Compensation

The Company’s stock-based compensation expense amounted to $24, $29, and $19 for the years ended December 31, 2018, 2017, and 2016, respectively.

On April 26, 2017, Chemours’ stockholders approved The Chemours Company 2017 Equity and Incentive Plan (the “2017 Plan”), which provides for grants to certain employees, independent contractors, or non-employee directors of the Company of different forms of awards, including stock options, RSUs, and PSUs. The 2017 Plan replaced The Chemours Company Equity and Incentive Plan (the “Prior Plan”), which was adopted by the Company at Separation. As a result, no further grants will be made under the Prior Plan.

A total of 19,000,000 shares of the Company’s common stock may be subject to awards granted under the 2017 Plan, less one share for every one share that was subject to an option or stock appreciation right granted after December 31, 2016 under the Prior Plan, and one-and-a-half shares for every one share that was subject to an award other than an option or stock appreciation right granted after December 31, 2016 under the Prior Plan. Any shares that are subject to options or stock appreciation rights will be counted against this limit as one share for every one share granted, and any shares that are subject to awards other than options or stock appreciation rights will be counted against this limit as one-and-a-half shares for every one share granted. Awards that were outstanding under the Prior Plan remain outstanding under the Prior Plan in accordance with their terms. Shares underlying awards granted under the Prior Plan after December 31, 2016 that are forfeited, cancelled, or that otherwise do not result in the issuance of shares, will be available for issuance under the 2017 Plan. At December 31, 2018, approximately 16,800,000 shares of equity and incentive plan reserve are available for grants under the 2017 Plan.

The Chemours Compensation Committee determines the long-term incentive mix, including stock options, RSUs, and PSUs, and may authorize new grants annually.

Stock Options

In connection with the Separation from DuPont, Chemours granted non-qualified stock options to certain employees in July 2015, which represented the replacement of previously-granted performance stock unit awards at DuPont. The July 2015 grant cliff vested on March 1, 2018 and will expire 10 years from the date of grant.

During 2018, 2017, and 2016, Chemours granted non-qualified stock options to certain of its employees, which will serially vest over a three-year period and expire 10 years from the date of grant.

The following table sets forth the weighted-average assumptions used to determine expense related to stock option awards granted during the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Risk-free interest rate		2.65	%		2.14	%		1.46	%
Expected term (years)		6			6			6
Volatility		47.56	%		44.49	%		60.00	%
Dividend yield		1.42	%		0.35	%		2.14	%
Fair value per stock option	$	20.47		$	15.21		$	3.41

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on the average volatility of peer companies adjusted for the Company’s debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. The expected life is determined using a simplified approach, calculated as the mid-point between the graded vesting period and the contractual life of the award.

The following table sets forth Chemours’ stock option activity for the year ended December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Exercise Price (per Share)		Weighted-average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Outstanding, December 31, 2017		6,597		$	15.72		5.11	$	226,524
Granted		495			48.41
Exercised		(1,073	)		14.69
Forfeited		(46	)		37.77
Expired		(3	)		18.80
Outstanding, December 31, 2018		5,970		$	18.45		4.80	$	72,108
Exercisable, December 31, 2018		4,401		$	15.00		3.91	$	59,486

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day at the end of the year and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at year-end. The amount changes based on the fair market value of the Company’s stock. The total intrinsic value of all options exercised for the years ended December 31, 2018, 2017, and 2016 amounted to $37, $49, and $9, respectively.

At December 31, 2018, there was $7 of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 1.86 years.

Restricted Stock Units

In the years following the Separation, as well as at the time of Separation in accordance with the employee matters agreement, Chemours granted RSUs to key management employees that generally vest over a three-year period and, upon vesting, convert one-for-one to Chemours’ common stock. The fair value of all stock-settled RSUs is based on the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs primarily include awards without a performance condition, as well as a small subset of awards for which specific levels of cost savings and revenue enhancements must be achieved for vesting to occur.

The following table sets forth non-vested RSUs, both with and without a performance condition, at December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Grant Date Fair Value (per Share)
Non-vested, December 31, 2017		1,165		$	15.34
Granted		135			48.35
Vested		(1,034	)		14.86
Forfeited		(19	)		30.94
Non-vested, December 31, 2018		247		$	34.22

At December 31, 2018, there was $6 of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 0.57 years.

Performance Share Units

Beginning in 2016, Chemours issued PSUs to key senior management employees which, upon vesting, convert one-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against stated performance goals.

The following table sets forth non-vested PSUs at 100% of target amounts at December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Grant Date Fair Value (per Share)
Non-vested, December 31, 2017		987		$	12.94
Granted		139			52.34
Vested		(19	)		24.16
Non-vested, December 31, 2018		1,107		$	17.71

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses the probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted-average fair value at the date of grant for PSUs granted during the year ended December 31, 2018 was $52.34. The fair value of each PSU grant is amortized monthly into compensation expense based on its respective vesting conditions over four equally weighted measurement periods, three of which are annual and one of which is cumulative. Compensation cost is incurred based on the Company’s estimate of the final expected value of the award, which is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

At December 31, 2018, based on the Company’s assessment of its performance goals, approximately 900,000 additional shares may be awarded under the 2017 Plan.

Employee Stock Purchase Plan

On January 26, 2017, the Company’s board of directors approved The Chemours Company Employee Stock Purchase Plan (the “ESPP”), which was approved by Chemours’ stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours’ common stock are reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with four purchase periods beginning and ending on the calendar quarters within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees are eligible to purchase the Company’s common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period. To date, the Company has executed open market transactions to purchase the Company’s common stock on behalf of its ESPP participants, which amounted to 38,111 shares. An additional 12,411 shares have been issued from the Company’s treasury stock to ESPP participants at December 31, 2018. The total amount of Chemours’ common stock issued in connection with the ESPP amounted to $2 at December 31, 2018.

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Accumulated Other Comprehensive Loss

Note 24. Accumulated Other Comprehensive Loss

The following table sets forth the components of accumulated other comprehensive loss, net of income taxes, for the years ended December 31, 2018, 2017, and 2016.

	Cumulative Translation Adjustment			Net Investment Hedge			Cash Flow Hedge		Employee Benefits			Total
Balance at January 1, 2016	$	(285	)	$	8		$	—	$	(259	)	$	(536	)
Other comprehensive (loss) income		(73	)		14			—		18			(41	)
Balance at December 31, 2016		(358	)		22			—		(241	)		(577	)
Other comprehensive income (loss)		200			(62	)		—		(3	)		135
Balance at December 31, 2017		(158	)		(40	)		—		(244	)		(442	)
Other comprehensive (loss) income		(75	)		15			6		(68	)		(122	)
Balance at December 31, 2018	$	(233	)	$	(25	)	$	6	$	(312	)	$	(564	)

Financial Instruments

12 Months Ended

Dec. 31, 2018

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Financial Instruments

Note 25. Financial Instruments

Derivative Instruments

Net Monetary Assets and Liabilities Hedge – Foreign Currency Forward Contracts

At December 31, 2018, the Company had 20 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of $503, and an average maturity of one month. There were no foreign currency forward contracts outstanding at December 31, 2017. Chemours recognized net gains of $3 and $4 for the years ended December 31, 2018 and 2017, respectively, and a net loss of $15 for the year ended December 31, 2016, which were recorded in other income, net in the consolidated statements of operations.

Cash Flow Hedge – Foreign Currency Forward Contracts

At December 31, 2018, the Company had 75 foreign currency forward contracts outstanding under Chemours’ cash flow hedge program with an aggregate notional U.S. dollar equivalent of $143, and an average maturity of four months. The Company recognized a pre-tax gain of $10 for the year ended December 31, 2018 on its cash flow hedge within accumulated other comprehensive loss. For the year ended December 31, 2018, $4 of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss.

The Company expects to reclassify an approximate $6 of net gain from accumulated other comprehensive loss to the cost of goods sold over the next 12 months, based on current foreign currency exchange rates.

Net Investment Hedge – Foreign Currency Borrowings

The Company recognized a pre-tax gain of $32, a pre-tax loss of $86, and a pre-tax gain of $14 for the years ended December 31, 2018, 2017, and 2016 on its net investment hedges within accumulated other comprehensive loss. No amounts were reclassified from accumulated other comprehensive loss for the Company’s net investment hedges during the years ended December 31, 2018, 2017, and 2016.

Fair Value of Derivative Instruments

The following table sets forth the fair value of the Company’s derivative assets and liabilities, and their level within the fair value hierarchy, at December 31, 2018 and 2017.

		December 31,
	Balance Sheet Location	2018		2017
Asset derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Accounts and notes receivable, net	$	1	$	—
Foreign currency forward contracts designated as a cash flow hedge	Accounts and notes receivable, net		3		—
Total asset derivatives		$	4	$	—

Liability derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Other accrued liabilities	$	1	$	—
Total liability derivatives		$	1	$	—

The Company’s foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and are subjected to tolerance and/or quality checks.

Summary of Derivative Instruments

The following table sets forth the pre-tax changes in fair value of the Company’s derivative assets and liabilities for the years ended December 31, 2018, 2017, and 2016.

	Gain (Loss) Recognized In
						Accumulated Other
Year Ended December 31,	Cost of Goods Sold		Other Income, Net			Comprehensive Loss
2018
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	3		$	—
Foreign currency forward contracts designated as a cash flow hedge		4		—			10
Euro-denominated debt designated as a net investment hedge		—		—			32

2017
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	4		$	—
Euro-denominated debt designated as a net investment hedge		—		—			(86	)

2016
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	(15	)	$	—
Euro-denominated debt designated as a net investment hedge		—		—			14

Long-term Employee Benefits

12 Months Ended

Dec. 31, 2018

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Long-term Employee Benefits

Note 26. Long-term Employee Benefits

Plans Covering Employees in the U.S.

On July 1, 2015, Chemours established a defined contribution plan, which covered all eligible U.S. employees. The purpose of the plan is to encourage employees to save for their future retirement needs. The plan is a tax-qualified contributory profit-sharing plan, with cash or deferred arrangement, and any eligible employee of Chemours may participate. Chemours matches 100% of the first 6% of the employee’s contribution election, and the plan’s matching contributions vest immediately upon contribution. Chemours may also provide an additional discretionary retirement savings contribution to eligible employees’ compensation. The amount of this contribution, if any, is at the sole discretion of the Company, and the discretionary contribution vests for employees with at least three years of service. From time to time, Chemours provides additional discretionary retirement savings contributions to eligible employees’ compensation.

In lieu of a defined benefit plan, Chemours provides an enhanced 401(k) contribution for employees who previously participated in DuPont’s pension plan. The enhanced benefits consist of an additional contribution of 1% to 7% of the employee’s eligible compensation, depending upon the employee’s length of service with DuPont at the time of the Separation. The enhancement will continue until 2019, and is subject to early termination.

Plans Covering Employees Outside the U.S.

Pension coverage for employees of Chemours’ non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans established after the Separation and comparable to the DuPont plans in those countries. Obligations under such plans are either funded by depositing funds with trustees, covered by insurance contracts, or unfunded.

The following table sets forth the Company’s net periodic pension income and amounts recognized in other comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Net periodic pension cost (income):
Service cost	$	14		$	16		$	14
Interest cost		16			16			19
Expected return on plan assets		(58	)		(75	)		(63	)
Amortization of prior service gain		(2	)		(2	)		(1	)
Amortization of actuarial loss		12			22			23
Curtailment gain		—			—			(2	)
Settlement loss		—			1			5
Net periodic pension income		(18	)		(22	)		(5	)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss (gain)		115			(24	)		17
Amortization of actuarial loss		(16	)		(24	)		(28	)
Amortization of prior service gain		2			2			3
Effect of foreign exchange rates		(8	)		38			(15	)
Cost (benefit) recognized in other comprehensive income		93			(8	)		(23	)
Total net periodic pension income and cost (benefit) recognized in other comprehensive income	$	75		$	(30	)	$	(28	)

The following table sets forth the pre-tax amounts recognized in accumulated other comprehensive loss for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Net loss	$	419		$	329		$	336
Prior service credit		(10	)		(11	)		(11	)
Total amount recognized in accumulated other comprehensive loss	$	409		$	318		$	325

The estimated pre-tax net loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive loss into net periodic pension cost (income) during 2019 are $24 and $2, respectively.

The following table sets forth summarized information on the Company’s pension plans at December 31, 2018 and 2017.

	December 31,
	2018			2017
Change in benefit obligation:
Benefit obligation at beginning of year	$	1,177		$	1,105
Service cost		14			16
Interest cost		16			16
Plan participants’ contributions		2			2
Actuarial loss (gain)		45			(39	)
Benefits paid		(46	)		(53	)
Plan amendments		—			(1	)
Settlements and transfers		2			(3	)
Other events		—			(4	)
Currency translation		(42	)		138
Benefit obligation at end of year		1,168			1,177
Change in plan assets:
Fair value of plan assets at beginning of year		1,363			1,169
Actual (loss) return on plan assets		(17	)		60
Employer contributions		15			38
Plan participants’ contributions		2			2
Benefits paid		(46	)		(53	)
Settlements and transfers		2			(3	)
Other events		—			(3	)
Currency translation		(51	)		153
Fair value of plan assets at end of year		1,268			1,363
Total funded status at end of year	$	100		$	186

The following table sets forth the net amounts recognized in the Company’s consolidated balance sheets at December 31, 2018 and 2017.

	December 31,
	2018			2017
Non-current assets	$	174		$	258
Current liabilities		(1	)		(1	)
Non-current liabilities		(73	)		(71	)
Total net amount recognized	$	100		$	186

The accumulated benefit obligation for all pension plans was $1,106 and $1,112 as of December 31, 2018 and 2017, respectively.

The following tables set forth information related to the Company’s pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2018 and 2017.

	December 31,
Pension plans with projected benefit obligation in excess of plan assets	2018		2017
Projected benefit obligation	$	177	$	178
Accumulated benefit obligation		149		149
Fair value of plan assets		103		106

	December 31,
Pension plans with accumulated benefit obligation in excess of plan assets	2018		2017
Projected benefit obligation	$	177	$	178
Accumulated benefit obligation		149		149
Fair value of plan assets		103		106

Assumptions

The Company generally utilizes discount rates that are developed by matching the expected cash flows of each benefit plan to various yield curves constructed from a portfolio of high-quality, fixed income instruments provided by the plans’ actuaries as of the measurement date. The expected rate of return on plan assets reflects economic assumptions applicable to each country.

The following tables set forth the assumptions that have been used to determine the Company’s benefit obligations and net benefit cost at December 31, 2018 and 2017.

	December 31,
Weighted-average assumptions used to determine benefit obligations	2018			2017
Discount rate		2.0	%		1.9	%
Rate of compensation increase (1)		2.5	%		2.5	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

	December 31,
Weighted-average assumptions used to determine net benefit cost	2018			2017
Discount rate		1.9	%		1.8	%
Rate of compensation increase (1)		2.5	%		2.5	%
Expected return on plan assets		4.1	%		5.7	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Plan Assets

Each pension plan’s assets are invested through either an insurance vehicle, a master trust fund, or a stand-alone pension fund. The strategic asset allocation for each plan is selected by management, together with the pension board, where appropriate, reflecting the results of comprehensive asset and liability modeling. For assets under its control, Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The following table sets forth the weighted-average allocation for the Company’s pension plan assets at December 31, 2018 and 2017.

	December 31,
	2018			2017
Cash and cash equivalents		5	%		5	%
U.S. and non-U.S. equity securities		45	%		42	%
Fixed income securities		50	%		53	%
Total weighted-average allocation		100	%		100	%

Fixed income securities include corporate-issued, government-issued, and asset-backed securities. Corporate debt investments encompass a range of credit risk and industry diversification.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following tables set forth the fair values of the Company’s pension assets by level within the fair value hierarchy at December 31, 2018 and 2017.

	Fair Value Measurements at December 31, 2018
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	487		$	3	$	484
Debt - corporate issued		130			33		97
U.S. and non-U.S. equities		264			263		1
Mututal Funds		296			—		296
Derivatives - asset position		9			—		9
Derivatives - liability position		(5	)		—		(5	)
Cash and cash equivalents		67			67		—
Other		12			8		4
Total pension assets before pension receivables		1,260		$	374	$	886
Pension trust receivables, net (1)		8
Total pension assets	$	1,268

(1)

Receivables are primarily for investment income earned but not yet received.

	Fair Value Measurements at December 31, 2017
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	505		$	1	$	504
Debt - corporate issued		144			24		120
Debt - asset backed		40			—		40
U.S. and non-U.S. equities		581			295		286
Derivatives - asset position		8			2		6
Derivatives - liability position		(1	)		—		(1	)
Cash and cash equivalents		65			65		—
Other		14			11		3
Total pension assets before pension receivables		1,356		$	398	$	958
Pension trust receivables, net (1)		7
Total pension assets	$	1,363

(1)

Receivables are primarily for investment income earned but not yet received.

For pension plan assets classified as Level 1 instruments within the fair value hierarchy, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension plan assets classified as Level 2 instruments within the fair value hierarchy, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established, recognized vendors of market data and subjected to tolerance and/or quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates, and implied volatilities obtained from various market sources.

Cash Flows

Defined Benefit Plan

For the years ended December 31, 2018, 2017, and 2016 Chemours contributed $15, $38, and $16, respectively, to its defined benefit plans.

Of the contributions made in 2017, $10 relates to the settlement of the U.S. Pension Restoration Plan (“U.S. PRP”), which was a supplemental pension plan for certain U.S. employees. The liability associated with the U.S. PRP was transferred to Chemours from DuPont at the Separation Date, at which point the plan ceased accepting new participants. In October 2017, the Company made a cash payment of $10 to settle the remaining liability attributable to the remaining participants in the U.S. PRP.

Chemours expects to contribute $16 to its pension plans in 2019.

The following table sets forth the benefit payments that are expected to be paid by the Company over the next five years and the five years thereafter as of December 31, 2018.

	Year Ended
	December 31,
2019	$	45
2020		47
2021		46
2022		47
2023		50
2024 to 2028		264

Defined Contribution Plan

For the years ended December 31, 2018, 2017, and 2016, Chemours contributed $51, $45, and $44, respectively, to its defined contribution plan.

Geographic and Segment Information

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Geographic and Segment Information

Note 27. Geographic and Segment Information

Geographic Information

The following table sets forth the geographic locations of the Company’s net sales and property, plant, and equipment as of, and for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018				2017				2016
	Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net
North America	$	2,378	$	2,279	$	2,255	$	2,018	$	2,288	$	1,861
Asia Pacific		1,720		124		1,593		131		1,315		129
Europe, the Middle East, and Africa		1,685		293		1,506		302		1,081		278
Latin America (2)		855		595		829		557		716		516
Total net sales and property, plant, and equipment, net	$	6,638	$	3,291	$	6,183	$	3,008	$	5,400	$	2,784

(1)

Net sales are attributed to countries based on customer location.

(2)

Latin America includes Mexico.

Segment Information

Chemours’ operations consist of three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution, and regulatory environments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. Corporate costs and certain legacy legal and environmental expenses, stock-based compensation costs, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of the Company’s legal entities are reflected in Corporate and Other.

Segment net sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on R&D facilities and amortization of other intangible assets, excluding any write-downs of assets. Segment net assets include net working capital, net property, plant, and equipment, and other non-current operating assets and liabilities of the segment. This is the measure of segment assets reviewed by the Company’s Chief Operating Decision Maker (“CODM”).

Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is the primary measure of segment performance used by the CODM and is defined as income (loss) before income taxes, excluding the following:

•

interest expense, depreciation, and amortization;

•

non-operating pension and other post-retirement employee benefit costs, which represent the components of net periodic pension (income) costs excluding the service cost component;

•

exchange (gains) losses included in other income (expense), net;

•

restructuring, asset-related, and other charges;

•

asset impairments;

•

(gains) losses on sales of assets and businesses; and,

•

other items not considered indicative of the Company’s ongoing operational performance and expected to occur infrequently.

The following table sets forth certain summary financial information for the Company’s reportable segments and Corporate and Other as of, and for the years ended December 31, 2018, 2017, and 2016.

Year Ended December 31,	Fluoroproducts		Chemical Solutions		Titanium Technologies		Corporate and Other			Total
2018
Net sales to external customers	$	2,862	$	602	$	3,174	$	—		$	6,638
Adjusted EBITDA		783		64		1,055		(162	)		1,740
Depreciation and amortization		117		20		119		28			284
Equity in earnings of affiliates		43		—		—		—			43
Net assets		2,309		506		1,487		(3,282	)		1,020
Investments in affiliates		160		—		—		—			160
Purchases of property, plant, and equipment		274		75		91		58			498

2017
Net sales to external customers	$	2,654	$	571	$	2,958	$	—		$	6,183
Adjusted EBITDA		669		57		862		(166	)		1,422
Depreciation and amortization		109		18		118		28			273
Equity in earnings of affiliates		33		—		—		—			33
Net assets		1,842		460		1,785		(3,222	)		865
Investments in affiliates		173		—		—		—			173
Purchases of property, plant, and equipment		249		65		65		32			411

2016
Net sales to external customers	$	2,264	$	772	$	2,364	$	—		$	5,400
Adjusted EBITDA		445		39		466		(128	)		822
Depreciation and amortization		101		30		119		34			284
Equity in earnings of affiliates		26		—		—		3			29
Net assets		1,400		292		1,513		(3,101	)		104
Investments in affiliates		116		—		—		20			136
Purchases of property, plant, and equipment		120		104		105		9			338

The following table sets forth a reconciliation of Adjusted EBITDA to the Company’s consolidated net income (loss) before income taxes for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Income (loss) before income taxes	$	1,155		$	912		$	(11	)
Interest expense, net		195			214			219
Depreciation and amortization		284			273			284
Non-operating pension and other post-retirement employee benefit income		(27	)		(34	)		(20	)
Exchange (gains) losses, net		(1	)		(3	)		57
Restructuring, asset-related, and other charges (1)		49			57			170
Loss (gain) on extinguishment of debt		38			1			(6	)
Gain on sales of assets and businesses (2)		(45	)		(22	)		(254	)
Transaction costs (3)		9			3			19
Legal charges (4)		82			9			343
Other charges		1			12			21
Adjusted EBITDA	$	1,740		$	1,422		$	822

(1)

Includes restructuring, asset-related, and other charges, which are discussed in further detail in “Note 7 – Restructuring, Asset-related, and Other Charges.”

(2)

The year ended December 31, 2018, included gains of $3 and $42 associated with the sales of the Company’s East Chicago, Indiana and Linden, New Jersey sites, respectively. The year ended December 31, 2017 included gains of $13 and $12 associated with the sale of the Company’s land in Repauno, New Jersey that was previously deferred and realized upon meeting certain milestones, and for the sale of its Edge Moor, Delaware plant site, respectively, net of certain losses on other disposals. The year ended December 31, 2016 included gains of $169 and $89 associated with the sales of the Company’s C&D business and its Aniline facility in Beaumont, Texas, respectively.

(3)

Includes costs associated with the Company’s debt transactions, as well as accounting, legal, and bankers’ transaction costs incurred in connection with the Company’s strategic initiatives.

(4)

Includes litigation settlements, PFOA drinking water treatment accruals, and other legal charges. The year ended December 31, 2018 included $63 in additional charges for the estimated liability associated with the Company’s Fayetteville, North Carolina site, which was included as a component of selling, general, and administrative expense in the consolidated statements of operations. See “Note 21 – Commitments and Contingent Liabilities” for further detail. For the year ended December 31, 2016, legal and other charges included $335 in litigation accruals associated with the PFOA MDL Settlement.

The following table sets forth the Company’s net sales to external customers by product group for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Fluorochemicals	$	1,497	$	1,378	$	1,093
Fluoropolymers		1,365		1,276		1,171
Mining solutions		289		261		262
Performance chemicals and intermediates		313		306		298
Titanium dioxide and other minerals		3,174		2,958		2,364
Divested businesses (1)		—		4		212
Total net sales	$	6,638	$	6,183	$	5,400

(1)

Inclusive of the Company’s C&D and Sulfur businesses, as well as its Aniline facility in Beaumont, Texas, which were all sold in 2016.

Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events

Note 28. Subsequent Events

In connection with its 2018 Share Repurchase Program, the Company purchased an additional 4,363,277 shares of Chemours’ issued and outstanding common stock subsequent to December 31, 2018, which amounted to $150 at an average share price of $34.38 per share.

On February 13, 2019, the Company’s board of directors increased the authorization amount of the 2018 Share Repurchase Program from $750 to $1,000.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Note 29. Quarterly Financial Data (Unaudited)

The following table sets forth a summary of the Company’s quarterly results of operations for the years ended December 31, 2018 and 2017.

	For the Three Months Ended
2018	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,730	$	1,816	$	1,628	$	1,464	$	6,638
Cost of goods sold		1,193		1,259		1,151		1,064		4,667
Income before income taxes		381		323		269		182		1,155
Net income		297		282		275		142		996
Net income attributable to Chemours		297		281		275		142		995
Basic earnings per share of common stock		1.63		1.58		1.56		0.83		5.62
Diluted earnings per share of common stock		1.58		1.53		1.51		0.81		5.45

	For the Three Months Ended
2017	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,437	$	1,588	$	1,584	$	1,575	$	6,183
Cost of goods sold		1,081		1,150		1,119		1,090		4,438
Income before income taxes		173		225		250		264		912
Net income		151		161		207		228		747
Net income attributable to Chemours		150		161		207		228		746
Basic earnings per share of common stock		0.82		0.87		1.12		1.23		4.04
Diluted earnings per share of common stock		0.79		0.84		1.08		1.19		3.91

(1)

Individual quarters may not sum to full year amounts due to rounding.

Guarantor Condensed Consolidating Financial Information

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Guarantor Condensed Consolidating Financial Information

Note 30. Guarantor Condensed Consolidating Financial Information

The following guarantor condensed consolidating financial information is included in accordance with Rule 3-10 of Regulation S-X (“Rule 3-10”) in connection with the subsidiary guarantees of the “Notes” (collectively, the 2023 Dollar Notes, the 2025 Notes, the 2026 Euro Notes, and 2027 Notes), in each case, issued by The Chemours Company (the “Parent Issuer”). As of the dates indicated, each series of the Notes was fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis, subject to certain exceptions, by the same group of subsidiaries of the Parent Issuer (together, the “Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the “Non-Guarantor Subsidiaries”). Pursuant to the indentures governing the Notes, the Guarantor Subsidiaries will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:

•

the consolidating statements of comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016;

•

the consolidating balance sheets at December 31, 2018 and 2017; and,

•

the consolidating statements of cash flows for the years ended December 31, 2018, 2017, and 2016.

The following guarantor condensed financial information is presented using the equity method of accounting for the Company’s investments in its wholly-owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for the Company’s share of its subsidiaries’ cumulative results of operations, capital contributions, distributions, and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information included herein may not necessarily be indicative of the financial positions, results of operations, or cash flows of the Company’s subsidiaries had they operated as independent entities, and should be read in conjunction with the consolidated financial statements and the related notes thereto.

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2018
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,974	$	4,484		$	(1,820	)	$	6,638
Cost of goods sold		—			3,112		3,380			(1,825	)		4,667
Gross profit		—			862		1,104			5			1,971
Selling, general, and administrative expense		33			485		163			(24	)		657
Research and development expense		—			76		6			—			82
Restructuring, asset-related, and other charges		—			46		3			—			49
Total other operating expenses		33			607		172			(24	)		788
Equity in earnings of affiliates		—			—		43			—			43
Equity in earnings of subsidiaries		1,155			2		—			(1,157	)		—
Interest (expense) income, net		(210	)		5		10			—			(195	)
Loss on extinguishment of debt		(38	)		—		—			—			(38	)
Intercompany interest income (expense), net		47			10		(57	)		—			—
Other income (expense), net		25			199		(40	)		(22	)		162
Income before income taxes		946			471		888			(1,150	)		1,155
(Benefit from) provision for income taxes		(50	)		98		111			—			159
Net income		996			373		777			(1,150	)		996
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	996		$	373	$	776		$	(1,150	)	$	995
Comprehensive income attributable to Chemours	$	873		$	375	$	637		$	(1,012	)	$	873

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,887	$	4,030		$	(1,734	)	$	6,183
Cost of goods sold		—			3,084		3,045			(1,691	)		4,438
Gross profit		—			803		985			(43	)		1,745
Selling, general, and administrative expense		36			449		179			(38	)		626
Research and development expense		—			74		7			—			81
Restructuring, asset-related, and other charges		—			56		1			—			57
Total other operating expenses		36			579		187			(38	)		764
Equity in earnings of affiliates		—			—		33			—			33
Equity in earnings of subsidiaries		849			—		—			(849	)		—
Interest (expense) income, net		(220	)		3		3			—			(214	)
Loss on extinguishment of debt		(1	)		—		—			—			(1	)
Intercompany interest income (expense), net		64			—		(64	)		—			—
Other income (expense), net		29			139		(21	)		(34	)		113
Income before income taxes		685			366		749			(888	)		912
(Benefit from) provision for income taxes		(62	)		117		114			(4	)		165
Net income		747			249		635			(884	)		747
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	747		$	249	$	634		$	(884	)	$	746
Comprehensive income attributable to Chemours	$	881		$	253	$	828		$	(1,081	)	$	881

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,622			(1,543	)		4,297
Gross profit		—			531			600			(28	)		1,103
Selling, general, and administrative expense		21			794			151			(20	)		946
Research and development expense		—			77			4			—			81
Restructuring, asset-related, and other charges		—			168			2			—			170
Total other operating expenses		21			1,039			157			(20	)		1,197
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(217	)		(3	)		1			—			(219	)
Gain on extinguishment of debt		6			—			—			—			6
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			74			(20	)		267
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2018
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	239		$	962		$	—		$	1,201
Accounts and notes receivable, net		—		297			564			—			861
Intercompany receivable		2		1,057			91			(1,150	)		—
Inventories		—		483			749			(85	)		1,147
Prepaid expenses and other		—		58			26			—			84
Total current assets		2		2,134			2,392			(1,235	)		3,293
Property, plant, and equipment		—		6,870			2,122			—			8,992
Less: Accumulated depreciation		—		(4,591	)		(1,110	)		—			(5,701	)
Property, plant, and equipment, net		—		2,279			1,012			—			3,291
Goodwill and other intangible assets, net		—		167			14			—			181
Investments in affiliates		—		—			160			—			160
Investments in subsidiaries		4,487		11			—			(4,498	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		17		154			274			(8	)		437
Total assets	$	5,656	$	4,745		$	3,852		$	(6,891	)	$	7,362
Liabilities
Current liabilities:
Accounts payable	$	—	$	637		$	500		$	—		$	1,137
Current maturities of long-term debt		13		—			—			—			13
Intercompany payable		698		92			360			(1,150	)		—
Other accrued liabilities		21		341			198			(1	)		559
Total current liabilities		732		1,070			1,058			(1,151	)		1,709
Long-term debt, net		3,902		57			—			—			3,959
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		8		143			82			(16	)		217
Other liabilities		—		372			85			—			457
Total liabilities		4,642		1,642			2,375			(2,317	)		6,342
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		1,014		3,103			1,471			(4,574	)		1,014
Non-controlling interests		—		—			6			—			6
Total equity		1,014		3,103			1,477			(4,574	)		1,020
Total liabilities and equity	$	5,656	$	4,745		$	3,852		$	(6,891	)	$	7,362

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	761		$	795		$	—		$	1,556
Accounts and notes receivable, net		—		308			611			—			919
Intercompany receivable		3		904			581			(1,488	)		—
Inventories		—		394			631			(90	)		935
Prepaid expenses and other		—		57			15			11			83
Total current assets		3		2,424			2,633			(1,567	)		3,493
Property, plant, and equipment		—		6,449			2,062			—			8,511
Less: Accumulated depreciation		—		(4,438	)		(1,065	)		—			(5,503	)
Property, plant, and equipment, net		—		2,011			997			—			3,008
Goodwill and other intangible assets, net		—		152			14			—			166
Investments in affiliates		—		—			173			—			173
Investments in subsidiaries		4,393		—			—			(4,393	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		23		115			328			(13	)		453
Total assets	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293
Liabilities
Current liabilities:
Accounts payable	$	31	$	606		$	438		$	—		$	1,075
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		542		581			365			(1,488	)		—
Other accrued liabilities		34		343			181			—			558
Total current liabilities		622		1,530			984			(1,488	)		1,648
Long-term debt, net		4,087		10			—			—			4,097
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		127			105			(24	)		208
Other liabilities		—		388			87			—			475
Total liabilities		4,709		2,055			2,326			(2,662	)		6,428
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		860		2,647			1,814			(4,461	)		860
Non-controlling interests		—		—			5			—			5
Total equity		860		2,647			1,819			(4,461	)		865
Total liabilities and equity	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2018
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(159	)	$	10		$	1,289		$	—		$	1,140
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(390	)		(108	)		—			(498	)
Acquisition of business, net		—			(37	)		—			—			(37	)
Proceeds from sales of assets and businesses, net		—			46			—			—			46
Intercompany investing activities		—			(153	)		(999	)		1,152			—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(532	)		(1,107	)		1,152			(487	)
Cash flows from financing activities
Proceeds from issuance of debt, net		520			—			—			—			520
Debt repayments		(679	)		—			—			—			(679	)
Payments related to extinguishment of debt		(29	)		—			—			—			(29	)
Payments of debt issuance costs		(12	)		—			—			—			(12	)
Purchases of treasury stock, at cost		(644	)		—			—			—			(644	)
Intercompany financing activities		1,152			—			—			(1,152	)		—
Proceeds from exercised stock options, net		16			—			—			—			16
Payments related to tax withholdings on vested restricted stock units		(17	)		—			—			—			(17	)
Payments of dividends		(148	)		—			—			—			(148	)
Cash provided by (used for) financing activities		159			—			—			(1,152	)		(993	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(15	)		—			(15	)
(Decrease) increase in cash and cash equivalents		—			(522	)		167			—			(355	)
Cash and cash equivalents at January 1,		—			761			795			—			1,556
Cash and cash equivalents at December 31,	$	—		$	239		$	962		$	—		$	1,201

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(132	)	$	603		$	169		$	—		$	640
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(327	)		(84	)		—			(411	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			220			—			(220	)		—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(66	)		(84	)		(220	)		(370	)
Cash flows from financing activities
Intercompany short-term borrowings, net		(220	)		—			—			220			—
Proceeds from issuance of debt, net		495			—			—			—			495
Debt repayments		(27	)		—			—			—			(27	)
Payments related to extinguishment of debt		(1	)		—			—			—			(1	)
Payments of debt issuance costs		(6	)		—			—			—			(6	)
Purchases of treasury stock, at cost		(106	)		—			—			—			(106	)
Proceeds from exercised stock options, net		31			—			—			—			31
Payments related to tax withholdings on vested restricted stock units		(12	)		—			—			—			(12	)
Payments of dividends		(22	)		—			—			—			(22	)
Cash provided by financing activities		132			—			—			220			352
Effect of exchange rate changes on cash and cash equivalents		—			—			32			—			32
Increase in cash and cash equivalents		—			537			117			—			654
Cash and cash equivalents at January 1,		—			224			678			—			902
Cash and cash equivalents at December 31,	$	—		$	761		$	795		$	—		$	1,556

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets and businesses, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Investments in affiliates		—			—			(1	)		—			(1	)
Foreign exchange contract settlements, net		—			(12	)		—			—			(12	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Cash flows from financing activities
Intercompany short-term borrowings, net		560			—			—			(560	)		—
Debt repayments		(369	)		(12	)		—			—			(381	)
Payments of debt issuance costs		(4	)		—			—			—			(4	)
Proceeds from exercised stock options, net		11			—			—			—			11
Payments of dividends		(22	)		—			—			—			(22	)
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at January 1,		—			95			271			—			366
Cash and cash equivalents at December 31,	$	—		$	224		$	678		$	—		$	902

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Preparation of Financial Statements

Principles of Consolidation

All intercompany accounts and transactions were eliminated in the preparation of the accompanying consolidated financial statements.

Revenue Recognition

Research and Development Expense

Provision for (Benefit from) Income Taxes

Earnings Per Share

Cash and Cash Equivalents

Cash and cash equivalents generally include cash, time deposits, or highly-liquid investments with original maturities of three months or less.

Accounts and Notes Receivable and Allowance for Doubtful Accounts

Inventories

Property, Plant and Equipment

Property, Plant, and Equipment

Impairment of Long-Lived Assets

Impairment of Long-lived Assets

Goodwill and Other Intangible Assets

Asset Retirement Obligations

Insurance

Litigation

Environmental Liabilities and Expenditures

Treasury Stock

Chemours accounts for repurchases of the Company’s common stock as treasury stock using the cost method, whereby the entire cost of the acquired common stock is recorded as treasury stock.

Stock-based Compensation

Derivatives

Derivative assets and liabilities are reported on a gross basis on the consolidated balance sheets.

Foreign Currency Translation

Defined Benefit Plans

Fair Value Measurement

Chemours applies the following valuation hierarchy in measuring the fair values of its assets and liabilities:

Level 1 – Quoted prices in active markets for identical assets and liabilities;

Level 3 – Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability.

Recent Accounting Pronouncements

Accounting Guidance Issued and Not Yet Adopted

Leases

Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

Recently Adopted Accounting Guidance

Revenue from Contracts with Customers

The following table sets forth the impacts of the adoption of Topic 606 on the Company’s consolidated statements of operations for the year ended December 31, 2018.

	Year Ended December 31, 2018
	Without			Topic 606
	Topic 606			Adjustments			As Reported
Net sales	$	6,634		$	4		$	6,638
Cost of goods sold		4,665			2			4,667
Gross profit		1,969			2			1,971
Selling, general, and administrative expense		659			(2	)		657
Research and development expense		82			—			82
Restructuring, asset-related, and other charges		49			—			49
Total other operating expenses		790			(2	)		788
Equity in earnings of affiliates		43			—			43
Interest expense, net		(195	)		—			(195	)
Loss on extinguishment of debt		(38	)		—			(38	)
Other income, net		166			(4	)		162
Income before income taxes		1,155			—			1,155
Provision for income taxes		159			—			159
Net income		996			—			996
Less: Net income attributable to non-controlling interests		1			—			1
Net income attributable to Chemours	$	995		$	—		$	995

Classification of Certain Cash Receipts and Cash Payments

Clarifying the Definition of a Business

Retirement Benefits

The following table sets forth a reclassification of the Company’s non-operating pension and other post-retirement employee benefit income for the years ended December 31, 2017 and 2016.

	Year Ended December 31, 2017									Year Ended December 31, 2016
	As Reported			Adjustments			As Reclassified			As Reported			Adjustments			As Reclassified
Net sales	$	6,183		$	—		$	6,183		$	5,400		$	—		$	5,400
Cost of goods sold		4,429			9			4,438			4,290			7			4,297
Gross profit		1,754			(9	)		1,745			1,110			(7	)		1,103
Selling, general, and administrative expense		602			24			626			934			12			946
Research and development expense		80			1			81			80			1			81
Restructuring, asset-related, and other charges		57			—			57			170			—			170
Total other operating expenses		739			25			764			1,184			13			1,197
Equity in earnings of affiliates		33			—			33			29			—			29
Interest expense, net		(214	)		—			(214	)		(219	)		—			(219	)
(Loss) gain on extinguishment of debt		(1	)		—			(1	)		6			—			6
Other income, net		79			34			113			247			20			267
Income (loss) before income taxes		912			—			912			(11	)		—			(11	)
Provision for (benefit from) income taxes		165			—			165			(18	)		—			(18	)
Net income		747			—			747			7			—			7
Less: Net income attributable to non-controlling interests		1			—			1			—			—			—
Net income attributable to Chemours	$	746		$	—		$	746		$	7		$	—		$	7

Derivatives and Hedging

Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

ASU 2014-09 [Member]

Impacts of Adoption of New Accounting Guidance on Consolidated Statements of Operations

The following table sets forth the impacts of the adoption of Topic 606 on the Company’s consolidated statements of operations for the year ended December 31, 2018.

	Year Ended December 31, 2018
	Without			Topic 606
	Topic 606			Adjustments			As Reported
Net sales	$	6,634		$	4		$	6,638
Cost of goods sold		4,665			2			4,667
Gross profit		1,969			2			1,971
Selling, general, and administrative expense		659			(2	)		657
Research and development expense		82			—			82
Restructuring, asset-related, and other charges		49			—			49
Total other operating expenses		790			(2	)		788
Equity in earnings of affiliates		43			—			43
Interest expense, net		(195	)		—			(195	)
Loss on extinguishment of debt		(38	)		—			(38	)
Other income, net		166			(4	)		162
Income before income taxes		1,155			—			1,155
Provision for income taxes		159			—			159
Net income		996			—			996
Less: Net income attributable to non-controlling interests		1			—			1
Net income attributable to Chemours	$	995		$	—		$	995

ASU 2017-07 [Member]

Impacts of Adoption of New Accounting Guidance on Consolidated Statements of Operations

The following table sets forth a reclassification of the Company’s non-operating pension and other post-retirement employee benefit income for the years ended December 31, 2017 and 2016.

	Year Ended December 31, 2017									Year Ended December 31, 2016
	As Reported			Adjustments			As Reclassified			As Reported			Adjustments			As Reclassified
Net sales	$	6,183		$	—		$	6,183		$	5,400		$	—		$	5,400
Cost of goods sold		4,429			9			4,438			4,290			7			4,297
Gross profit		1,754			(9	)		1,745			1,110			(7	)		1,103
Selling, general, and administrative expense		602			24			626			934			12			946
Research and development expense		80			1			81			80			1			81
Restructuring, asset-related, and other charges		57			—			57			170			—			170
Total other operating expenses		739			25			764			1,184			13			1,197
Equity in earnings of affiliates		33			—			33			29			—			29
Interest expense, net		(214	)		—			(214	)		(219	)		—			(219	)
(Loss) gain on extinguishment of debt		(1	)		—			(1	)		6			—			6
Other income, net		79			34			113			247			20			267
Income (loss) before income taxes		912			—			912			(11	)		—			(11	)
Provision for (benefit from) income taxes		165			—			165			(18	)		—			(18	)
Net income		747			—			747			7			—			7
Less: Net income attributable to non-controlling interests		1			—			1			—			—			—
Net income attributable to Chemours	$	746		$	—		$	746		$	7		$	—		$	7

Significant Transactions and Events (Tables)

12 Months Ended

Dec. 31, 2018

Significant Transactions And Events [Abstract]

Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed in Acquisition

The following table sets forth the Company’s fair value estimates of the assets acquired and liabilities assumed in the acquisition of ICOR, which were finalized during the fourth quarter of 2018.

	Fair Value At Acquisition Date		Measurement Period Adjustments			Adjusted Fair Value		Weighted-average Useful Life (in Years)
Assets acquired:
Accounts receivable - trade	$	4	$	—		$	4
Inventories		8		—			8
Property, plant, and equipment		1		—			1
Identifiable intangible asset:
Customer relationships (1)		20		2			22		5
Total assets acquired		33		2			35
Liabilities assumed:
Accounts payable		1		—			1
Other accrued liabilities		1		—			1
Total liabilities assumed		2		—			2
Total identifiable net assets acquired		31		2			33
Goodwill (1)		6		(2	)		4
Net assets acquired	$	37	$	—		$	37

(1)

Net Sales (Tables)

12 Months Ended

Dec. 31, 2018

Revenue From Contract With Customer [Abstract]

Summary of Disaggregation of Net Sales by Geographical Region, Product Group, and Segment

The following table sets forth a disaggregation of the Company’s net sales by geographic region, product group, and segment for the year ended December 31, 2018.

	Year Ended December 31, 2018
			Chemical		Titanium
	Fluoroproducts		Solutions		Technologies		Total
Net sales by geographic region (1)
North America	$	1,143	$	341	$	894	$	2,378
Asia Pacific		675		81		964		1,720
Europe, the Middle East, and Africa		825		18		842		1,685
Latin America (2)		219		162		474		855
Total net sales	$	2,862	$	602	$	3,174	$	6,638

Net sales by product group
Fluorochemicals	$	1,497	$	—	$	—	$	1,497
Fluoropolymers		1,365		—		—		1,365
Mining solutions		—		289		—		289
Performance chemicals and intermediates		—		313		—		313
Titanium dioxide and other minerals		—		—		3,174		3,174
Total net sales	$	2,862	$	602	$	3,174	$	6,638

(1)

Net sales are attributable to countries based on customer location.

(2)

Latin America includes Mexico.

Summary of Contract Balances from Contracts with Customers

The following table sets forth the Company’s contract balances from contracts with customers for the year ended December 31, 2018 and 2017.

	Year Ended December 31,
	2018		2017
Accounts receivable - trade, net (1)	$	790	$	847
Customer rebates		79		83

(1)

Research and Development Expense (Tables)

12 Months Ended

Dec. 31, 2018

Research And Development [Abstract]

Summary of R&D Expense by Segment

The following table sets forth the Company’s R&D expense by segment for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Fluoroproducts	$	50	$	48	$	46
Chemical Solutions		2		3		7
Titanium Technologies		28		29		27
Corporate and Other		2		1		1
Total research and development expense	$	82	$	81	$	81

Restructuring, Asset-Related, and Other Charges (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring And Related Activities [Abstract]

Schedule of Restructuring Program

The following table sets forth the components of the Company’s restructuring, asset-related, and other charges by category for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Restructuring and other charges:
Employee separation charges	$	14	$	23	$	4
Decommissioning and other charges		31		33		47
Total restructuring and other charges		45		56		51
Asset-related charges (1)		4		1		119
Total restructuring, asset-related, and other charges	$	49	$	57	$	170

(1)

Schedule of Restructuring Charges

The following table sets forth the impacts of the Company’s restructuring, asset-related, and other charges to segment earnings for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Restructuring and other charges:
Plant and product line closures:
Fluoroproducts	$	—	$	3	$	7
Chemical Solutions		4		17		8
Titanium Technologies		—		4		30
Corporate and Other		9		—		—
Total plant and product line closures		13		24		45
2015 Global Restructuring Program:
Fluoroproducts		—		—		4
Titanium Technologies		—		—		2
Total 2015 Global Restructuring Program		—		—		6
2017 Restructuring Program:
Fluoroproducts		9		—		—
Chemical Solutions		2		—		—
Titanium Technologies		1		—		—
Corporate and Other		15		32		—
Total 2017 Restructuring Program		27		32		—
2018 Restructuring Program		5		—		—
Total restructuring and other charges		45		56		51
Asset-related charges:
Chemical Solutions		4		—		106
Corporate and Other		—		1		13
Total asset-related charges		4		1		119
Total restructuring, asset-related, and other charges	$	49	$	57	$	170

The following table sets forth the change in the Company’s employee separation-related liabilities associated with its restructuring programs for the years ended December 31, 2018 and 2017.

	Fluoroproducts Line Shutdown			Chemical Solutions Site Closures			Titanium Technologies Site Closures			2015 Global Restructuring Program			2017 Restructuring Program			2018 Restructuring Program		Total
Balance at January 1, 2017	$	1		$	8		$	4		$	21		$	—		$	—	$	34
Charges to income		—			—			—			1			23			—		24
Payments		(1	)		(6	)		(3	)		(21	)		—			—		(31	)
Balance at December 31, 2017		—			2			1			1			23			—		27
Charges to income		—			—			—			—			9			5		14
Payments		—			(2	)		(1	)		—			(22	)		—		(25	)
Balance at December 31, 2018	$	—		$	—		$	—		$	1		$	10		$	5	$	16

Other Income, Net (Tables)

12 Months Ended

Dec. 31, 2018

Other Income And Expenses [Abstract]

Components of Other Income

The following table sets forth the components of the Company’s other income, net for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Leasing, contract services, and miscellaneous income (1)	$	79	$	30	$	35
Royalty income (2)		10		24		15
Gain on sales of assets and businesses (3)		45		22		254
Exchange gains (losses), net (4)		1		3		(57	)
Non-operating pension and other post-retirement employee benefit income		27		34		20
Total other income, net	$	162	$	113	$	267

(1)

(2)

(3)

(4)

Exchange gains (losses), net includes gains and losses on the Company’s foreign currency forward contracts that have not been designated as a cash flow hedge.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Provision for (Benefit from) Income Taxes

The following table sets forth the components of the Company’s provision for (benefit from) income taxes for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Current tax expense (benefit):
U.S. federal	$	23		$	(8	)	$	—
U.S. state and local		4			1			—
International		110			89			93
Total current tax expense		137			82			93
Deferred tax expense (benefit):
U.S. federal		20			60			(101	)
U.S. state and local		3			6			(17	)
International		(1	)		17			7
Total deferred tax expense (benefit)		22			83			(111	)
Total provision for (benefit from) income taxes	$	159		$	165		$	(18	)

Schedule of Deferred Tax Assets and Liabilities Components

The following table sets forth the components of the Company’s deferred tax assets and liabilities at December 31, 2018 and 2017.

	December 31,
	2018			2017
Deferred tax assets:
Environmental and other reserves	$	80		$	89
Litigation reserves		28			14
Stock-based compensation and accrued employee benefits		28			26
Other assets and other accrued liabilities		8			8
Tax attribute carryforwards		29			27
Foreign tax credit carryforwards		18			17
Total deferred tax assets		191			181
Less: Valuation allowance		(2	)		(17	)
Total deferred tax assets, net		189			164
Deferred tax liabilities:
Pension and other liabilities		(35	)		(55	)
Property, plant, and equipment		(313	)		(274	)
Inventories and other assets		(12	)		(4	)
Total deferred tax liabilities		(360	)		(333	)
Deferred tax liability, net	$	(171	)	$	(169	)

Schedule of Effective Income Tax Rate

The following table sets forth an analysis of the Company’s effective tax rates for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018						2017						2016
	$			%			$			%			$			%
Statutory U.S. federal income tax rate	$	243			21.0	%	$	319			35.0	%	$	(4	)		35.0	%
State income taxes, net of federal benefit		7			0.6	%		7			0.7	%		(16	)		150.4	%
Lower effective tax rate on international operations, net		(44	)		(3.8	)%		(149	)		(16.3	)%		(61	)		552.5	%
Depletion		(6	)		(0.5	)%		(8	)		(0.9	)%		(6	)		51.2	%
Goodwill		—			—	%		—			—	%		5			(47.9	)%
Exchange losses (gains)		(4	)		(0.3	)%		5			0.6	%		4			(39.1	)%
Provision to return and other adjustments		(9	)		(0.8	)%		6			0.6	%		6			(57.9	)%
Permanent items		12			1.0	%		9			1.0	%		3			(27.3	)%
Valuation allowance		(15	)		(1.3	)%		(33	)		(3.6	)%		50			(451.6	)%
Net impact of U.S. tax reform		(10	)		(0.9	)%		39			4.3	%		—			(—	)%
Stock-based compensation		(14	)		(1.2	)%		(20	)		(2.2	)%		—			(—	)%
Other, net		(1	)		—	%		(10	)		(1.1	)%		1			(1.7	)%
Total effective tax rate	$	159			13.8	%	$	165			18.1	%	$	(18	)		163.6	%

Schedule of Income (Loss) before Income Taxes

The following table sets forth the Company’s income (loss) before income taxes for its U.S. and international operations for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017			2016
U.S. operations (including exports)	$	114	$	(306	)	$	(481	)
International operations		1,041		1,218			470
Total income (loss) before income taxes	$	1,155	$	912		$	(11	)

Schedule of open tax years by significant jurisdiction

Each year, Chemours and/or its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions.

The following table sets forth the Company’s significant jurisdictions’ tax returns that are subject to examination by their respective taxing authorities for the open years listed.

Jurisdiction		Open Years
China		2014 through 2018
Mexico		2012 through 2018
Netherlands		2015 through 2018
Singapore		2015 through 2018
Switzerland		2015 through 2018
Taiwan		2015 through 2018
U.S.		2015 through 2018

Schedule of Unrecognized Tax Benefits

The following table sets forth the change in the Company’s unrecognized tax benefits for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017			2016
Balance at January 1,	$	—	$	6		$	7
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		—		(6	)		(1	)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		2		—			—
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations		—		—			—
Balance at December 31,	$	2	$	—		$	6

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	2	$	—		$	—
Total amount of interest and penalties recognized in the consolidated statements of operations		—		—			—
Total amount of interest and penalties recognized in the consolidated balance sheets		—		—			—

Summary of Deferred Tax Asset Valuation Allowance

The following table sets forth a rollforward of the Company’s deferred tax asset valuation allowance for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Balance at January 1,	$	17		$	50		$	—
Net charges to income tax expense		—			—			50
Release of valuation allowance		(15	)		(33	)		—
Balance at December 31,	$	2		$	17		$	50

Earnings Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

	Year Ended December 31,
	2018		2017		2016
Numerator:
Net income attributable to Chemours	$	995	$	746	$	7
Denominator:
Weighted-average number of common shares outstanding - basic		176,968,554		184,844,106		181,621,422
Dilutive effect of the Company’s employee compensation plans		5,603,467		6,139,885		1,795,078
Weighted-average number of common shares outstanding - diluted		182,572,021		190,983,991		183,416,500

Basic earnings per share of common stock	$	5.62	$	4.04	$	0.04
Diluted earnings per share of common stock		5.45		3.91		0.04

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

	Year Ended December 31,
	2018		2017		2016
Average number of stock options		393,016		43,072		5,820,499

Accounts and Notes Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2018

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable

The following table sets forth the components of the Company’s accounts and notes receivable, net at December 31, 2018 and 2017.

	December 31,
	2018		2017
Accounts receivable - trade, net (1)	$	790	$	847
VAT, GST, and other taxes (2)		56		54
Other receivables (3)		15		18
Total accounts and notes receivable, net	$	861	$	919

(1)

(2)

Value added tax (“VAT”) and goods and services tax (“GST”) for various jurisdictions.

(3)

Other receivables consist of notes receivable, advances, the fair value of derivative assets, and other deposits.

Inventories (Tables)

12 Months Ended

Dec. 31, 2018

Inventory Net [Abstract]

Schedule of Inventories

The following table sets forth the components of the Company’s inventories at December 31, 2018 and 2017.

	December 31,
	2018			2017
Finished products	$	701		$	648
Semi-finished products		195			164
Raw materials, stores, and supplies		476			313
Inventories before LIFO adjustment		1,372			1,125
Less: Adjustment of inventories to LIFO basis		(225	)		(190	)
Total inventories	$	1,147		$	935

Property, Plant, and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Summary of Property, Plant, and Equipment, Net

The following table sets forth the components of the Company’s property, plant, and equipment, net at December 31, 2018 and 2017.

	December 31,
	2018			2017
Equipment	$	7,344		$	6,961
Buildings		914			875
Construction-in-progress		579			520
Land		119			119
Mineral rights		36			36
Property, plant, and equipment		8,992			8,511
Less: Accumulated depreciation		(5,701	)		(5,503	)
Total property, plant, and equipment, net	$	3,291		$	3,008

Goodwill and Other Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table sets forth the changes in the carrying amount of the Company’s goodwill by segment for the years ended December 31, 2018 and 2017.

	December 31,
	2018			2017
Fluoroproducts:
Balance at January 1,	$	85		$	85
Acquisition of business		4			—
Balance at December 31,		89			85
Chemical Solutions:
Balance at January 1,		55			55
Goodwill impairment		(4	)		—
Balance at December 31,		51			55
Titanium Technologies:
Balance at January 1,		13			13
Balance at December 31,		13			13
Total goodwill	$	153		$	153

Schedule of Other Intangible Assets

The following table sets forth the gross carrying amounts and accumulated amortization of the Company’s other intangible assets by major class at December 31, 2018 and 2017.

	December 31, 2018							December 31, 2017
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(8	)	$	1	$	9	$	(8	)	$	1
Customer relationships		22		(3	)		19		—		—			—
Patents		19		(19	)		—		19		(18	)		1
Purchased trademarks		5		(3	)		2		5		(2	)		3
Purchased and licensed technology		3		(3	)		—		3		(2	)		1
Other (1)		10		(4	)		6		10		(3	)		7
Total other intangible assets, net	$	68	$	(40	)	$	28	$	46	$	(33	)	$	13

(1)

Investments in Affiliates (Tables)

12 Months Ended

Dec. 31, 2018

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Investments in Affiliates

The following table sets forth the carrying value, jurisdiction, and ownership percentages of the Company’s investments in affiliates at December 31, 2018 and 2017.

		December 31, 2018			December 31, 2017
Investee	Jurisdiction	Carrying Value		Ownership	Carrying Value		Ownership
Chemours-Mitsui Fluorochemicals Company, Ltd.	Japan	$	94	50.0%	$	112	50.0%
The Chemours Chenguang Fluoromaterials Company Limited	China		36	50.0%		36	50.0%
Changshu 3F Zhonghao New Chemical Materials Co., Ltd.	China		30	10.0%		25	10.0%
		$	160		$	173

Schedule of Changes in Investments in Affiliates

The following table sets forth the changes in the Company’s investments in affiliates for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017		2016
Balance at January 1,	$	173		$	136	$	136
Equity in earnings of affiliates		43			33		29
Investments in affiliates		—			—		1
Dividends		(58	)		—		(18	)
Divestment		—			—		(12	)
Currency translation and other		2			4		—
Balance at December 31,	$	160		$	173	$	136

Other Assets (Tables)

12 Months Ended

Dec. 31, 2018

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Assets

The following table sets forth the components of the Company’s other assets at December 31, 2018 and 2017.

	December 31,
	2018		2017
Capitalized repair and maintenance costs	$	178	$	117
Pension assets (1)		174		260
Deferred income taxes		46		40
Miscellaneous		39		36
Total other assets	$	437	$	453

(1)

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

Accounts Payable (Tables)

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Schedule of Accounts Payable

The following table sets forth the components of the Company’s accounts payable at December 31, 2018 and 2017.

	December 31,
	2018		2017
Trade payables	$	1,111	$	1,008
Dividends payable		—		31
VAT and other payables		26		36
Total accounts payable	$	1,137	$	1,075

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Payables And Accruals [Abstract]

Schedule of Other Accrued Liabilities

The following table sets forth the components of the Company’s other accrued liabilities at December 31, 2018 and 2017.

	December 31,
	2018		2017
Compensation and other employee-related costs	$	108	$	174
Employee separation costs (1)		16		27
Accrued litigation (2)		76		13
Environmental remediation (2)		74		66
Income taxes		87		58
Customer rebates		79		83
Deferred income		6		8
Accrued interest		21		24
Miscellaneous (3)		92		105
Total other accrued liabilities	$	559	$	558

(1)

Represents the current portion of accrued employee separation costs related to the Company’s restructuring and other activities.

(2)

Represents the current portion of accrued litigation and environmental remediation, which are discussed further in “Note 21 – Commitments and Contingent Liabilities.”

(3)

Debt (Tables)

12 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Components of Debt

The following table sets forth the components of the Company’s debt at December 31, 2018 and 2017.

	December 31,
	2018			2017
Senior secured term loans:
Tranche B-1 Dollar Term Loan due May 2022	$	—		$	923
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		—			469
Tranche B-2 Dollar Term Loan due May 2025		893			—
Tranche B-2 Euro Term Loan due May 2025 (€347 at December 31, 2018)		396			—
Senior unsecured notes:
6.625% due May 2023		908			1,158
7.000% due May 2025		750			750
6.125% due May 2023 (€295 at December 31, 2017)		—			350
4.000% due May 2026 (€450 at December 31, 2018)		513			—
5.375% due May 2027		500			500
Capital lease obligations		2			3
Build-to-suit lease obligation		55			8
Total debt		4,017			4,161
Less: Unamortized issue discounts		(10	)		(8	)
Less: Unamortized debt issuance costs		(35	)		(41	)
Less: Current maturities of long-term debt		(13	)		(15	)
Total long-term debt, net	$	3,959		$	4,097

Schedule of Debt Principal Maturities

The following table sets forth the Company’s debt principal maturities for the next five years and thereafter.

	Year Ended
	December 31,
2019	$	13
2020		13
2021		13
2022		13
2023		921
Thereafter		2,987
Total principal maturities on senior debt	$	3,960

Estimated Fair Values of Senior Debt Issues

	December 31, 2018					December 31, 2017
	Carrying Value			Fair Value		Carrying Value			Fair Value
Senior secured term loans:
Tranche B-1 Dollar Term Loan due May 2022	$	—		$	—	$	923		$	928
Tranche B-1 Euro Term Loan due May 2022 (€394 at December 31, 2017)		—			—		469			471
Tranche B-2 Dollar Term Loan due May 2025		893			862		—			—
Tranche B-2 Euro Term Loan due May 2025 (€347 at December 31, 2018)		396			394		—			—
Senior unsecured notes:
6.625% due May 2023		908			918		1,158			1,228
7.000% due May 2025		750			761		750			816
6.125% due May 2023 (€295 at December 31, 2017)		—			—		350			373
4.000% due May 2026 (€450 at December 31, 2018)		513			487		—			—
5.375% due May 2027		500			454		500			521
Total senior debt		3,960		$	3,876		4,150		$	4,337
Less: Unamortized issue discounts		(10	)				(8	)
Less: Unamortized debt issuance costs		(35	)				(41	)
Total senior debt, net	$	3,915				$	4,101

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Other Liabilities Disclosure [Abstract]

Schedule of Other Liabilities

The following table sets forth the components of the Company’s other liabilities at December 31, 2018 and 2017.

	December 31,
	2018		2017
Environmental remediation (1)	$	152	$	187
Employee-related costs (2)		130		123
Accrued litigation (1)		53		48
Asset retirement obligations		51		43
Deferred revenue		7		6
Miscellaneous (3)		64		68
Total other liabilities	$	457	$	475

(1)

The Company’s accrued environmental remediation and accrued litigation liabilities are discussed further in “Note 21 – Commitments and Contingent Liabilities.”

(2)

Employee-related costs primarily represent liabilities associated with the Company’s long-term employee benefits plans.

(3)

Miscellaneous primarily includes an accrued indemnification liability of $46 and $52 at December 31, 2018 and 2017, respectively.

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Commitments And Contingencies Disclosure [Abstract]

Summary of Asset Retirement Obligations

The following table sets forth the activity in the Company’s asset retirement obligations for the years ended December 31, 2018 and 2017.

	Year Ended December 31,
	2018			2017
Balance at January 1,	$	48		$	43
Accretion expense		10			6
Settlements and payments		(1	)		(1	)
Balance at December 31,	$	57		$	48

Current portion	$	6		$	5
Non-current portion		51			43

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Weighted Average Assumptions of Stock Options

The following table sets forth the weighted-average assumptions used to determine expense related to stock option awards granted during the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Risk-free interest rate		2.65	%		2.14	%		1.46	%
Expected term (years)		6			6			6
Volatility		47.56	%		44.49	%		60.00	%
Dividend yield		1.42	%		0.35	%		2.14	%
Fair value per stock option	$	20.47		$	15.21		$	3.41

Schedule of Stock Options Activity

The following table sets forth Chemours’ stock option activity for the year ended December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Exercise Price (per Share)		Weighted-average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Outstanding, December 31, 2017		6,597		$	15.72		5.11	$	226,524
Granted		495			48.41
Exercised		(1,073	)		14.69
Forfeited		(46	)		37.77
Expired		(3	)		18.80
Outstanding, December 31, 2018		5,970		$	18.45		4.80	$	72,108
Exercisable, December 31, 2018		4,401		$	15.00		3.91	$	59,486

Schedule of Restricted Stock Units Activity

The following table sets forth non-vested RSUs, both with and without a performance condition, at December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Grant Date Fair Value (per Share)
Non-vested, December 31, 2017		1,165		$	15.34
Granted		135			48.35
Vested		(1,034	)		14.86
Forfeited		(19	)		30.94
Non-vested, December 31, 2018		247		$	34.22

Schedule of Performance Share Units Activity

The following table sets forth non-vested PSUs at 100% of target amounts at December 31, 2018.

	Number of Shares (in Thousands)			Weighted-average Grant Date Fair Value (per Share)
Non-vested, December 31, 2017		987		$	12.94
Granted		139			52.34
Vested		(19	)		24.16
Non-vested, December 31, 2018		1,107		$	17.71

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Loss

The following table sets forth the components of accumulated other comprehensive loss, net of income taxes, for the years ended December 31, 2018, 2017, and 2016.

	Cumulative Translation Adjustment			Net Investment Hedge			Cash Flow Hedge		Employee Benefits			Total
Balance at January 1, 2016	$	(285	)	$	8		$	—	$	(259	)	$	(536	)
Other comprehensive (loss) income		(73	)		14			—		18			(41	)
Balance at December 31, 2016		(358	)		22			—		(241	)		(577	)
Other comprehensive income (loss)		200			(62	)		—		(3	)		135
Balance at December 31, 2017		(158	)		(40	)		—		(244	)		(442	)
Other comprehensive (loss) income		(75	)		15			6		(68	)		(122	)
Balance at December 31, 2018	$	(233	)	$	(25	)	$	6	$	(312	)	$	(564	)

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2018

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets and Liabilities At Fair Value

The following table sets forth the fair value of the Company’s derivative assets and liabilities, and their level within the fair value hierarchy, at December 31, 2018 and 2017.

		December 31,
	Balance Sheet Location	2018		2017
Asset derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Accounts and notes receivable, net	$	1	$	—
Foreign currency forward contracts designated as a cash flow hedge	Accounts and notes receivable, net		3		—
Total asset derivatives		$	4	$	—

Liability derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Other accrued liabilities	$	1	$	—
Total liability derivatives		$	1	$	—

Schedule of Pre-tax Charge the Fair Value of Derivative Assets and Liabilities

The following table sets forth the pre-tax changes in fair value of the Company’s derivative assets and liabilities for the years ended December 31, 2018, 2017, and 2016.

	Gain (Loss) Recognized In
						Accumulated Other
Year Ended December 31,	Cost of Goods Sold		Other Income, Net			Comprehensive Loss
2018
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	3		$	—
Foreign currency forward contracts designated as a cash flow hedge		4		—			10
Euro-denominated debt designated as a net investment hedge		—		—			32

2017
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	4		$	—
Euro-denominated debt designated as a net investment hedge		—		—			(86	)

2016
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	(15	)	$	—
Euro-denominated debt designated as a net investment hedge		—		—			14

Long-term Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2018

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Schedules of Net Periodic Pension Income

The following table sets forth the Company’s net periodic pension income and amounts recognized in other comprehensive income (loss) for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Net periodic pension cost (income):
Service cost	$	14		$	16		$	14
Interest cost		16			16			19
Expected return on plan assets		(58	)		(75	)		(63	)
Amortization of prior service gain		(2	)		(2	)		(1	)
Amortization of actuarial loss		12			22			23
Curtailment gain		—			—			(2	)
Settlement loss		—			1			5
Net periodic pension income		(18	)		(22	)		(5	)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss (gain)		115			(24	)		17
Amortization of actuarial loss		(16	)		(24	)		(28	)
Amortization of prior service gain		2			2			3
Effect of foreign exchange rates		(8	)		38			(15	)
Cost (benefit) recognized in other comprehensive income		93			(8	)		(23	)
Total net periodic pension income and cost (benefit) recognized in other comprehensive income	$	75		$	(30	)	$	(28	)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The following table sets forth the pre-tax amounts recognized in accumulated other comprehensive loss for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Net loss	$	419		$	329		$	336
Prior service credit		(10	)		(11	)		(11	)
Total amount recognized in accumulated other comprehensive loss	$	409		$	318		$	325

Summary of Benefit Obligations and Fair Value of Plan Assets and Funded Status of Plan

The following table sets forth summarized information on the Company’s pension plans at December 31, 2018 and 2017.

	December 31,
	2018			2017
Change in benefit obligation:
Benefit obligation at beginning of year	$	1,177		$	1,105
Service cost		14			16
Interest cost		16			16
Plan participants’ contributions		2			2
Actuarial loss (gain)		45			(39	)
Benefits paid		(46	)		(53	)
Plan amendments		—			(1	)
Settlements and transfers		2			(3	)
Other events		—			(4	)
Currency translation		(42	)		138
Benefit obligation at end of year		1,168			1,177
Change in plan assets:
Fair value of plan assets at beginning of year		1,363			1,169
Actual (loss) return on plan assets		(17	)		60
Employer contributions		15			38
Plan participants’ contributions		2			2
Benefits paid		(46	)		(53	)
Settlements and transfers		2			(3	)
Other events		—			(3	)
Currency translation		(51	)		153
Fair value of plan assets at end of year		1,268			1,363
Total funded status at end of year	$	100		$	186

Schedule of Amounts Recognized in the Consolidated Balance Sheet

The following table sets forth the net amounts recognized in the Company’s consolidated balance sheets at December 31, 2018 and 2017.

	December 31,
	2018			2017
Non-current assets	$	174		$	258
Current liabilities		(1	)		(1	)
Non-current liabilities		(73	)		(71	)
Total net amount recognized	$	100		$	186

Schedule of Projected Benefit Obligations in Excess of Fair Value of Plan Assets

	December 31,
Pension plans with projected benefit obligation in excess of plan assets	2018		2017
Projected benefit obligation	$	177	$	178
Accumulated benefit obligation		149		149
Fair value of plan assets		103		106

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets

	December 31,
Pension plans with accumulated benefit obligation in excess of plan assets	2018		2017
Projected benefit obligation	$	177	$	178
Accumulated benefit obligation		149		149
Fair value of plan assets		103		106

Schedule of Assumptions Used

The following tables set forth the assumptions that have been used to determine the Company’s benefit obligations and net benefit cost at December 31, 2018 and 2017.

	December 31,
Weighted-average assumptions used to determine benefit obligations	2018			2017
Discount rate		2.0	%		1.9	%
Rate of compensation increase (1)		2.5	%		2.5	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

	December 31,
Weighted-average assumptions used to determine net benefit cost	2018			2017
Discount rate		1.9	%		1.8	%
Rate of compensation increase (1)		2.5	%		2.5	%
Expected return on plan assets		4.1	%		5.7	%

(1)

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Schedule of Allocation of Plan Assets

The following table sets forth the weighted-average allocation for the Company’s pension plan assets at December 31, 2018 and 2017.

	December 31,
	2018			2017
Cash and cash equivalents		5	%		5	%
U.S. and non-U.S. equity securities		45	%		42	%
Fixed income securities		50	%		53	%
Total weighted-average allocation		100	%		100	%

The following tables set forth the fair values of the Company’s pension assets by level within the fair value hierarchy at December 31, 2018 and 2017.

	Fair Value Measurements at December 31, 2018
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	487		$	3	$	484
Debt - corporate issued		130			33		97
U.S. and non-U.S. equities		264			263		1
Mututal Funds		296			—		296
Derivatives - asset position		9			—		9
Derivatives - liability position		(5	)		—		(5	)
Cash and cash equivalents		67			67		—
Other		12			8		4
Total pension assets before pension receivables		1,260		$	374	$	886
Pension trust receivables, net (1)		8
Total pension assets	$	1,268

(1)

Receivables are primarily for investment income earned but not yet received.

	Fair Value Measurements at December 31, 2017
	Total			Level 1		Level 2
Asset category:
Debt - government issued	$	505		$	1	$	504
Debt - corporate issued		144			24		120
Debt - asset backed		40			—		40
U.S. and non-U.S. equities		581			295		286
Derivatives - asset position		8			2		6
Derivatives - liability position		(1	)		—		(1	)
Cash and cash equivalents		65			65		—
Other		14			11		3
Total pension assets before pension receivables		1,356		$	398	$	958
Pension trust receivables, net (1)		7
Total pension assets	$	1,363

(1)

Receivables are primarily for investment income earned but not yet received.

Schedule of Expected Benefit Payments

The following table sets forth the benefit payments that are expected to be paid by the Company over the next five years and the five years thereafter as of December 31, 2018.

	Year Ended
	December 31,
2019	$	45
2020		47
2021		46
2022		47
2023		50
2024 to 2028		264

Geographic and Segment Information (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Schedule of Net Sales and Net Property, Plant and Equipment by Geographical Area

The following table sets forth the geographic locations of the Company’s net sales and property, plant, and equipment as of, and for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018				2017				2016
	Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net		Net Sales (1)		Property, Plant, and Equipment, Net
North America	$	2,378	$	2,279	$	2,255	$	2,018	$	2,288	$	1,861
Asia Pacific		1,720		124		1,593		131		1,315		129
Europe, the Middle East, and Africa		1,685		293		1,506		302		1,081		278
Latin America (2)		855		595		829		557		716		516
Total net sales and property, plant, and equipment, net	$	6,638	$	3,291	$	6,183	$	3,008	$	5,400	$	2,784

(1)

Net sales are attributed to countries based on customer location.

(2)

Latin America includes Mexico.

Schedule of Segment Information

The following table sets forth certain summary financial information for the Company’s reportable segments and Corporate and Other as of, and for the years ended December 31, 2018, 2017, and 2016.

Year Ended December 31,	Fluoroproducts		Chemical Solutions		Titanium Technologies		Corporate and Other			Total
2018
Net sales to external customers	$	2,862	$	602	$	3,174	$	—		$	6,638
Adjusted EBITDA		783		64		1,055		(162	)		1,740
Depreciation and amortization		117		20		119		28			284
Equity in earnings of affiliates		43		—		—		—			43
Net assets		2,309		506		1,487		(3,282	)		1,020
Investments in affiliates		160		—		—		—			160
Purchases of property, plant, and equipment		274		75		91		58			498

2017
Net sales to external customers	$	2,654	$	571	$	2,958	$	—		$	6,183
Adjusted EBITDA		669		57		862		(166	)		1,422
Depreciation and amortization		109		18		118		28			273
Equity in earnings of affiliates		33		—		—		—			33
Net assets		1,842		460		1,785		(3,222	)		865
Investments in affiliates		173		—		—		—			173
Purchases of property, plant, and equipment		249		65		65		32			411

2016
Net sales to external customers	$	2,264	$	772	$	2,364	$	—		$	5,400
Adjusted EBITDA		445		39		466		(128	)		822
Depreciation and amortization		101		30		119		34			284
Equity in earnings of affiliates		26		—		—		3			29
Net assets		1,400		292		1,513		(3,101	)		104
Investments in affiliates		116		—		—		20			136
Purchases of property, plant, and equipment		120		104		105		9			338

Reconciliation of EBITDA from Segments to Consolidated Net Income (Loss) Before Income Taxes

The following table sets forth a reconciliation of Adjusted EBITDA to the Company’s consolidated net income (loss) before income taxes for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018			2017			2016
Income (loss) before income taxes	$	1,155		$	912		$	(11	)
Interest expense, net		195			214			219
Depreciation and amortization		284			273			284
Non-operating pension and other post-retirement employee benefit income		(27	)		(34	)		(20	)
Exchange (gains) losses, net		(1	)		(3	)		57
Restructuring, asset-related, and other charges (1)		49			57			170
Loss (gain) on extinguishment of debt		38			1			(6	)
Gain on sales of assets and businesses (2)		(45	)		(22	)		(254	)
Transaction costs (3)		9			3			19
Legal charges (4)		82			9			343
Other charges		1			12			21
Adjusted EBITDA	$	1,740		$	1,422		$	822

(1)

Includes restructuring, asset-related, and other charges, which are discussed in further detail in “Note 7 – Restructuring, Asset-related, and Other Charges.”

(2)

(3)

Includes costs associated with the Company’s debt transactions, as well as accounting, legal, and bankers’ transaction costs incurred in connection with the Company’s strategic initiatives.

(4)

Schedule of Net Sales to External Customers by Product Group

The following table sets forth the Company’s net sales to external customers by product group for the years ended December 31, 2018, 2017, and 2016.

	Year Ended December 31,
	2018		2017		2016
Fluorochemicals	$	1,497	$	1,378	$	1,093
Fluoropolymers		1,365		1,276		1,171
Mining solutions		289		261		262
Performance chemicals and intermediates		313		306		298
Titanium dioxide and other minerals		3,174		2,958		2,364
Divested businesses (1)		—		4		212
Total net sales	$	6,638	$	6,183	$	5,400

(1)

Inclusive of the Company’s C&D and Sulfur businesses, as well as its Aniline facility in Beaumont, Texas, which were all sold in 2016.

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Data

The following table sets forth a summary of the Company’s quarterly results of operations for the years ended December 31, 2018 and 2017.

	For the Three Months Ended
2018	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,730	$	1,816	$	1,628	$	1,464	$	6,638
Cost of goods sold		1,193		1,259		1,151		1,064		4,667
Income before income taxes		381		323		269		182		1,155
Net income		297		282		275		142		996
Net income attributable to Chemours		297		281		275		142		995
Basic earnings per share of common stock		1.63		1.58		1.56		0.83		5.62
Diluted earnings per share of common stock		1.58		1.53		1.51		0.81		5.45

	For the Three Months Ended
2017	March 31,		June 30,		September 30,		December 31,		Full Year (1),
Net sales	$	1,437	$	1,588	$	1,584	$	1,575	$	6,183
Cost of goods sold		1,081		1,150		1,119		1,090		4,438
Income before income taxes		173		225		250		264		912
Net income		151		161		207		228		747
Net income attributable to Chemours		150		161		207		228		746
Basic earnings per share of common stock		0.82		0.87		1.12		1.23		4.04
Diluted earnings per share of common stock		0.79		0.84		1.08		1.19		3.91

(1)

Individual quarters may not sum to full year amounts due to rounding.

Guarantor Condensed Consolidating Financial Information (Tables)

12 Months Ended

Dec. 31, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2018
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,974	$	4,484		$	(1,820	)	$	6,638
Cost of goods sold		—			3,112		3,380			(1,825	)		4,667
Gross profit		—			862		1,104			5			1,971
Selling, general, and administrative expense		33			485		163			(24	)		657
Research and development expense		—			76		6			—			82
Restructuring, asset-related, and other charges		—			46		3			—			49
Total other operating expenses		33			607		172			(24	)		788
Equity in earnings of affiliates		—			—		43			—			43
Equity in earnings of subsidiaries		1,155			2		—			(1,157	)		—
Interest (expense) income, net		(210	)		5		10			—			(195	)
Loss on extinguishment of debt		(38	)		—		—			—			(38	)
Intercompany interest income (expense), net		47			10		(57	)		—			—
Other income (expense), net		25			199		(40	)		(22	)		162
Income before income taxes		946			471		888			(1,150	)		1,155
(Benefit from) provision for income taxes		(50	)		98		111			—			159
Net income		996			373		777			(1,150	)		996
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	996		$	373	$	776		$	(1,150	)	$	995
Comprehensive income attributable to Chemours	$	873		$	375	$	637		$	(1,012	)	$	873

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,887	$	4,030		$	(1,734	)	$	6,183
Cost of goods sold		—			3,084		3,045			(1,691	)		4,438
Gross profit		—			803		985			(43	)		1,745
Selling, general, and administrative expense		36			449		179			(38	)		626
Research and development expense		—			74		7			—			81
Restructuring, asset-related, and other charges		—			56		1			—			57
Total other operating expenses		36			579		187			(38	)		764
Equity in earnings of affiliates		—			—		33			—			33
Equity in earnings of subsidiaries		849			—		—			(849	)		—
Interest (expense) income, net		(220	)		3		3			—			(214	)
Loss on extinguishment of debt		(1	)		—		—			—			(1	)
Intercompany interest income (expense), net		64			—		(64	)		—			—
Other income (expense), net		29			139		(21	)		(34	)		113
Income before income taxes		685			366		749			(888	)		912
(Benefit from) provision for income taxes		(62	)		117		114			(4	)		165
Net income		747			249		635			(884	)		747
Less: Net income attributable to non-controlling interests		—			—		1			—			1
Net income attributable to Chemours	$	747		$	249	$	634		$	(884	)	$	746
Comprehensive income attributable to Chemours	$	881		$	253	$	828		$	(1,081	)	$	881

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,622			(1,543	)		4,297
Gross profit		—			531			600			(28	)		1,103
Selling, general, and administrative expense		21			794			151			(20	)		946
Research and development expense		—			77			4			—			81
Restructuring, asset-related, and other charges		—			168			2			—			170
Total other operating expenses		21			1,039			157			(20	)		1,197
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(217	)		(3	)		1			—			(219	)
Gain on extinguishment of debt		6			—			—			—			6
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			74			(20	)		267
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to non-controlling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2018
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	239		$	962		$	—		$	1,201
Accounts and notes receivable, net		—		297			564			—			861
Intercompany receivable		2		1,057			91			(1,150	)		—
Inventories		—		483			749			(85	)		1,147
Prepaid expenses and other		—		58			26			—			84
Total current assets		2		2,134			2,392			(1,235	)		3,293
Property, plant, and equipment		—		6,870			2,122			—			8,992
Less: Accumulated depreciation		—		(4,591	)		(1,110	)		—			(5,701	)
Property, plant, and equipment, net		—		2,279			1,012			—			3,291
Goodwill and other intangible assets, net		—		167			14			—			181
Investments in affiliates		—		—			160			—			160
Investments in subsidiaries		4,487		11			—			(4,498	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		17		154			274			(8	)		437
Total assets	$	5,656	$	4,745		$	3,852		$	(6,891	)	$	7,362
Liabilities
Current liabilities:
Accounts payable	$	—	$	637		$	500		$	—		$	1,137
Current maturities of long-term debt		13		—			—			—			13
Intercompany payable		698		92			360			(1,150	)		—
Other accrued liabilities		21		341			198			(1	)		559
Total current liabilities		732		1,070			1,058			(1,151	)		1,709
Long-term debt, net		3,902		57			—			—			3,959
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		8		143			82			(16	)		217
Other liabilities		—		372			85			—			457
Total liabilities		4,642		1,642			2,375			(2,317	)		6,342
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		1,014		3,103			1,471			(4,574	)		1,014
Non-controlling interests		—		—			6			—			6
Total equity		1,014		3,103			1,477			(4,574	)		1,020
Total liabilities and equity	$	5,656	$	4,745		$	3,852		$	(6,891	)	$	7,362

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2017
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	761		$	795		$	—		$	1,556
Accounts and notes receivable, net		—		308			611			—			919
Intercompany receivable		3		904			581			(1,488	)		—
Inventories		—		394			631			(90	)		935
Prepaid expenses and other		—		57			15			11			83
Total current assets		3		2,424			2,633			(1,567	)		3,493
Property, plant, and equipment		—		6,449			2,062			—			8,511
Less: Accumulated depreciation		—		(4,438	)		(1,065	)		—			(5,503	)
Property, plant, and equipment, net		—		2,011			997			—			3,008
Goodwill and other intangible assets, net		—		152			14			—			166
Investments in affiliates		—		—			173			—			173
Investments in subsidiaries		4,393		—			—			(4,393	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		23		115			328			(13	)		453
Total assets	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293
Liabilities
Current liabilities:
Accounts payable	$	31	$	606		$	438		$	—		$	1,075
Current maturities of long-term debt		15		—			—			—			15
Intercompany payable		542		581			365			(1,488	)		—
Other accrued liabilities		34		343			181			—			558
Total current liabilities		622		1,530			984			(1,488	)		1,648
Long-term debt, net		4,087		10			—			—			4,097
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		127			105			(24	)		208
Other liabilities		—		388			87			—			475
Total liabilities		4,709		2,055			2,326			(2,662	)		6,428
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		860		2,647			1,814			(4,461	)		860
Non-controlling interests		—		—			5			—			5
Total equity		860		2,647			1,819			(4,461	)		865
Total liabilities and equity	$	5,569	$	4,702		$	4,145		$	(7,123	)	$	7,293

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2018
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(159	)	$	10		$	1,289		$	—		$	1,140
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(390	)		(108	)		—			(498	)
Acquisition of business, net		—			(37	)		—			—			(37	)
Proceeds from sales of assets and businesses, net		—			46			—			—			46
Intercompany investing activities		—			(153	)		(999	)		1,152			—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(532	)		(1,107	)		1,152			(487	)
Cash flows from financing activities
Proceeds from issuance of debt, net		520			—			—			—			520
Debt repayments		(679	)		—			—			—			(679	)
Payments related to extinguishment of debt		(29	)		—			—			—			(29	)
Payments of debt issuance costs		(12	)		—			—			—			(12	)
Purchases of treasury stock, at cost		(644	)		—			—			—			(644	)
Intercompany financing activities		1,152			—			—			(1,152	)		—
Proceeds from exercised stock options, net		16			—			—			—			16
Payments related to tax withholdings on vested restricted stock units		(17	)		—			—			—			(17	)
Payments of dividends		(148	)		—			—			—			(148	)
Cash provided by (used for) financing activities		159			—			—			(1,152	)		(993	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(15	)		—			(15	)
(Decrease) increase in cash and cash equivalents		—			(522	)		167			—			(355	)
Cash and cash equivalents at January 1,		—			761			795			—			1,556
Cash and cash equivalents at December 31,	$	—		$	239		$	962		$	—		$	1,201

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2017
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(132	)	$	603		$	169		$	—		$	640
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(327	)		(84	)		—			(411	)
Proceeds from sales of assets and businesses, net		—			39			—			—			39
Intercompany investing activities		—			220			—			(220	)		—
Foreign exchange contract settlements, net		—			2			—			—			2
Cash used for investing activities		—			(66	)		(84	)		(220	)		(370	)
Cash flows from financing activities
Intercompany short-term borrowings, net		(220	)		—			—			220			—
Proceeds from issuance of debt, net		495			—			—			—			495
Debt repayments		(27	)		—			—			—			(27	)
Payments related to extinguishment of debt		(1	)		—			—			—			(1	)
Payments of debt issuance costs		(6	)		—			—			—			(6	)
Purchases of treasury stock, at cost		(106	)		—			—			—			(106	)
Proceeds from exercised stock options, net		31			—			—			—			31
Payments related to tax withholdings on vested restricted stock units		(12	)		—			—			—			(12	)
Payments of dividends		(22	)		—			—			—			(22	)
Cash provided by financing activities		132			—			—			220			352
Effect of exchange rate changes on cash and cash equivalents		—			—			32			—			32
Increase in cash and cash equivalents		—			537			117			—			654
Cash and cash equivalents at January 1,		—			224			678			—			902
Cash and cash equivalents at December 31,	$	—		$	761		$	795		$	—		$	1,556

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Cash flows from operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Cash flows from investing activities
Purchases of property, plant, and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets and businesses, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Investments in affiliates		—			—			(1	)		—			(1	)
Foreign exchange contract settlements, net		—			(12	)		—			—			(12	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Cash flows from financing activities
Intercompany short-term borrowings, net		560			—			—			(560	)		—
Debt repayments		(369	)		(12	)		—			—			(381	)
Payments of debt issuance costs		(4	)		—			—			—			(4	)
Proceeds from exercised stock options, net		11			—			—			—			11
Payments of dividends		(22	)		—			—			—			(22	)
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash and cash equivalents		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at January 1,		—			95			271			—			366
Cash and cash equivalents at December 31,	$	—		$	224		$	678		$	—		$	902

Background and Description of the Business Narrative (Details)	12 Months Ended
	Dec. 31, 2018 segment facility
Segment Reporting Information [Line Items]
Number of reportable segments \| segment	3
Number of facilities	28
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities	2
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities	5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities	20
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities	1

Basis of Presentation (Details) $ in Millions	12 Months Ended
Basis of Presentation (Details) $ in Millions	Dec. 31, 2016 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Cumulative translation adjustment	$ 31

Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)
ASU 2014-09 [Member] \| Net Sales [Member]
Summary Of Significant Accounting Policies [Line Items]
Changes in classification of amounts on adoption of new guidance	$ 4
ASU 2014-09 [Member] \| Cost of Goods Sold [Member]
Summary Of Significant Accounting Policies [Line Items]
Changes in classification of amounts on adoption of new guidance	$ 2
Consolidated Subsidiaries [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Voting stock ownership percentage	50.00%
Consolidated Subsidiaries [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Voting stock ownership percentage	20.00%
Consolidated Subsidiaries [Member] \| Outside Shareholders [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Non controlling interests, ownership percentage by parent	100.00%

Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2018
Equipment and Buildings [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Useful Life	15 years
Equipment and Buildings [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Useful Life	25 years
Software Development [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Useful Life	5 years
Software Development [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Useful Life	7 years

Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets and Asset Retirement Obligations (Details)	12 Months Ended
	Dec. 31, 2018
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Useful life of asset retirement obligation	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Useful life of asset retirement obligation	25 years

Summary of Significant Accounting Policies - Impacts of Adoption of New Accounting Guidance on Consolidated Statements of Operations (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary Of Significant Accounting Policies [Line Items]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Cost of goods sold	1,064	1,151	1,259	1,193	1,090	1,119	1,150	1,081	4,667	4,438	4,297
Gross profit									1,971	1,745	1,103
Selling, general, and administrative expense									657	626	946
Research and development expense									82	81	81
Restructuring, asset-related, and other charges									49	57	170
Total other operating expenses									788	764	1,197
Equity in earnings of affiliates									43	33	29
Interest expense, net									(195)	(214)	(219)
(Loss) gain on extinguishment of debt									(38)	(1)	6
Other income, net									162	113	267
Income (loss) before income taxes	182	269	323	381	264	250	225	173	1,155	912	(11)
Provision for (benefit from) income taxes									159	165	(18)
Net income (loss)	142	275	282	297	228	207	161	151	996	747	7
Less: Net income attributable to non-controlling interests									1	1	0
Net income (loss) attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	995	$ 746	$ 7
ASU 2014-09 [Member] \| Without Topic 606 [Member]
Summary Of Significant Accounting Policies [Line Items]
Net sales									6,634
Cost of goods sold									4,665
Gross profit									1,969
Selling, general, and administrative expense									659
Research and development expense									82
Restructuring, asset-related, and other charges									49
Total other operating expenses									790
Equity in earnings of affiliates									43
Interest expense, net									(195)
(Loss) gain on extinguishment of debt									(38)
Other income, net									166
Income (loss) before income taxes									1,155
Provision for (benefit from) income taxes									159
Net income (loss)									996
Less: Net income attributable to non-controlling interests									1
Net income (loss) attributable to Chemours									995
ASU 2014-09 [Member] \| Topic 606 Adjustments [Member]
Summary Of Significant Accounting Policies [Line Items]
Net sales									4
Cost of goods sold									2
Gross profit									2
Selling, general, and administrative expense									(2)
Total other operating expenses									(2)
Other income, net									$ (4)

Summary of Significant Accounting Policies - Reclassification of Non-operating Pension and Other Post-retirement Employee Benefit Income (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary Of Significant Accounting Policies [Line Items]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Cost of goods sold	1,064	1,151	1,259	1,193	1,090	1,119	1,150	1,081	4,667	4,438	4,297
Gross profit									1,971	1,745	1,103
Selling, general, and administrative expense									657	626	946
Research and development expense									82	81	81
Restructuring, asset-related, and other charges									49	57	170
Total other operating expenses									788	764	1,197
Equity in earnings of affiliates									43	33	29
Interest expense, net									(195)	(214)	(219)
(Loss) gain on extinguishment of debt									(38)	(1)	6
Other income, net									162	113	267
Income (loss) before income taxes	182	269	323	381	264	250	225	173	1,155	912	(11)
Provision for (benefit from) income taxes									159	165	(18)
Net income (loss)	142	275	282	297	228	207	161	151	996	747	7
Less: Net income attributable to non-controlling interests									1	1	0
Net income (loss) attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	$ 995	746	7
As Reported [Member]
Summary Of Significant Accounting Policies [Line Items]
Net sales										6,183	5,400
Cost of goods sold										4,429	4,290
Gross profit										1,754	1,110
Selling, general, and administrative expense										602	934
Research and development expense										80	80
Restructuring, asset-related, and other charges										57	170
Total other operating expenses										739	1,184
Equity in earnings of affiliates										33	29
Interest expense, net										(214)	(219)
(Loss) gain on extinguishment of debt										(1)	6
Other income, net										79	247
Income (loss) before income taxes										912	(11)
Provision for (benefit from) income taxes										165	(18)
Net income (loss)										747	7
Less: Net income attributable to non-controlling interests										1
Net income (loss) attributable to Chemours										746	7
ASU 2017-07 [Member] \| Adjustments [Member]
Summary Of Significant Accounting Policies [Line Items]
Cost of goods sold										9	7
Gross profit										(9)	(7)
Selling, general, and administrative expense										24	12
Research and development expense										1	1
Total other operating expenses										25	13
Other income, net										$ 34	$ 20

Significant Transactions and Events - Narrative (Details) $ in Millions	1 Months Ended						3 Months Ended	12 Months Ended
	Apr. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Aug. 31, 2016 USD ($)	Jul. 31, 2016 USD ($)	May 31, 2016 USD ($)	Mar. 31, 2016 USD ($) a	Jun. 30, 2016 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Apr. 30, 2016 USD ($)
Significant Transactions And Events [Line Items]
Asset related and other charges								$ 4	$ 1	$ 119
Recognized gain on sale of land		$ 42						45	22	254
Net cash proceeds of transaction		39						46	39	708
Environmental remediation activities amount		$ 3						36	$ 48	44
ICOR International, Inc. [Member]
Significant Transactions And Events [Line Items]
Total consideration in all cash acquisition	$ 37
ICOR International, Inc. [Member] \| Maximum [Member]
Significant Transactions And Events [Line Items]
Acquisition related expense								$ 1
Linden, New Jersey [Member]
Significant Transactions And Events [Line Items]
Number of acre of land for sale \| a						210
Other Income, Net [Member]
Significant Transactions And Events [Line Items]
Gain on sale of assets										89
Sulfur Business [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Significant Transactions And Events [Line Items]
Purchase price							$ 325
Proceeds from sale				$ 311
Sulfur Business [Member] \| Assets Held-for-sale [Member]
Significant Transactions And Events [Line Items]
Cash proceeds from sale of facility					$ 10
Loss on sale				$ 4
Sulfur Business [Member] \| Disposed by Sale [Member]
Significant Transactions And Events [Line Items]
Asset related and other charges							$ 58			58
Clean and Disinfect Product Line [Member]
Significant Transactions And Events [Line Items]
Gain on sale of assets										169
Clean and Disinfect Product Line [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Significant Transactions And Events [Line Items]
Purchase price											$ 230
Proceeds from sale			$ 223
Cash transferred in sale			$ 2
Transaction and other charges										$ 9
Aniline Facility, Beaumont, Texas [Member] \| Disposed by Sale [Member]
Significant Transactions And Events [Line Items]
Cash proceeds from sale of facility						$ 140
Transaction costs						$ 11

Significant Transactions and Events - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed in Acquisition (Details) - ICOR International, Inc. [Member] - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2018	Apr. 03, 2018
Fair Value, Assets acquired:
Fair Value, Accounts receivable - trade	$ 4	$ 4
Fair Value, Inventories	8	8
Fair Value,Property, plant, and equipment	1	1
Fair Value, Identifiable intangible asset:
Fair Value, Customer relationships	22	20
Fair Value, Total assets acquired	35	33
Fair Value, Liabilities assumed:
Fair Value, Accounts payable	1	1
Fair Value, Other accrued liabilities	1	1
Fair Value, Total liabilities assumed	2	2
Fair Value, Total identifiable net assets acquired	33	31
Fair Value, Goodwill	4	6
Fair Value, Net assets acquired	$ 37	$ 37
Weighted-average Useful Life (Years), Customer relationships	5 years
Adjustments [Member]
Fair Value, Identifiable intangible asset:
Fair Value, Customer relationships	$ 2
Fair Value, Total assets acquired	2
Fair Value, Liabilities assumed:
Fair Value, Total identifiable net assets acquired	2
Fair Value, Goodwill	$ (2)

Net Sales - Summary of Contract Balances from Contracts with Customers (Details) - Topic 606 [Member] - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Accounts receivable - trade, net	$ 790	$ 847
Customer rebates	$ 79	$ 83

Net Sales - Summary of Contract Balances from Contracts with Customers (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Allowance for doubtful accounts	$ 5	$ 5
Topic 606 [Member]
Disaggregation Of Revenue [Line Items]
Allowance for doubtful accounts	$ 5	$ 5

Net Sales - Narrative (Details) - Topic 606 [Member]	12 Months Ended
Net Sales - Narrative (Details) - Topic 606 [Member]	Dec. 31, 2018 USD ($)
Disaggregation Of Revenue [Line Items]
Contract asset balances	$ 0
Capitalized costs	0
Remaining performance obligations	$ 119,000,000
Revenue, practical expedient, financing component	true

Net Sales - Narrative (Details1) - Topic 606 [Member]	Dec. 31, 2018
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Percentage of remaining performance obligations as revenue	35.00%
Remaining performance obligations original expected period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Percentage of remaining performance obligations as revenue	45.00%
Remaining performance obligations original expected period	1 year

Research and Development Expense - Summary of R&D Expense by Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research and Development [Line Items]
Total research and development expense	$ 82	$ 81	$ 81
Fluoroproducts [Member]
Research and Development [Line Items]
Total research and development expense	50	48	46
Chemical Solutions [Member]
Research and Development [Line Items]
Total research and development expense	2	3	7
Titanium Technologies [Member]
Research and Development [Line Items]
Total research and development expense	28	29	27
Corporate and Other [Member]
Research and Development [Line Items]
Total research and development expense	$ 2	$ 1	$ 1

Restructuring, Asset-Related, and Other Charges - Schedule of Restructuring Program (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Employee separation charges	$ 14	$ 23	$ 4
Decommissioning and other charges	31	33	47
Total restructuring and other charges	45	56	51
Asset-related charges	4	1	119
Total restructuring, asset-related, and other charges	$ 49	$ 57	$ 170

Restructuring, Asset-Related, and Other Charges - Schedule of Restructuring Program (Parenthetical) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Goodwill impairment charge		$ 0	$ 0
Asset-related charges - impairment		4,000,000	1,000,000	$ 119,000,000
Disposed by Sale [Member] \| Sulfur Business [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment	$ 58,000,000			58,000,000
Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Goodwill impairment charge		4,000,000
Asset-related charges - impairment		$ 4,000,000	$ 0	106,000,000
Chemical Solutions [Member] \| Corporate Headquarter Building [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment				13,000,000
Pascagoula, Mississippi [Member] \| Aniline Facility [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges - impairment				$ 48,000,000

Restructuring, Asset-Related, and Other Charges - Schedule of Restructuring Charges (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		$ 45	$ 56	$ 51
Asset-related charges		4	1	119
Restructuring, asset-related and other charges		49	57	170
2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		0	0	6
2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		27	32	0
Restructuring, asset-related and other charges		27	32
2018 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		5	0	0
Restructuring, asset-related and other charges	$ 5
Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		13	24	45
Titanium Technologies [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		1	0	0
Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges		4	0	106
Operating Segments [Member] \| Titanium Technologies [Member] \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		0	0	2
Operating Segments [Member] \| Titanium Technologies [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		0	4	30
Operating Segments [Member] \| Fluoroproducts [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		9	0	0
Operating Segments [Member] \| Fluoroproducts [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		0	3	7
Operating Segments [Member] \| Chemical Solutions [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		2	0	0
Operating Segments [Member] \| Chemical Solutions [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		4	17	8
Operating Segments [Member] \| Fluroproducts \| 2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		0	0	4
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Asset-related charges		0	1	13
Corporate and Other [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		15	32	0
Corporate and Other [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and other charges		$ 9	$ 0	$ 0

Restructuring, Asset-Related, and Other Charges - Narrative (Details)	1 Months Ended		3 Months Ended				12 Months Ended
	Oct. 31, 2017 USD ($) Employee	Aug. 31, 2015 production_line	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2015 position	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges							$ 49,000,000	$ 57,000,000	$ 170,000,000
2015 Global Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated (more than) \| position						430
Employee separation and asset related charges									6,000,000
2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges							27,000,000	32,000,000
Aggregate restructuring costs							59,000,000
2018 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges			$ 5,000,000
New Johnsonville, Tennessee [Member]
Restructuring Cost and Reserve [Line Items]
Number of production lines shut down during period \| production_line		1
Operating Segments [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs, excluding asset-related charges							35,000,000
Expected number of positions to be eliminated \| position						200
Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs, excluding asset-related charges								17,000,000
Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Proceeds from sale of land					$ 10,000,000
Operating Segments [Member] \| Titanium Technologies [Member] \| Edge Moor, Delaware Site [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs, excluding asset-related charges								60,000,000
Decommissioning Costs [Member] \| Operating Segments [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges							4,000,000	17,000,000	8,000,000
Decommissioning Costs [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges								3,000,000	7,000,000
Decommissioning Costs [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges								4,000,000	$ 30,000,000
Decommissioning Costs [Member] \| Corporate and Other [Member] \| Deepwater, New Jersey [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring, asset-related and other charges							9,000,000
Additional Restructuring Charges [Member] \| Operating Segments [Member] \| Niagara Falls, NY [Member]
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges expected to be incurred			10,000,000				10,000,000
Additional Restructuring Charges [Member] \| Corporate and Other [Member] \| Deepwater, New Jersey [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges expected to be incurred			20,000,000				20,000,000
Additional Restructuring Charges [Member] \| Corporate and Other [Member] \| Deepwater, New Jersey [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Additional restructuring charges expected to be incurred			$ 25,000,000				25,000,000
Corporate Function Efforts [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							$ 18,000,000	$ 14,000,000
Voluntary Separation Program [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of positions to be eliminated \| Employee	300
Accrual of termination benefits recognized				$ 18,000,000
Voluntary Separation Program One-Time Financial Incentives [Member] \| 2017 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Accrual of termination benefits recognized	$ 9,000,000

Restructuring, Asset-Related, and Other Charges - Restructuring Program Schedule (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	$ 27	$ 34
Charges to income	14	24
Payments	(25)	(31)
Restructuring reserve, ending	16	27
Fluoroproducts Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	1
Charges to income	0	0
Payments	0	(1)
Restructuring reserve, ending	0	0
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	2	8
Charges to income	0	0
Payments	(2)	(6)
Restructuring reserve, ending	0	2
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	1	4
Charges to income	0	0
Payments	(1)	(3)
Restructuring reserve, ending	0	1
2015 Global Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	1	21
Charges to income	0	1
Payments	0	(21)
Restructuring reserve, ending	1	1
2017 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	23	0
Charges to income	9	23
Payments	(22)	0
Restructuring reserve, ending	10	23
2018 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	0
Charges to income	5	0
Payments	0	0
Restructuring reserve, ending	$ 5	$ 0

Other Income, Net - Components of Other Income (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income										$ 79	$ 30	$ 35
Royalty income		$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	6,638	6,183	5,400
Gain on sales of assets and businesses	$ 42									45	22	254
Exchange gains (losses), net										1	3	(57)
Non-operating pension and other post-retirement employee benefit income										27	34	20
Total other income, net										162	113	267
Royalty Income [Member]
Component of Other Income [Line Items]
Royalty income										$ 10	$ 24	$ 15

Other Income, Net - Components of Other Income (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	$ 79	$ 30	$ 35
Clean and Disinfect Product Line [Member]
Component of Other Income [Line Items]
Gain on sale of asset			169
European Union [Member] \| Fluorinated Greenhouse Gas [Member]
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	67	15	6
East Chicago, Indiana [Member]
Component of Other Income [Line Items]
Gain on sale of asset	3
Repauno New Jersey [Member] \| Land [Member]
Component of Other Income [Line Items]
Gain on sale of asset		13
Linden, New Jersey Sites [Member]
Component of Other Income [Line Items]
Gain on sale of asset	$ 42
Edge Moor, Delaware Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset		$ 12
Beaumont Site [Member]
Component of Other Income [Line Items]
Gain on sale of asset			$ 89

Income Taxes - Components of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current tax expense (benefit):
U.S. federal	$ 23	$ (8)	$ 0
U.S. state and local	4	1	0
International	110	89	93
Total current tax expense	137	82	93
Deferred tax expense (benefit):
U.S. federal	20	60	(101)
U.S. state and local	3	6	(17)
International	(1)	17	7
Total deferred tax expense (benefit)	22	83	(111)
Total provision for (benefit from) income taxes	$ 159	$ 165	$ (18)

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Environmental and other reserves	$ 80	$ 89
Litigation reserves	28	14
Stock-based compensation and accrued employee benefits	28	26
Other assets and other accrued liabilities	8	8
Tax attribute carryforwards	29	27
Foreign tax credit carryforwards	18	17
Total deferred tax assets	191	181
Less: Valuation allowance	(2)	(17)
Total deferred tax assets, net	189	164
Deferred tax liabilities:
Pension and other liabilities	(35)	(55)
Property, plant, and equipment	(313)	(274)
Inventories and other assets	(12)	(4)
Total deferred tax liabilities	(360)	(333)
Deferred tax liability, net	$ (171)	$ (169)

Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21.00%	35.00%	35.00%
State income taxes, net of federal benefit	0.60%	0.70%	150.40%
Lower effective tax rate on international operations, net	(3.80%)	(16.30%)	552.50%
Depletion	(0.50%)	(0.90%)	51.20%
Goodwill	0.00%	0.00%	(47.90%)
Exchange losses (gains)	(0.30%)	0.60%	(39.10%)
Provision to return and other adjustments	(0.80%)	0.60%	(57.90%)
Permanent items	1.00%	1.00%	(27.30%)
Valuation allowance	(1.30%)	(3.60%)	(451.60%)
Net impact of U.S. tax reform	(0.90%)	4.30%	0.00%
Stock-based compensation	(1.20%)	(2.20%)	0.00%
Other, net	0.00%	(1.10%)	(1.70%)
Total effective tax rate	13.80%	18.10%	163.60%

Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory U.S. federal income tax rate	$ 243	$ 319	$ (4)
State income taxes, net of federal benefit	7	7	(16)
Lower effective tax rate on international operations, net	(44)	(149)	(61)
Depletion	(6)	(8)	(6)
Goodwill			5
Exchange losses (gains)	(4)	5	4
Provision to return and other adjustments	(9)	6	6
Permanent items	12	9	3
Valuation allowance	(15)	(33)	50
Net impact of U.S. tax reform	(10)	39
Stock-based compensation	(14)	(20)
Other, net	(1)	(10)	1
Total provision for (benefit from) income taxes	$ 159	$ 165	$ (18)

Income Taxes - Summary of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S. operations (including exports)									$ 114	$ (306)	$ (481)
International operations									1,041	1,218	470
Income (loss) before income taxes	$ 182	$ 269	$ 323	$ 381	$ 264	$ 250	$ 225	$ 173	$ 1,155	$ 912	$ (11)

Income Taxes - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Tax Credit Carryforward [Line Items]
U.S. federal corporate tax rate		21.00%	35.00%	35.00%
Percentage of pro rata portion shareholder equity		10.00%
Income tax benefit as impact of Tax Act			$ 3
Maximum measurement period for estimation of Tax Act			1 year
Income tax benefit to adjust its initial provisional estimates for U.S. tax reform in its income tax provisions	$ 10
Effective tax rate impact for U.S. tax reform		(1.00%)
E&P of foreign subsidiaries		$ 550
Change in valuation allowance on foreign tax credits		(15)	$ (33)	$ 50
Expiration Year 2035 [Member]
Tax Credit Carryforward [Line Items]
R&D tax credits		13
U.S Federal and State [Member] \| Expiration Between Years 2036 To 2038 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards		6
U.S Federal [Member] \| Expiration Year 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards		18
Foreign [Member] \| Expiration Between Years 2026 to 2029 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards		$ 3

Income Taxes - Summary of open tax years by significant jurisdiction (Details)	12 Months Ended
	Dec. 31, 2018
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2014
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2012
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Singapore [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Switzerland [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Singapore [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Switzerland [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018
U.S Federal [Member] \| Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
U.S Federal [Member] \| Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2018

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at January 1,	$ 0	$ 6	$ 7
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	0	(6)	(1)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	2	0	0
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	0	0	0
Balance at December 31,	2	0	6
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	2	0	0
Total amount of interest and penalties recognized in the consolidated statements of operations	0	0	0
Total amount of interest and penalties recognized in the consolidated balance sheets	$ 0	$ 0	$ 0

Income Taxes - Summary of Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at January 1,	$ 17	$ 50	$ 0
Net charges to income tax expense	0	0	50
Release of valuation allowance	(15)	(33)	0
Balance at December 31,	$ 2	$ 17	$ 50

Earnings Per Share of Common Stock - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net income attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	$ 995	$ 746	$ 7
Denominator:
Weighted-average number of common shares outstanding - basic									176,968,554	184,844,106	181,621,422
Dilutive effect of the Company’s employee compensation plans									5,603,467	6,139,885	1,795,078
Weighted-average number of common shares outstanding - diluted									182,572,021	190,983,991	183,416,500
Basic earnings per share of common stock	$ 0.83	$ 1.56	$ 1.58	$ 1.63	$ 1.23	$ 1.12	$ 0.87	$ 0.82	$ 5.62	$ 4.04	$ 0.04
Diluted earnings per share of common stock	$ 0.81	$ 1.51	$ 1.53	$ 1.58	$ 1.19	$ 1.08	$ 0.84	$ 0.79	$ 5.45	$ 3.91	$ 0.04

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Share of Common Stock - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Average number of stock options	393,016	43,072	5,820,499

Accounts and Notes Receivable, Net - Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Receivables [Abstract]
Accounts receivable - trade, net	$ 790	$ 847
VAT, GST and other taxes	56	54
Other receivables	15	18
Total accounts and notes receivable, net	$ 861	$ 919

Accounts and Notes Receivable, Net - Schedule of Accounts, Notes, Loans and Financing Receivable (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable - trade, net	$ 790	$ 847
Allowance for doubtful accounts receivable	5	5
Trade Notes Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable - trade, net	$ 2
Trade Notes Receivable [Member] \| Maximum [Member]
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable - trade, net		$ 1

Accounts and Notes Receivable, Net - (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounts Notes And Loans Receivable [Line Items]
Bad debt expense		$ 1,000,000	$ 7,000,000
Maximum [Member]
Accounts Notes And Loans Receivable [Line Items]
Bad debt expense	$ 1,000,000

Inventories - Schedule of Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Inventory Net [Abstract]
Finished products	$ 701	$ 648
Semi-finished products	195	164
Raw materials, stores, and supplies	476	313
Inventories before LIFO adjustment	1,372	1,125
Less: Adjustment of inventories to LIFO basis	(225)	(190)
Total inventories	$ 1,147	$ 935

Inventories - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Inventory Net [Abstract]
LIFO inventory amount	$ 622	$ 509
Percentage of LIFO inventory	45.00%	45.00%

Property, Plant, and Equipment, Net - Summary of Property, Plant, and Equipment, Net (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 8,992	$ 8,511
Less: Accumulated depreciation	(5,701)	(5,503)
Property, plant, and equipment, net	3,291	3,008	$ 2,784
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	7,344	6,961
Building [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	914	875
Construction-in-progress [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	579	520
Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	119	119
Mineral rights [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 36	$ 36

Property, Plant, and Equipment, Net - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 276	$ 269	$ 281
Capital leased assets	7	7
Build to suit lease assets	55	8
Interest capitalized	$ 17	$ 9	$ 18

Goodwill and Other Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill impairment	$ 0	$ 0
Operating Segments [Member]
Goodwill [Roll Forward]
Total goodwill	153,000,000	153,000,000
Fluoroproducts [Member] \| Operating Segments [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	85,000,000	85,000,000
Acquisition of business	4,000,000
Goodwill, ending balance	89,000,000	85,000,000
Chemical Solutions [Member]
Goodwill [Roll Forward]
Goodwill impairment	4,000,000
Chemical Solutions [Member] \| Operating Segments [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	55,000,000	55,000,000
Goodwill impairment	(4,000,000)
Goodwill, ending balance	51,000,000	55,000,000
Titanium Technologies [Member] \| Operating Segments [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	13,000,000	13,000,000
Goodwill, ending balance	$ 13,000,000	$ 13,000,000

Goodwill and Other Intangible Assets, Net - Narrative (Details)	12 Months Ended
	Dec. 31, 2018 USD ($) segment	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Oct. 01, 2018 USD ($)
Goodwill and Other Intangible Assets
Number of operating segments \| segment	3
Goodwill impairments	$ 0	$ 0
Accumulated impairment losses included in goodwill	4,000,000	0
Amortization expense, 2019	7,000,000
Amortization expense, 2020	7,000,000
Amortization expense, 2021	7,000,000
Amortization expense, 2022	5,000,000
Amortization expense, 2023	$ 1,000,000
Minimum [Member]
Goodwill and Other Intangible Assets
Useful life	5 years
Maximum [Member]
Goodwill and Other Intangible Assets
Useful life	20 years
Continuing Operations [Member]
Goodwill and Other Intangible Assets
Aggregate pre-tax amortization expense	$ 6,000,000	$ 4,000,000	$ 3,000,000
Performance Chemicals and Intermediates [Member]
Goodwill and Other Intangible Assets
Goodwill				$ 4,000,000

Goodwill and Other Intangible Assets, Net - Schedule of Other Intangible Assets (Details) - USD ($)
$ in Millions

Dec. 31, 2018

Dec. 31, 2017

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

$ 68

$ 46

Accumulated Amortization

(40)

(33)

Net

Customer Lists [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(8)

Net

Customer Relationships [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(3)

Net

Patents [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(19)

(18)

Net

Purchased Trademarks [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(3)

(2)

Net

Purchased and Licensed Technology [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

Accumulated Amortization

(3)

(2)

Net

Other [Member]

Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]

Cost

^[1]

Accumulated Amortization

^[1]

(4)

(3)

Net

^[1]

$ 6

$ 7

[1]

Investments in Affiliates - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Investments in Affiliates
Net sales			$ 12
Purchases	$ 0	$ 0	1
Equity Method Investee [Member]
Investments in Affiliates
Net sales	143	99	70
Purchases	$ 125	$ 87	$ 97
Consolidated Subsidiaries [Member] \| Minimum [Member]
Investments in Affiliates
Voting stock ownership percentage	20.00%
Consolidated Subsidiaries [Member] \| Maximum [Member]
Investments in Affiliates
Voting stock ownership percentage	50.00%

Investments in Affiliates - Schedule of Investments in Affiliates (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Investments in Affiliates
Investments in affiliates	$ 160	$ 173	$ 136	$ 136
Chemours-Mitsui Fluorochemicals Company, Ltd. [Member] \| Japan [Member]
Investments in Affiliates
Investments in affiliates	$ 94	$ 112
Ownership	50.00%	50.00%
The Chemours Chenguang Fluoromaterials Company Limited [Member] \| China [Member]
Investments in Affiliates
Investments in affiliates	$ 36	$ 36
Ownership	50.00%	50.00%
Changshu 3F Zhonghao New Chemical Materials Co., Ltd. [Member] \| China [Member]
Investments in Affiliates
Investments in affiliates	$ 30	$ 25
Ownership	10.00%	10.00%

Investments in Affiliates - Schedule of Changes in Investments in Affiliates (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]
Beginning Balance	$ 173	$ 136	$ 136
Equity in earnings of affiliates	43	33	29
Investments in affiliates	0	0	1
Dividends	(58)		(18)
Divestment			(12)
Currency translation and other	2	4
Ending Balance	$ 160	$ 173	$ 136

- Definition

This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.

+ References + Details

Other Assets Schedule of Other Assets - (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Capitalized repair and maintenance costs	$ 178	$ 117
Pension assets	174	260
Deferred income taxes	46	40
Miscellaneous	39	36
Total other assets	$ 437	$ 453

Accounts Payable - Schedule of Accounts Payable (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Trade payables	$ 1,111	$ 1,008
Dividends payable		31
VAT and other payables	26	36
Total accounts payable	$ 1,137	$ 1,075

Other Accrued Liabilities - Schedule of Other Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Compensation and other employee-related costs	$ 108	$ 174
Employee separation costs	16	27
Accrued litigation	76	13
Environmental remediation	74	66
Income taxes	87	58
Customer rebates	79	83
Deferred income	6	8
Accrued interest	21	24
Miscellaneous	92	105
Total other accrued liabilities	$ 559	$ 558

Debt - Components of Debt (Details) € in Millions, $ in Millions	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Capital lease obligations		$ 2		$ 3
Build-to-suit lease obligation		55		8
Total debt		4,017		4,161
Less: Unamortized issue discounts		(10)		(8)
Less: Unamortized debt issuance costs		(35)		(41)
Less: Current maturities of long-term debt		(13)		(15)
Total long-term debt, net		3,959		4,097
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt					$ 2,503
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt		908		1,158
Senior unsecured notes [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt		750		750
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 295	350
Senior unsecured notes [Member] \| 4.000% Senior Notes Due May 2026 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 450	513
Senior unsecured notes [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt		500		500
Senior Secured Tranche B-1 Dollar Term Loan Due May 2022 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt				923
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt			€ 394	$ 469
Senior Secured Tranche B-2 Dollar Term Loan Due May 2025 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt		893
Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt	€ 347	$ 396

Debt - Components of Debt (Parenthetical) (Details) - Senior unsecured notes [Member] € in Millions, $ in Millions	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Long-term debt					$ 2,503
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 394	$ 469
Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 347	$ 396
6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 908		$ 1,158
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%	6.625%
7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 295	$ 350
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%	6.125%
5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 500		$ 500
Debt instrument interest rate	5.375%	5.375%	5.375%	5.375%
4.000% Senior Notes Due May 2026 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 450	$ 513
Debt instrument interest rate	4.00%	4.00%	4.00%	4.00%

Debt - Senior Secured Credit Facilities (Narrative) (Details)				12 Months Ended			51 Months Ended
	Apr. 03, 2018 EUR (€)	Apr. 03, 2018 USD ($)	Apr. 03, 2017 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Apr. 03, 2023	Apr. 03, 2018 USD ($)	Apr. 03, 2017 USD ($)
Line of Credit Facility [Line Items]
Loss on extinguishment of debt				$ (38,000,000)	$ (1,000,000)	$ 6,000,000
Senior Secured Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	7 years	7 years	7 years
Senior Secured Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	5 years	5 years	5 years
Line of credit facility, maximum borrowing capacity								$ 800,000,000	$ 750,000,000
Line of credit facility, maturity date	Apr. 03, 2023	Apr. 03, 2023
Maximum net leverage ratio	0.25%	0.25%
Commitment fee percentage				0.10%
Loss on extinguishment of debt				$ 3,000,000
Senior Secured Revolving Credit Facility [Member] \| Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	100.00%	100.00%
Senior Secured Revolving Credit Facility [Member] \| Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	65.00%	65.00%
Senior Secured Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.25%	0.25%
Senior Secured Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.10%	0.10%
Senior Secured Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	1.25%	1.25%
Senior Secured Revolving Credit Facility [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate	1.00%	1.00%
Senior Secured Revolving Credit Facility [Member] \| Euro Interbank Offered Rate [Member]
Line of Credit Facility [Line Items]
Variable rate	2.00%	2.00%
Dollar Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity								$ 900,000,000	$ 940,000,000
Proceeds from new term loans		$ 921,000,000
Line of credit facility, maturity date	Apr. 03, 2025	Apr. 03, 2025
Effective interest rates on senior secured term loan				4.28%
Dollar Term Loan [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.75%	1.75%
Dollar Term Loan [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.00%	0.00%
Dollar Term Loan [Member] \| Base Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.75%	0.75%
Dollar Term Loan [Member] \| Base Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.00%	1.00%
Euro Term Loan [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity \| €	€ 350,000,000		€ 400,000,000
Proceeds from new term loans \| €	€ 393,000,000
Line of credit facility, maturity date	Apr. 03, 2025	Apr. 03, 2025
Effective interest rates on senior secured term loan				2.50%
Euro Term Loan [Member] \| Euro Interbank Offered Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	2.00%	2.00%
Euro Term Loan [Member] \| Euro Interbank Offered Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.50%	0.50%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio				2.25%
Long-term debt				$ 0	0
Letters of credit outstanding				$ 104,000,000	$ 101,000,000
Revolving Credit Facility [Member] \| Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio							2.00%

Debt - Senior Unsecured Notes (Narrative) (Details)					12 Months Ended
Debt - Senior Unsecured Notes (Narrative) (Details)	Jun. 06, 2018 EUR (€)	May 21, 2018 USD ($) Tender $ / shares	May 23, 2017 USD ($)	May 12, 2015 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Jun. 08, 2018 EUR (€)	Jun. 06, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of debt, net					$ 520,000,000	$ 495,000,000	$ 0
Debt instrument net issue discount									$ 10,000,000				$ 8,000,000
(Loss) gain on extinguishment of debt					$ (38,000,000)	$ (1,000,000)	$ 6,000,000
PFOA MDL Settlement [Member]
Debt Instrument [Line Items]
Settlement payments			$ 335,000,000
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt														$ 2,503,000,000
Senior unsecured notes, payment terms					The Original Notes required or require, as applicable, payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and September 15 of each year.
Proceeds from issuance of debt, net			489,000,000
Senior unsecured notes [Member] \| 2026 Euro Notes [Member]
Debt Instrument [Line Items]
Net proceeds from offering \| €	€ 445,000,000
Senior unsecured notes [Member] \| Redemption of 2023 Euro Notes and Issuance of 2026 Euro Notes [Member]
Debt Instrument [Line Items]
(Loss) gain on extinguishment of debt					$ 35,000,000
Senior unsecured notes [Member] \| Dollar Tender Offer [Member]
Debt Instrument [Line Items]
Tender offer aggregate purchase price											$ 264,000,000
Tender offer early participation premium											13,000,000
Tender offer accrued interest											1,000,000
Senior unsecured notes [Member] \| Euro Tender Offer [member]
Debt Instrument [Line Items]
Tender offer aggregate purchase price \| €										€ 310,000,000
Tender offer early participation premium \| €										14,000,000
Tender offer accrued interest \| €										€ 1,000,000
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt									$ 908,000,000				$ 1,158,000,000
Debt Instrument, face amount														$ 1,350,000,000
Debt instrument interest rate				6.625%				6.625%	6.625%			6.625%	6.625%	6.625%
Debt instrument maturity date				May 31, 2023
Debt instrument outstanding amount		$ 250,000,000									$ 250,000,000			$ 250,000,000
Number of tender offers \| Tender		2
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member] \| Dollar Tender Offer [Member] \| Tender Offer Purchase Price One [Member]
Debt Instrument [Line Items]
Tender offer purchase price per share \| $ / shares		$ 1,052.50
Tender offer principal amount price per share		1,000.00
Tender offer expiration date		Jun. 04, 2018
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member] \| Dollar Tender Offer [Member] \| Tender Offer Purchase Price Two [Member]
Debt Instrument [Line Items]
Tender offer purchase price per share \| $ / shares		$ 1,022.50
Tender offer principal amount price per share		1,000.00
Tender offer expiration date		Jun. 18, 2018
Senior unsecured notes [Member] \| 2025 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount														$ 750,000,000
Debt instrument interest rate				7.00%										7.00%
Debt instrument maturity date				May 31, 2025
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt												€ 295,000,000	$ 350,000,000
Debt Instrument, face amount \| €				€ 360,000,000
Debt instrument interest rate				6.125%				6.125%	6.125%			6.125%	6.125%	6.125%
Debt instrument maturity date				May 31, 2023
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member] \| Euro Tender Offer [member] \| Tender Offer Purchase Price One [Member]
Debt Instrument [Line Items]
Tender offer purchase price per share \| $ / shares		$ 1,048.75
Tender offer principal amount price per share		1,000.00
Tender offer expiration date		Jun. 04, 2018
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member] \| Euro Tender Offer [member] \| Tender Offer Purchase Price Two [Member]
Debt Instrument [Line Items]
Tender offer purchase price per share \| $ / shares		$ 1,018.75
Tender offer principal amount price per share		1,000.00
Tender offer expiration date		Jun. 18, 2018
Senior unsecured notes [Member] \| Original Notes [Member]
Debt Instrument [Line Items]
Obligation threshold for debt to become guaranteed														$ 75,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of control				101.00%										101.00%
Repurchase price obligation, percentage of principal amount redeemed in event of change of asset dispositions				100.00%										100.00%
Senior unsecured notes [Member] \| 2027 Notes [Member]
Debt Instrument [Line Items]
Long-term debt			$ 500,000,000
Debt instrument interest rate			5.375%
Obligation threshold for debt to become guaranteed			$ 100,000,000
Debt instrument net issue discount			5,000,000
Underwriting fees and other related expenses			$ 6,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of control			101.00%
Repurchase price obligation, percentage of principal amount redeemed			100.00%
Senior unsecured notes [Member] \| 4.000% Senior Notes Due May 2026 [Member]
Debt Instrument [Line Items]
Long-term debt								€ 450,000,000	$ 513,000,000
Debt instrument interest rate								4.00%	4.00%			4.00%	4.00%
Senior unsecured notes [Member] \| 4.000% Senior Notes Due May 2026 [Member] \| 2026 Euro Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount \| €	€ 450,000,000
Debt instrument interest rate	4.00%										4.00%
Debt instrument maturity date	May 31, 2026
Senior unsecured notes, payment terms					The 2026 Euro Notes require payment of principal at maturity and payments of interest semi-annually in cash and in arrears on May 15 and November 15 of each year.
Repurchase price obligation, percentage of principal amount redeemed in event of change of control	101.00%										101.00%
Repurchase price obligation, percentage of principal amount redeemed	100.00%
Debt instrument redemption price percentage of principal amount with net cash proceeds	35.00%										35.00%
Debt instrument redemption price percentage of principal amount excluding redemption date	104.00%										104.00%
Senior unsecured notes [Member] \| 4.000% Senior Notes Due May 2026 [Member] \| Minimum [Member] \| 2026 Euro Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount											$ 100,000,000

Debt - Build-to-suit Lease Obligation (Narrative) (Details) - Discovery Hub [Member] $ in Millions	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Oct. 31, 2017 ft²
Debt Instrument [Line Items]
Build to suit lease area of land \| ft²			312,000
Build to suit lease project costs paid by third party owner lessor \| $	$ 55	$ 8

Debt - Maturities and Fair Value (Narrative) (Details) - Senior Secured Revolving Credit Facility [Member]	Apr. 03, 2018
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
Additional principal repayment, percentage of excess cash flows	50.00%
Additional principal repayment, percentage of excess cash flow, stepdown level one	25.00%
Additional principal repayment, percentage of excess cash flow, stepdown level two	0.00%
Target leverage ratio	3.50%

Debt - Schedule of Debt Principal Maturities (Details) - Senior Secured Revolving Credit Facility [Member] $ in Millions	Dec. 31, 2018 USD ($)
Debt Instrument [Line Items]
2019	$ 13
2020	13
2021	13
2022	13
2023	921
Thereafter	2,987
Total principal maturities on senior debt	$ 3,960

Debt - Estimated Fair Values of Senior Debt Issues (Details) € in Millions, $ in Millions	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Less: Unamortized issue discounts		$ (10)		$ (8)
Less: Unamortized debt issuance costs		(35)		(41)
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value					$ 2,503
Senior unsecured notes [Member] \| Senior Secured Tranche B-1 Dollar Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value				923
Senior unsecured notes [Member] \| Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value			€ 394	469
Senior unsecured notes [Member] \| Senior Secured Tranche B-2 Dollar Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		893
Senior unsecured notes [Member] \| Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value	€ 347	396
6.625% Senior Notes Due May 2023 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		908		1,158
7.000% Senior Notes Due May 2025 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		750		750
Senior Notes 6.125% Due May 2023 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value			295	350
4.000% Senior Notes Due May 2026 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value	450	513
5.375% Senior Notes Due May 2027 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		500		500
Level 2 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Senior debt, Fair Value		3,876		4,337
Total senior debt, net		3,915		4,101
Less: Unamortized issue discounts		(10)		(8)
Less: Unamortized debt issuance costs		(35)		(41)
Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Debt Obligations
Debt Instrument [Line Items]
Total senior debt, Carrying Value		3,960		4,150
Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Secured Tranche B-1 Dollar Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value				923
Senior debt, Fair Value				928
Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value			394	469
Senior debt, Fair Value				471
Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Secured Tranche B-2 Dollar Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		893
Senior debt, Fair Value		862
Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value	347	396
Senior debt, Fair Value		394
Level 2 [Member] \| 6.625% Senior Notes Due May 2023 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		908		1,158
Senior debt, Fair Value		918		1,228
Level 2 [Member] \| 7.000% Senior Notes Due May 2025 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		750		750
Senior debt, Fair Value		761		816
Level 2 [Member] \| Senior Notes 6.125% Due May 2023 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value			€ 295	350
Senior debt, Fair Value				373
Level 2 [Member] \| 4.000% Senior Notes Due May 2026 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value	€ 450	513
Senior debt, Fair Value		487
Level 2 [Member] \| 5.375% Senior Notes Due May 2027 [Member] \| Senior unsecured notes [Member]
Debt Instrument [Line Items]
Total senior debt, Carrying Value		500		500
Senior debt, Fair Value		$ 454		$ 521

Debt - Estimated Fair Values of Senior Debt Issues (Parenthetical) (Details) - Senior unsecured notes [Member] € in Millions, $ in Millions	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Long-term debt					$ 2,503
Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 394	$ 469
Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 347	$ 396
6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 908		$ 1,158
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%	6.625%
7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 295	$ 350
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%	6.125%
4.000% Senior Notes Due May 2026 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 450	$ 513
Debt instrument interest rate	4.00%	4.00%	4.00%	4.00%
5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 500		$ 500
Debt instrument interest rate	5.375%	5.375%	5.375%	5.375%
Level 2 [Member] \| Senior Secured Tranche B-1 Euro Term Loan Due May 2022 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 394	$ 469
Level 2 [Member] \| Senior Secured Tranche B-2 Euro Term Loan Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 347	$ 396
Level 2 [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 908		$ 1,158
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Level 2 [Member] \| 7.000% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Level 2 [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt			€ 295	$ 350
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Level 2 [Member] \| 4.000% Senior Notes Due May 2026 [Member]
Debt Instrument [Line Items]
Long-term debt	€ 450	$ 513
Debt instrument interest rate	4.00%	4.00%	4.00%	4.00%
Level 2 [Member] \| 5.375% Senior Notes Due May 2027 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 500		$ 500
Debt instrument interest rate	5.375%	5.375%	5.375%	5.375%

Other Liabilities - Schedule of Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities Noncurrent [Abstract]
Environmental remediation	$ 152	$ 187
Employee-related costs	130	123
Accrued litigation	53	48
Asset retirement obligations	51	43
Deferred revenue	7	6
Miscellaneous	64	68
Total other liabilities	$ 457	$ 475

Other Liabilities - Schedule of Other Liabilities (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Other Liabilities Noncurrent [Abstract]
Accrued indemnification liability	$ 46	$ 52

Commitments and Contingent Liabilities (Operating Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments, 2019	$ 68
Future minimum lease payments, 2020	48
Future minimum lease payments, 2021	41
Future minimum lease payments, 2022	36
Future minimum lease payments, 2023	31
Future minimum lease payments, thereafter	134
Net expense under operating leases	$ 81	$ 76	$ 68

Commitments and Contingent Liabilities (Summary of Asset Retirement Obligations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Balance at January 1,	$ 48	$ 43
Accretion expense	10	6
Settlements and payments	(1)	(1)
Balance at December 31,	57	48
Current portion	6	5
Non-current portion	$ 51	$ 43

Commitments and Contingent Liabilities - Litigation (Narrative) (Details)			3 Months Ended	12 Months Ended
	Nov. 21, 2018 USD ($)	May 23, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2018 USD ($) lawsuit water_district	Dec. 31, 2004 resident	Dec. 31, 2017 USD ($) lawsuit
Loss Contingencies [Line Items]
Accrued environmental liability				$ 226,000,000		$ 253,000,000
Accrued litigation				53,000,000		48,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss						$ 450,000,000
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements				$ 1,500,000
MDL Settlement [Member]
Loss Contingencies [Line Items]
Date of Agreement				Mar. 31, 2017
Total settlement amount			$ 670,700,000
PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				40
Settlement payments		$ 335,000,000
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				19		17
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 22,000,000		$ 14,000,000
Civil penalty and investigative costs	$ 13,000,000
Accrued environmental liability				75,000,000
Accrued litigation				65,000,000
PFOA Matters [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments				$ 25,000,000
Period of payments				5 years
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident					80,000
Number of water districts Company must provide treatment \| water_district				6
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 235,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				3,500
DuPont [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				25
DuPont [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments				$ 25,000,000
DuPont [Member] \| Business Seeking to Recover Losses [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				2
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				1,300		1,600
Accrual balance				$ 37,000,000		$ 38,000,000

Commitments and Contingent Liabilities - Environmental (Narrative) (Details) - USD ($) $ in Millions			1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 27, 2018	Jun. 29, 2018	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Environmental Remediation [Line Items]
Accrual for environmental remediation activities				$ 226	$ 226	$ 253
Environmental remediation activities amount			$ 3		36	48	$ 44
Sale of asset to third party			$ 39		$ 46	39	$ 708
East Chicago, Indiana [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities		$ 21
Sale of asset to third party		1
Environmental remediation cost assumed by seller		21
Gain on sale of asset		3
Purchase price of asset sold		1
Environmental remediation liability		$ 2
Potomac River Site [Member]
Environmental Remediation [Line Items]
Sale of asset to third party	$ 4
Gain on sale of asset	3
Environmental remediation liability	$ 4
Fayetteville Facility [Member]
Environmental Remediation [Line Items]
Environmental liabilities reclassified to accrued litigation				$ 2
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation					15 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation					20 years
Loss contingency, potential additional loss						$ 450

Equity - (Narrative) (Details) - USD ($)			12 Months Ended
Equity - (Narrative) (Details) - USD ($)	May 31, 2018	Nov. 30, 2017	Dec. 31, 2018	Aug. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity Class Of Treasury Stock [Line Items]
Purchase of common stock value under the share repurchase program			$ 750,000,000		$ 116,000,000
Accrued dividend payable					$ 31,000,000
2018 Share Repurchase Program [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, authorized amount			$ 750,000,000
Common Stock [Member]
Equity Class Of Treasury Stock [Line Items]
Cash dividend declared, per share		$ 0.17	$ 0.67		$ 0.29	$ 0.12
Cash dividend date declared		Nov. 30, 2017
Dividends payable, date of record		Feb. 15, 2018
Dividends payable, date to be paid		Mar. 15, 2018
Accrued dividend payable					$ 31,000,000
Common Stock [Member] \| 2017 Share Repurchase Program [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, authorized amount	$ 500,000,000
Stock repurchase program effective date			Nov. 30, 2017
Average share price	$ 49.58
Purchase of common stock under the share repurchase program	10,085,647
Common Stock [Member] \| 2017 Share Repurchase Program [Member] \| Maximum [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, authorized amount		$ 500,000,000
Common Stock [Member] \| 2018 Share Repurchase Program [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program effective date			Aug. 01, 2018
Average share price			$ 39.31
Purchase of common stock under the share repurchase program			6,350,857
Stock repurchase program expiration date			Dec. 31, 2020
Purchase of common stock value under the share repurchase program			$ 250,000,000
Remaining available amount of common stock under the share repurchase program			$ 500,000,000
Common Stock [Member] \| 2018 Share Repurchase Program [Member] \| Maximum [Member]
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, authorized amount				$ 750,000,000

Stock-based Compensation - Narrative (Details) $ / shares in Units, $ in Millions		1 Months Ended	12 Months Ended
	Jan. 26, 2017 Period shares	Jul. 31, 2015	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Apr. 26, 2017 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $			$ 24	$ 29	$ 19
Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period		10 years	10 years	10 years	10 years
Stock-based compensation award vesting period			3 years	3 years	3 years
Total intrinsic value of options exercised \| $			$ 37	$ 49	$ 9
Unrecognized stock-based compensation expense related to stock options \| $			$ 7
Unrecognized stock-based compensation expense period for recognition			1 year 10 months 9 days
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation award vesting period			3 years
Unrecognized stock-based compensation expense period for recognition			6 months 25 days
Shares issued upon conversion of equity award			1
Unrecognized compensation cost related to equity awards other than options \| $			$ 6
Weighted-average fair value at grant date (in dollars per share) \| $ / shares			$ 48.35
Performance Share Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation award vesting period			3 years
Shares issued upon conversion of equity award			1
Percentage of target award available for grant			100.00%
Weighted-average fair value at grant date (in dollars per share) \| $ / shares			$ 52.34
Number of additional shares to be awarded			900,000
Number of common stock shares reserved for issuance	7,000,000
Consecutive offering periods	12 months
Number of purchase periods in offer period \| Period	4
Employee stock purchase plan initial offering period	Oct. 02, 2017
Percentage of common stock discount rate equal to the fair value	95.00%
Stock purchased under employee stock purchase plan, Shares			38,111
Addtional stock purchased under employee stock purchase plan, Shares			12,411
Stock purchased under employee stock purchase plan, Value \| $			$ 2
Performance Share Units [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of target award available for grant			0.00%
Performance Share Units [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of target award available for grant			200.00%
Chemours Company 2017 Equity and Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for grants (in shares)			16,800,000			0
Shares authorized for grants (in shares)						19,000,000
Chemours Company Equity and Incentive Plan (the “Prior Plan”) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued upon conversion of equity stock option awards granted						1
Shares issued upon conversion of equity stock other than option awards granted						1.5

Stock-based Compensation - Weighted Average Assumptions of Stock Option (Details) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	2.65%	2.14%	1.46%
Expected term (years)	6 years	6 years	6 years
Volatility	47.56%	44.49%	60.00%
Dividend yield	1.42%	0.35%	2.14%
Fair value per stock option	$ 20.47	$ 15.21	$ 3.41

Stock-based Compensation - Stock Option Activity (Details) - Stock Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares	6,597
Granted, shares	495
Exercised, shares	(1,073)
Forfeited, shares	(46)
Expired, shares	(3)
Outstanding, ending balance, shares	5,970	6,597
Exercisable, shares	4,401
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 15.72
Granted, weighted average exercise price (in dollars per share)	48.41
Exercised, weighted average exercise price (in dollars per share)	14.69
Forfeited, weighted average exercise price (in dollars per share)	37.77
Expired, weighted average exercise price (in dollars per share)	18.80
Outstanding, weighted average exercise price, ending balance (in dollars per share)	18.45	$ 15.72
Exercisable, weighted average exercise price (in dollars per share)	$ 15.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	4 years 9 months 18 days	5 years 1 month 9 days
Options exercisable, weighted average remaining contractual term	3 years 10 months 28 days
Options outstanding, aggregate intrinsic value	$ 72,108	$ 226,524
Options exercisable, aggregate intrinsic value	$ 59,486

Stock-based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares \| shares	1,165
Granted, shares \| shares	135
Vested, shares \| shares	(1,034)
Forfeited, shares \| shares	(19)
Non-vested, ending balance, shares \| shares	247
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 15.34
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	48.35
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	14.86
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	30.94
Non-vested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 34.22

Stock-based Compensation - Performance Share Units Activity (Details) - Performance Share Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested, beginning balance, shares \| shares	987
Granted, shares \| shares	139
Vested, shares \| shares	(19)
Non-vested, ending balance, shares \| shares	1,107
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 12.94
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	52.34
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	24.16
Non-vested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 17.71

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 860
Other comprehensive (loss) income	30	$ (62)	$ 14
Ending Balance	1,014	860
Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(158)	(358)	(285)
Other comprehensive (loss) income	(75)	200	(73)
Ending Balance	(233)	(158)	(358)
Net Investment Hedge [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(40)	22	8
Other comprehensive (loss) income	15	(62)	14
Ending Balance	(25)	(40)	22
Cash Flow Hedge [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	0	0	0
Other comprehensive (loss) income	6	0	0
Ending Balance	6	0	0
Employee Benefits [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(244)	(241)	(259)
Other comprehensive (loss) income	(68)	(3)	18
Ending Balance	(312)	(244)	(241)
Accumulated Other Comprehensive (Loss) Income [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(442)	(577)	(536)
Other comprehensive (loss) income	(122)	135	(41)
Ending Balance	$ (564)	$ (442)	$ (577)

Financial Instruments - Narrative (Details)	12 Months Ended
Financial Instruments - Narrative (Details)	Dec. 31, 2018 USD ($) contract	Dec. 31, 2017 USD ($) contract	Dec. 31, 2016 USD ($)
Derivative [Line Items]
Recognized gains (loss) on derivative cash flow hedge, pre-tax	$ 10,000,000	$ 0	$ 0
Designated as Hedging Instrument [Member] \| Net Investment Hedge [Member]
Derivative [Line Items]
Recognized gain (loss) on derivative net investment hedge, pre-tax	32,000,000	(86,000,000)	14,000,000
Reclassification on derivative net investment hedge, pre-tax	$ 0	$ 0	0
Foreign currency forward contracts [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	20	0
Derivative notional value	$ 503,000,000
Foreign currency forward contracts [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income (Expense), Net [Member]
Derivative [Line Items]
Derivative gains (losses)	3,000,000	$ 4,000,000	(15,000,000)
Gain reclassification to cost of goods sold on derivative cash flow hedge	$ 3,000,000	$ 4,000,000	$ (15,000,000)
Foreign currency forward contracts [Member] \| Designated as Hedging Instrument [Member] \| Cash Flow Hedge [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	75
Derivative notional value	$ 143,000,000
Recognized gains (loss) on derivative cash flow hedge, pre-tax	10,000,000
Derivative cash flow hedge gain from accumulated other comprehensive loss to cost of goods sold to be reclassified with in twelve months	6,000,000
Foreign currency forward contracts [Member] \| Designated as Hedging Instrument [Member] \| Cost of Goods Sold [Member] \| Cash Flow Hedge [Member]
Derivative [Line Items]
Gain reclassification to cost of goods sold on derivative cash flow hedge	$ 4,000,000

Financial Instruments - Schedule of Derivative Assets and Liabilities At Fair Value (Details) - Fair Value, Measurements, Recurring [Member] - Fair Value, Inputs, Level 2 [Member] - Foreign currency forward contracts [Member] $ in Millions	Dec. 31, 2018 USD ($)
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 4
Liability derivatives	1
Not Designated as Hedging Instrument [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	1
Not Designated as Hedging Instrument [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	1
Cash Flow Hedge [Member] \| Designated as Hedging Instrument [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 3

Financial Instruments - Schedule of Pre-tax Charge the Fair Value of Derivative Assets and Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized In Accumulated Other Comprehensive Loss	$ 32	$ (86)	$ 14
Foreign currency forward contracts [Member] \| Designated as Hedging Instrument [Member] \| Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized In Accumulated Other Comprehensive Loss	10
Foreign currency forward contracts [Member] \| Cost of Goods Sold [Member] \| Designated as Hedging Instrument [Member] \| Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized In Derivative Instruments	4
Foreign currency forward contracts [Member] \| Other Income (Expense), Net [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized In Derivative Instruments	3	4	(15)
Euro-denominated debt [Member] \| Designated as Hedging Instrument [Member] \| Net Investment Hedge [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized In Accumulated Other Comprehensive Loss	$ 32	$ (86)	$ 14

Long-term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Employer contributions during period		$ 51	$ 45	$ 44
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	1.00%
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	7.00%
Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of match	100.00%
Employer matching contribution percent of employees' gross pay	6.00%
Employer contribution vesting period	3 years

Long-term Employee Benefits (Schedule of Net Periodic Pension Income and Amounts Recognized in Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss (gain)	$ 115	$ (24)	$ 17
Amortization of actuarial loss	(16)	(24)	(23)
Amortization of prior service gain	2	2	1
Effect of foreign exchange rates	(8)	38	(15)
Cost (benefit) recognized in other comprehensive income	93	(8)	(23)
Pension Plan [Member] \| Foreign [Member]
Net periodic pension cost (income):
Service cost	14	16	14
Interest cost	16	16	19
Expected return on plan assets	(58)	(75)	(63)
Amortization of prior service gain	(2)	(2)	(1)
Amortization of actuarial loss	12	22	23
Curtailment gain			(2)
Settlement loss		1	5
Net periodic benefit income	(18)	(22)	(5)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss (gain)	115	(24)	17
Amortization of actuarial loss	(16)	(24)	(28)
Amortization of prior service gain	2	2	3
Effect of foreign exchange rates	(8)	38	(15)
Cost (benefit) recognized in other comprehensive income	93	(8)	(23)
Total net periodic pension income and cost (benefit) recognized in other comprehensive income	$ 75	$ (30)	$ (28)

Long-term Employee Benefits (Amounts Recognized in Accumulated Other Comprehensive Loss) (Details) - Pension Plan [Member] - Foreign [Member] - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	$ 419	$ 329	$ 336
Prior service credit	(10)	(11)	(11)
Total amount recognized in accumulated other comprehensive loss	409	$ 318	$ 325
Estimated net loss to be amortized into net periodic pension cost (income) in the next fiscal year	24
Prior service credit to be amortized into net periodic pension cost (income) in the next fiscal year	$ 2

Long-term Employee Benefits (Change in Benefit Obligation and Plan Assets) (Details) - Pension Plan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Employer contributions	$ 15	$ 38	$ 16
Foreign [Member]
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	1,177	1,105
Service cost	14	16	14
Interest cost	16	16	19
Plan participants’ contributions	2	2
Actuarial loss (gain)	45	(39)
Benefits paid	(46)	(53)
Plan amendments		(1)
Settlements and transfers	2	(3)
Other events		(4)
Currency translation	(42)	138
Benefit obligation at end of year	1,168	1,177	1,105
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,363	1,169
Actual (loss) return on plan assets	(17)	60
Employer contributions	15	38
Plan participants’ contributions	2	2
Benefits paid	(46)	(53)
Settlements and transfers	2	(3)
Other events		(3)
Currency translation	(51)	153
Fair value of plan assets at end of year	1,268	1,363	$ 1,169
Total funded status at end of year	$ 100	$ 186

Long-term Employee Benefits (Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	$ 174	$ 260
The accumulated benefit obligation for all pension plans	1,106	1,112
Pension Plan [Member] \| Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	174	258
Current liabilities	(1)	(1)
Non-current liabilities	(73)	(71)
Total net amount recognized	$ 100	$ 186

Long-term Employee Benefits (Summary of Projected Benefit Obligations and Accumulated Benefit Obligations in Excess of Plan Assets) (Details) - Pension Plan [Member] - Foreign [Member] - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Pension plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$ 177	$ 178
Accumulated benefit obligation	149	149
Fair value of plan assets	103	106
Pension plans with accumulated benefit obligation in excess of plan assets
Projected benefit obligation	177	178
Accumulated benefit obligation	149	149
Fair value of plan assets	$ 103	$ 106

Long-term Employee Benefits (Assumptions) (Details)	12 Months Ended
Long-term Employee Benefits (Assumptions) (Details)	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	2.00%	1.90%
Rate of compensation increase	2.50%	2.50%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	1.90%	1.80%
Rate of compensation increase	2.50%	2.50%
Expected return on plan assets	4.10%	5.70%

Long-term Employee Benefits (Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average allocation	100.00%	100.00%
Pension Plan [Member] \| Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 1,268	$ 1,363	$ 1,169
Pension Plan [Member] \| Foreign [Member] \| Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average allocation	5.00%	5.00%
Total pension assets before pension receivables	$ 67	$ 65
Pension Plan [Member] \| Foreign [Member] \| Cash and Cash Equivalents [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	67	65
Pension Plan [Member] \| Foreign [Member] \| Cash and Cash Equivalents [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	$ 0	$ 0
Pension Plan [Member] \| Foreign [Member] \| Equity securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average allocation	45.00%	42.00%
Total pension assets before pension receivables	$ 264	$ 581
Pension Plan [Member] \| Foreign [Member] \| Equity securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	263	295
Pension Plan [Member] \| Foreign [Member] \| Equity securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	$ 1	$ 286
Pension Plan [Member] \| Foreign [Member] \| Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total weighted-average allocation	50.00%	53.00%
Pension Plan [Member] \| Foreign [Member] \| Total Pension Assets Before Pension Receivables [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	$ 1,260	$ 1,356
Pension Plan [Member] \| Foreign [Member] \| Total Pension Assets Before Pension Receivables [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	374	398
Pension Plan [Member] \| Foreign [Member] \| Total Pension Assets Before Pension Receivables [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	886	958
Pension Plan [Member] \| Foreign [Member] \| Pension Trust Receivables, Net [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets	8	7
Pension Plan [Member] \| Foreign [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	487	505
Pension Plan [Member] \| Foreign [Member] \| Government Issued [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	3	1
Pension Plan [Member] \| Foreign [Member] \| Government Issued [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	484	504
Pension Plan [Member] \| Foreign [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	130	144
Pension Plan [Member] \| Foreign [Member] \| Corporate Issued [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	33	24
Pension Plan [Member] \| Foreign [Member] \| Corporate Issued [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	97	120
Pension Plan [Member] \| Foreign [Member] \| Mututal Funds [Member}
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	296
Pension Plan [Member] \| Foreign [Member] \| Mututal Funds [Member} \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	0
Pension Plan [Member] \| Foreign [Member] \| Mututal Funds [Member} \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	296
Pension Plan [Member] \| Foreign [Member] \| Derivatives - Asset Position[Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	9	8
Pension Plan [Member] \| Foreign [Member] \| Derivatives - Asset Position[Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	0	2
Pension Plan [Member] \| Foreign [Member] \| Derivatives - Asset Position[Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	9	6
Pension Plan [Member] \| Foreign [Member] \| Derivative Liability Position [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension liability before pension receivables	(5)	(1)
Pension Plan [Member] \| Foreign [Member] \| Derivative Liability Position [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension liability before pension receivables	0	0
Pension Plan [Member] \| Foreign [Member] \| Derivative Liability Position [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension liability before pension receivables	(5)	(1)
Pension Plan [Member] \| Foreign [Member] \| Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	12	14
Pension Plan [Member] \| Foreign [Member] \| Other [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	8	11
Pension Plan [Member] \| Foreign [Member] \| Other [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables	$ 4	3
Pension Plan [Member] \| Foreign [Member] \| Asset-backed Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables		40
Pension Plan [Member] \| Foreign [Member] \| Asset-backed Securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables		0
Pension Plan [Member] \| Foreign [Member] \| Asset-backed Securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total pension assets before pension receivables		$ 40

Long-term Employee Benefits (Cash Flows) (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
2019		$ 45
2020		47
2021		46
2022		47
2023		50
2024 to 2028		264
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer		15	$ 38	$ 16
Estimated future employer contributions in next fiscal year		$ 16
U.S. Pension Restoration Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer			$ 10
Cash payment to settle remaining liability	$ 10

Geographic and Segment Information - Schedule of Net Sales and Net Property, Plant and Equipment by Geographical Area (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Property, Plant, and Equipment, Net	3,291				3,008				3,291	3,008	2,784
North America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									2,378	2,255	2,288
Property, Plant, and Equipment, Net	2,279				2,018				2,279	2,018	1,861
Asia Pacific [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,720	1,593	1,315
Property, Plant, and Equipment, Net	124				131				124	131	129
Europe, the Middle East, and Africa [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,685	1,506	1,081
Property, Plant, and Equipment, Net	293				302				293	302	278
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									855	829	716
Property, Plant, and Equipment, Net	$ 595				$ 557				$ 595	$ 557	$ 516

Geographic and Segment Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2018 segment
Segments Geographical Areas [Abstract]
Number of reportable segments	3

Geographic and Segment Information - (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Adjusted EBITDA									1,740	1,422	822
Depreciation and amortization									284	273	284
Equity in earnings of affiliates									43	33	29
Net assets	1,020				865				1,020	865	104
Investments in affiliates	160				173				160	173	136	$ 136
Purchases of property, plant, and equipment									498	411	338
Operating Segments [Member] \| Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Net sales									2,862	2,654	2,264
Adjusted EBITDA									783	669	445
Depreciation and amortization									117	109	101
Equity in earnings of affiliates									43	33	26
Net assets	2,309				1,842				2,309	1,842	1,400
Investments in affiliates	160				173				160	173	116
Purchases of property, plant, and equipment									274	249	120
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Net sales									602	571	772
Adjusted EBITDA									64	57	39
Depreciation and amortization									20	18	30
Net assets	506				460				506	460	292
Purchases of property, plant, and equipment									75	65	104
Operating Segments [Member] \| Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Net sales									3,174	2,958	2,364
Adjusted EBITDA									1,055	862	466
Depreciation and amortization									119	118	119
Net assets	1,487				1,785				1,487	1,785	1,513
Purchases of property, plant, and equipment									91	65	105
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Adjusted EBITDA									(162)	(166)	(128)
Depreciation and amortization									28	28	34
Equity in earnings of affiliates											3
Net assets	$ (3,282)				$ (3,222)				(3,282)	(3,222)	(3,101)
Investments in affiliates											20
Purchases of property, plant, and equipment									$ 58	$ 32	$ 9

Geographic and Segment Information - (Reconciliation of EBITDA from Segments to Consolidated Net Income (Loss) Before Income Taxes) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended								12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting [Abstract]
Income (loss) before income taxes		$ 182	$ 269	$ 323	$ 381	$ 264	$ 250	$ 225	$ 173	$ 1,155	$ 912	$ (11)
Interest expense, net										195	214	219
Depreciation and amortization										284	273	284
Non-operating pension and other post-retirement employee benefit income										(27)	(34)	(20)
Exchange (gains) losses, net										(1)	(3)	57
Restructuring, asset-related, and other charges										49	57	170
Loss (gain) on extinguishment of debt										38	1	(6)
Gain on sales of assets and businesses	$ (42)									(45)	(22)	(254)
Transaction costs										9	3	19
Legal charges										82	9	343
Other charges										1	12	21
Adjusted EBITDA										$ 1,740	$ 1,422	$ 822

Geographic and Segment Information - (Reconciliation of EBITDA from Segments to Consolidated Net Income (Loss) Before Income Taxes) (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
GenX and Other Perfluorinated and Polyfluorinated Compounds [Member]
Segment Reporting Information [Line Items]
Litigation accruals	$ 63
PFOA MDL Settlement [Member]
Segment Reporting Information [Line Items]
Litigation accruals			$ 335
Edge Moor, Delaware Site [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset		$ 12
Clean and Disinfect Product Line [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset			169
Beaumont Site [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset			$ 89
East Chicago, Indiana [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset	3
Repauno New Jersey [Member] \| Land [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset		$ 13
Linden, New Jersey Sites [Member]
Segment Reporting Information [Line Items]
Gain on sale of asset	$ 42

Geographic and Segment Information - (Schedule of Net Sales to External Customers by Product Group) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total net sales	$ 6,638	$ 6,183	$ 5,400
Divested Business [Member]
Segment Reporting Information [Line Items]
Total net sales		4	212
Fluoropolymers [Member]
Segment Reporting Information [Line Items]
Total net sales	1,365	1,276	1,171
Fluorochemicals [Member]
Segment Reporting Information [Line Items]
Total net sales	1,497	1,378	1,093
Performance Chemicals and Intermediates [Member]
Segment Reporting Information [Line Items]
Total net sales	313	306	298
Mining Solutions [Member]
Segment Reporting Information [Line Items]
Total net sales	289	261	262
Titanium Dioxide and Other Minerals [Member]
Segment Reporting Information [Line Items]
Total net sales	$ 3,174	$ 2,958	$ 2,364

Subsequent Events - Narrative (Details) - USD ($)		12 Months Ended
Subsequent Events - Narrative (Details) - USD ($)	Feb. 15, 2019	Dec. 31, 2018	Feb. 13, 2019	Dec. 31, 2017
Subsequent Event [Line Items]
Purchase of common stock value under the share repurchase program		$ 750,000,000		$ 116,000,000
2018 Share Repurchase Program [Member]
Subsequent Event [Line Items]
Stock repurchase program, authorized amount		$ 750,000,000
Common Stock [Member] \| 2018 Share Repurchase Program [Member]
Subsequent Event [Line Items]
Purchase of common stock shares under the share repurchase program		6,350,857
Purchase of common stock value under the share repurchase program		$ 250,000,000
Average share price		$ 39.31
Subsequent Event [Member] \| 2018 Share Repurchase Program [Member]
Subsequent Event [Line Items]
Stock repurchase program, authorized amount			$ 1,000,000,000
Subsequent Event [Member] \| Common Stock [Member] \| 2018 Share Repurchase Program [Member]
Subsequent Event [Line Items]
Purchase of common stock shares under the share repurchase program	4,363,277
Purchase of common stock value under the share repurchase program	$ 150,000,000
Average share price	$ 34.38

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Cost of goods sold	1,064	1,151	1,259	1,193	1,090	1,119	1,150	1,081	4,667	4,438	4,297
Income before income taxes	182	269	323	381	264	250	225	173	1,155	912	(11)
Net income	142	275	282	297	228	207	161	151	996	747	7
Net income attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	$ 995	$ 746	$ 7
Basic earnings per share of common stock	$ 0.83	$ 1.56	$ 1.58	$ 1.63	$ 1.23	$ 1.12	$ 0.87	$ 0.82	$ 5.62	$ 4.04	$ 0.04
Diluted earnings per share of common stock	$ 0.81	$ 1.51	$ 1.53	$ 1.58	$ 1.19	$ 1.08	$ 0.84	$ 0.79	$ 5.45	$ 3.91	$ 0.04

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

Guarantor Condensed Consolidating Financial Information - Condensed Consolidating Statements of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Condensed Income Statements, Captions [Line Items]
Net sales	$ 1,464	$ 1,628	$ 1,816	$ 1,730	$ 1,575	$ 1,584	$ 1,588	$ 1,437	$ 6,638	$ 6,183	$ 5,400
Cost of goods sold	1,064	1,151	1,259	1,193	1,090	1,119	1,150	1,081	4,667	4,438	4,297
Gross profit									1,971	1,745	1,103
Selling, general, and administrative expense									657	626	946
Research and development expense									82	81	81
Restructuring, asset-related, and other charges									49	57	170
Total other operating expenses									788	764	1,197
Equity in earnings of affiliates									43	33	29
Equity in earnings of subsidiaries									0	0	0
Interest (expense) income, net									(195)	(214)	(219)
(Loss) gain on extinguishment of debt									(38)	(1)	6
Intercompany interest income (expense), net									0	0	0
Other income (expense), net									162	113	267
Income (loss) before income taxes	182	269	323	381	264	250	225	173	1,155	912	(11)
(Benefit from) provision for income taxes									159	165	(18)
Net income (loss)	142	275	282	297	228	207	161	151	996	747	7
Less: Net income attributable to non-controlling interests									1	1	0
Net income (loss) attributable to Chemours	$ 142	$ 275	$ 281	$ 297	$ 228	$ 207	$ 161	$ 150	995	746	7
Comprehensive (loss) income attributable to Chemours									873	881	(34)
Eliminations and Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									(1,820)	(1,734)	(1,571)
Cost of goods sold									(1,825)	(1,691)	(1,543)
Gross profit									5	(43)	(28)
Selling, general, and administrative expense									(24)	(38)	(20)
Research and development expense									0	0	0
Restructuring, asset-related, and other charges									0	0	0
Total other operating expenses									(24)	(38)	(20)
Equity in earnings of affiliates									0	0	0
Equity in earnings of subsidiaries									(1,157)	(849)	(100)
Interest (expense) income, net									0	0	0
(Loss) gain on extinguishment of debt									0	0	0
Intercompany interest income (expense), net									0	0	0
Other income (expense), net									(22)	(34)	(20)
Income (loss) before income taxes									(1,150)	(888)	(128)
(Benefit from) provision for income taxes									0	(4)	(7)
Net income (loss)									(1,150)	(884)	(121)
Less: Net income attributable to non-controlling interests									0	0	0
Net income (loss) attributable to Chemours									(1,150)	(884)	(121)
Comprehensive (loss) income attributable to Chemours									(1,012)	(1,081)	(66)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									0	0	0
Cost of goods sold									0	0	0
Gross profit									0	0	0
Selling, general, and administrative expense									33	36	21
Research and development expense									0	0	0
Restructuring, asset-related, and other charges									0	0	0
Total other operating expenses									33	36	21
Equity in earnings of affiliates									0	0	0
Equity in earnings of subsidiaries									1,155	849	100
Interest (expense) income, net									(210)	(220)	(217)
(Loss) gain on extinguishment of debt									(38)	(1)	6
Intercompany interest income (expense), net									47	64	60
Other income (expense), net									25	29	20
Income (loss) before income taxes									946	685	(52)
(Benefit from) provision for income taxes									(50)	(62)	(59)
Net income (loss)									996	747	7
Less: Net income attributable to non-controlling interests									0	0	0
Net income (loss) attributable to Chemours									996	747	7
Comprehensive (loss) income attributable to Chemours									873	881	(34)
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									3,974	3,887	3,749
Cost of goods sold									3,112	3,084	3,218
Gross profit									862	803	531
Selling, general, and administrative expense									485	449	794
Research and development expense									76	74	77
Restructuring, asset-related, and other charges									46	56	168
Total other operating expenses									607	579	1,039
Equity in earnings of affiliates									0	0	4
Equity in earnings of subsidiaries									2	0	0
Interest (expense) income, net									5	3	(3)
(Loss) gain on extinguishment of debt									0	0	0
Intercompany interest income (expense), net									10	0	4
Other income (expense), net									199	139	193
Income (loss) before income taxes									471	366	(310)
(Benefit from) provision for income taxes									98	117	(52)
Net income (loss)									373	249	(258)
Less: Net income attributable to non-controlling interests									0	0	0
Net income (loss) attributable to Chemours									373	249	(258)
Comprehensive (loss) income attributable to Chemours									375	253	(255)
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									4,484	4,030	3,222
Cost of goods sold									3,380	3,045	2,622
Gross profit									1,104	985	600
Selling, general, and administrative expense									163	179	151
Research and development expense									6	7	4
Restructuring, asset-related, and other charges									3	1	2
Total other operating expenses									172	187	157
Equity in earnings of affiliates									43	33	25
Equity in earnings of subsidiaries									0	0	0
Interest (expense) income, net									10	3	1
(Loss) gain on extinguishment of debt									0	0	0
Intercompany interest income (expense), net									(57)	(64)	(64)
Other income (expense), net									(40)	(21)	74
Income (loss) before income taxes									888	749	479
(Benefit from) provision for income taxes									111	114	100
Net income (loss)									777	635	379
Less: Net income attributable to non-controlling interests									1	1	0
Net income (loss) attributable to Chemours									776	634	379
Comprehensive (loss) income attributable to Chemours									$ 637	$ 828	$ 321

Guarantor Condensed Consolidating Financial Information - Condensed Consolidating Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,201	$ 1,556	$ 902	$ 366
Accounts and notes receivable, net	861	919
Inventories	1,147	935
Prepaid expenses and other	84	83
Total current assets	3,293	3,493
Property, plant, and equipment	8,992	8,511
Less: Accumulated depreciation	(5,701)	(5,503)
Property, plant, and equipment, net	3,291	3,008	2,784
Goodwill and other intangible assets, net	181	166
Investments in affiliates	160	173	136	136
Other assets	437	453
Total assets	7,362	7,293
Current liabilities:
Accounts payable	1,137	1,075
Current maturities of long-term debt	13	15
Other accrued liabilities	559	558
Total current liabilities	1,709	1,648
Long-term debt, net	3,959	4,097
Deferred income taxes	217	208
Other liabilities	457	475
Total liabilities	6,342	6,428
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	1,014	860
Non-controlling interests	6	5
Total equity	1,020	865	104	130
Total liabilities and equity	7,362	7,293
Eliminations and Adjustments [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Intercompany receivable	(1,150)	(1,488)
Inventories	(85)	(90)
Prepaid expenses and other		11
Total current assets	(1,235)	(1,567)
Investments in subsidiaries	(4,498)	(4,393)
Intercompany notes receivable	(1,150)	(1,150)
Other assets	(8)	(13)
Total assets	(6,891)	(7,123)
Current liabilities:
Intercompany payable	(1,150)	(1,488)
Other accrued liabilities	(1)
Total current liabilities	(1,151)	(1,488)
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes	(16)	(24)
Total liabilities	(2,317)	(2,662)
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	(4,574)	(4,461)
Total equity	(4,574)	(4,461)
Total liabilities and equity	(6,891)	(7,123)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Intercompany receivable	2	3
Total current assets	2	3
Investments in subsidiaries	4,487	4,393
Intercompany notes receivable	1,150	1,150
Other assets	17	23
Total assets	5,656	5,569
Current liabilities:
Accounts payable		31
Current maturities of long-term debt	13	15
Intercompany payable	698	542
Other accrued liabilities	21	34
Total current liabilities	732	622
Long-term debt, net	3,902	4,087
Deferred income taxes	8
Total liabilities	4,642	4,709
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	1,014	860
Total equity	1,014	860
Total liabilities and equity	5,656	5,569
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	239	761	224	95
Accounts and notes receivable, net	297	308
Intercompany receivable	1,057	904
Inventories	483	394
Prepaid expenses and other	58	57
Total current assets	2,134	2,424
Property, plant, and equipment	6,870	6,449
Less: Accumulated depreciation	(4,591)	(4,438)
Property, plant, and equipment, net	2,279	2,011
Goodwill and other intangible assets, net	167	152
Investments in subsidiaries	11
Other assets	154	115
Total assets	4,745	4,702
Current liabilities:
Accounts payable	637	606
Intercompany payable	92	581
Other accrued liabilities	341	343
Total current liabilities	1,070	1,530
Long-term debt, net	57	10
Deferred income taxes	143	127
Other liabilities	372	388
Total liabilities	1,642	2,055
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	3,103	2,647
Total equity	3,103	2,647
Total liabilities and equity	4,745	4,702
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	962	795	$ 678	$ 271
Accounts and notes receivable, net	564	611
Intercompany receivable	91	581
Inventories	749	631
Prepaid expenses and other	26	15
Total current assets	2,392	2,633
Property, plant, and equipment	2,122	2,062
Less: Accumulated depreciation	(1,110)	(1,065)
Property, plant, and equipment, net	1,012	997
Goodwill and other intangible assets, net	14	14
Investments in affiliates	160	173
Other assets	274	328
Total assets	3,852	4,145
Current liabilities:
Accounts payable	500	438
Intercompany payable	360	365
Other accrued liabilities	198	181
Total current liabilities	1,058	984
Intercompany notes payable	1,150	1,150
Deferred income taxes	82	105
Other liabilities	85	87
Total liabilities	2,375	2,326
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	1,471	1,814
Non-controlling interests	6	5
Total equity	1,477	1,819
Total liabilities and equity	$ 3,852	$ 4,145

Guarantor Condensed Consolidating Financial Information - Condensed Consolidating Statements of Cash Flows (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Cash (used for) provided by operating activities		$ 1,140	$ 640	$ 594
Cash flows from investing activities
Purchases of property, plant, and equipment		(498)	(411)	(338)
Acquisition of business, net		(37)	0	0
Proceeds from sales of assets and businesses, net	$ 39	46	39	708
Intercompany investing activities		0	0	0
Investments in affiliates		0	0	(1)
Foreign exchange contract settlements, net		2	2	(12)
Cash (used for) provided by investing activities		(487)	(370)	357
Cash flows from financing activities
Intercompany short-term borrowings, net			0	0
Proceeds from issuance of debt, net		520	495	0
Debt repayments		(679)	(27)	(381)
Payments related to extinguishment of debt		(29)	(1)	0
Payments of debt issuance costs		(12)	(6)	(4)
Purchases of treasury stock, at cost		(644)	(106)	0
Intercompany financing activities		0
Proceeds from exercised stock options, net		16	31	11
Payments related to tax withholdings on vested restricted stock units		(17)	(12)	0
Payments of dividends		(148)	(22)	(22)
Cash (used for) provided by financing activities		(993)	352	(396)
Effect of exchange rate changes on cash and cash equivalents		(15)	32	(19)
(Decrease) increase in cash and cash equivalents		(355)	654	536
Cash and cash equivalents at January 1,		1,556	902	366
Cash and cash equivalents at December 31,		1,201	1,556	902
Eliminations and Adjustments [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities		0	0	0
Cash flows from investing activities
Purchases of property, plant, and equipment		0	0	0
Acquisition of business, net		0
Proceeds from sales of assets and businesses, net		0	0	0
Intercompany investing activities		1,152	(220)	560
Investments in affiliates				0
Foreign exchange contract settlements, net		0	0	0
Cash (used for) provided by investing activities		1,152	(220)	560
Cash flows from financing activities
Intercompany short-term borrowings, net			220	(560)
Proceeds from issuance of debt, net		0	0
Debt repayments		0	0	0
Payments related to extinguishment of debt		0	0
Payments of debt issuance costs		0	0	0
Purchases of treasury stock, at cost		0	0
Intercompany financing activities		(1,152)
Proceeds from exercised stock options, net		0	0	0
Payments related to tax withholdings on vested restricted stock units		0	0
Payments of dividends		0	0	0
Cash (used for) provided by financing activities		(1,152)	220	(560)
Effect of exchange rate changes on cash and cash equivalents		0	0	0
(Decrease) increase in cash and cash equivalents		0	0	0
Cash and cash equivalents at January 1,		0	0	0
Cash and cash equivalents at December 31,		0	0	0
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities		(159)	(132)	(176)
Cash flows from investing activities
Purchases of property, plant, and equipment		0	0	0
Acquisition of business, net		0
Proceeds from sales of assets and businesses, net		0	0	0
Intercompany investing activities		0	0	0
Investments in affiliates				0
Foreign exchange contract settlements, net		0	0	0
Cash (used for) provided by investing activities		0	0	0
Cash flows from financing activities
Intercompany short-term borrowings, net			(220)	560
Proceeds from issuance of debt, net		520	495
Debt repayments		(679)	(27)	(369)
Payments related to extinguishment of debt		(29)	(1)
Payments of debt issuance costs		(12)	(6)	(4)
Purchases of treasury stock, at cost		(644)	(106)
Intercompany financing activities		1,152
Proceeds from exercised stock options, net		16	31	11
Payments related to tax withholdings on vested restricted stock units		(17)	(12)
Payments of dividends		(148)	(22)	(22)
Cash (used for) provided by financing activities		159	132	176
Effect of exchange rate changes on cash and cash equivalents		0	0	0
(Decrease) increase in cash and cash equivalents		0	0	0
Cash and cash equivalents at January 1,		0	0	0
Cash and cash equivalents at December 31,		0	0	0
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities		10	603	355
Cash flows from investing activities
Purchases of property, plant, and equipment		(390)	(327)	(233)
Acquisition of business, net		(37)
Proceeds from sales of assets and businesses, net		46	39	591
Intercompany investing activities		(153)	220	(560)
Investments in affiliates				0
Foreign exchange contract settlements, net		2	2	(12)
Cash (used for) provided by investing activities		(532)	(66)	(214)
Cash flows from financing activities
Intercompany short-term borrowings, net			0	0
Proceeds from issuance of debt, net		0	0
Debt repayments		0	0	(12)
Payments related to extinguishment of debt		0	0
Payments of debt issuance costs		0	0	0
Purchases of treasury stock, at cost		0	0
Intercompany financing activities		0
Proceeds from exercised stock options, net		0	0	0
Payments related to tax withholdings on vested restricted stock units		0	0
Payments of dividends		0	0	0
Cash (used for) provided by financing activities		0	0	(12)
Effect of exchange rate changes on cash and cash equivalents		0	0	0
(Decrease) increase in cash and cash equivalents		(522)	537	129
Cash and cash equivalents at January 1,		761	224	95
Cash and cash equivalents at December 31,		239	761	224
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Cash flows from operating activities
Cash (used for) provided by operating activities		1,289	169	415
Cash flows from investing activities
Purchases of property, plant, and equipment		(108)	(84)	(105)
Acquisition of business, net		0
Proceeds from sales of assets and businesses, net		0	0	117
Intercompany investing activities		(999)	0	0
Investments in affiliates				(1)
Foreign exchange contract settlements, net		0	0	0
Cash (used for) provided by investing activities		(1,107)	(84)	11
Cash flows from financing activities
Intercompany short-term borrowings, net			0	0
Proceeds from issuance of debt, net		0	0
Debt repayments		0	0	0
Payments related to extinguishment of debt		0	0
Payments of debt issuance costs		0	0	0
Purchases of treasury stock, at cost		0	0
Intercompany financing activities		0
Proceeds from exercised stock options, net		0	0	0
Payments related to tax withholdings on vested restricted stock units		0	0
Payments of dividends		0	0	0
Cash (used for) provided by financing activities		0	0	0
Effect of exchange rate changes on cash and cash equivalents		(15)	32	(19)
(Decrease) increase in cash and cash equivalents		167	117	407
Cash and cash equivalents at January 1,		795	678	271
Cash and cash equivalents at December 31,		$ 962	$ 795	$ 678